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Abstract 
Immunotherapy is a novel approach to disease treatment and has shown numerous clinical 
successes. In brief, immunotherapy exploits the principles of immunology to generate an 
anti-viral or anti-cancer response. One of the myriad methods that exist to stimulate an 
immunotherapeutic response is adoptive T-cell transfer (ACT). ACT is an immunotherapy 
approach whereby patient-derived antigen-specific T-cells are expanded in vitro and infused 
into the patient. Thus, a central factor of ACT immunotherapy is the in vitro T-cell stimulation 
and expansion step. In recent years, T-cell stimulation and expansion methods have 
focused on maximising cell yield. These expansion methods rely on the use of high-dose 
and often repeated cycles of stimulation. While effective in deriving large cell yields, this T-
cell expansion strategy appears to compromise T-cell quality. Furthermore, various antigen 
sources are used to stimulate and expand antigen-specific T-cells. The impact these 
differing antigen sources have on T-cell quality is poorly understood.  
An aspect of this project aims to describe the consequences of antigen stimulation 
dose on T-cell quality. This project also evaluated common antigen stimulation sources, 
including Epstein-Barr Virus (EBV) transformed lymphoblastoid cell lines (EBV-LCLs), 
adenoviral vector-infected antigen presenting cells (APCs), and peptide-pulsed APCs, to 
determine their impact on T-cell quality. Of particular interest is the impact of EBV-LCL-
based stimulation as this method is widely used for the manufacture of ACT drug products. 
To this end, we hypothesised that the therapeutic potential of an ACT drug product is heavily 
influenced by the stimulation and expansion method used. Furthermore, this project aimed 
to demonstrate the utility of comprehensive ACT drug product assessment.  
Indeed, our findings revealed that T-cell cultures stimulated with varying stimulation 
doses exhibit different phenotypic, transcriptional, and T cell receptor (TCR) repertoire 
profiles that reflect functional differences. This analysis can potentially be used to distinguish 
between ACT drug products of superior quality. The comprehensive analysis approach used 
also revealed that the dose of EBV-LCL-based stimulation had a profound impact on the 
overall ACT drug product composition. Specifically, it was observed that a high-dose EBV-
LCL stimulation promoted a significant increase in natural killer cells but limited expansion 
of CD4+ T-cells. In contrast, varying stimulation dose of other antigen stimulation sources—
adenoviral vector-infected APCs and peptide-pulsed APCs—had less influence on culture 
composition. Overall, these two stimulation approaches resulted in ACT drug products that 
predominately contained T-cells. Additionally, T-cells derived from a high-dose EBV-LCL 
stimulation showed hallmarks of T-cell exhaustion, via the co-expression of multiple 
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inhibitory receptors and decreased polyfunctionality. High-dose EBV-LCL stimulation also 
induced a transcriptional signature reflective of a type 2 response, in both CD4+ and CD8+ 
T-cells. Previous experimentation has demonstrated a type 2 response to be undesirable 
for anti-viral or anti-cancer immunotherapy. In contrast, a low-dose EBV-LCL stimulation 
generated a gene signature that could predict improved overall survival in patients with solid 
tumours. Further interrogation involving TCR sequencing revealed that EBV-LCL stimulation 
dose had a profound impact on the resultant TCR repertoire. In this regard, low-dose EBV-
LCL stimulation promoted a more clonal T-cell population—enriched for T-cells with inferred 
high affinity TCRs. In contrast, high-dose EBV-LCL stimulation induced a polyclonal TCR 
repertoire, hypothesised to be the result of the increased expansion of low affinity TCRs. 
 Altogether, the data generated as part of this study have important implications in the 
manufacture of ACT drug products. Our findings demonstrate that factors such as antigen 
source and stimulation dose significantly impact the quality of an ACT drug product. Notably, 
these results demonstrate that using adenoviral vector-infected APCs or peptide-pulsed 
APCs can generate a therapeutic drug product highly enriched for T-cells. Furthermore, 
these methods are robust to variations in stimulation dose. In contrast, the stimulation dose 
of EBV-LCLs significantly impacts T-cell quality and can derive drastically different ACT drug 
products. This is an important finding given the widespread use of high-dose and repeated-
dose EBV-LCL-based stimulation within the ACT therapy field. Additionally, these data 
clearly demonstrate the utility of comprehensive ACT drug product profiling. This notion is 
illustrated by TCR sequence analysis revealing the presence of predicted low affinity TCRs 
as well as transcriptional analysis inferring T-cell status, including T-cell exhaustion and type 
2 polarisation. Thus, this data demonstrates that comprehensive analysis of ACT drug 
products can aid in determining T-cell function and hence, the therapeutic fitness of a given 
drug product. Such analysis is seldom performed; however, this project suggests that this 
practise has its place within the manufacturing process in the ACT immunotherapy field. 
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1.0 Review of Literature 
1.1 Immune system 
Homo sapiens are equipped with a remarkable cellular defence system, known as our 
immune system, which protects against invading pathogens and the emergence of disease. 
Our immune system is comprised of bone marrow derived leukocytes, which may be 
grouped by their mechanism of action and their temporal functionality. Doing so derives two 
arms of immunity, the first termed innate immunity. The innate immune system functions via 
non-specific mechanisms and is mobilised rapidly in response to pathogen encounter. 
Innate immunity is therefore the first immunological barrier against an impending pathogenic 
infection. Although, capable of a rapid response, the innate immune system is limited by the 
non-specific machinery that it employs. These limitations are supplemented by the second 
arm of the immune system—termed the adaptive immune system, which provides highly 
specific and long-lasting immunity. However, the adaptive immune system is itself limited, 
temporally by the requirement for gene rearrangement and additional activation constraints. 
Therefore, both innate and adaptive arms of immunity complement each other’s limitations 
giving immunocompetent individuals a robust cellular defence system.  
 
1.1.1 Innate Immunity 
Innate immunity refers to a subset of leukocytes that provide the initial responses against a 
pathogen. The cells of the innate immune system achieve such rapid responses by utilising 
non-specific mechanisms of pathogen recognition. Innate leukocytes thus have pattern-
recognition receptors (PRRs), which bind to a broad array of pathogen-associated molecular 
patterns (PAMPs). Ligation of the transmembrane PRRs with PAMPs or danger-associated 
molecular patterns (DAMPs) serves to activate innate leukocytes [1]. PAMPs are molecular 
patterns highly conserved in pathogen molecules with an example being lipopolysaccharide 
(LPS), which can be found on almost all gram-negative bacteria [2]. This, therefore allows 
innate leukocytes to readily identify a target as a pathogen without being concerned with 
specificity. This is distinct from DAMPs, which are produced endogenously by damaged 
tissue and provide a signalling mechanism for activating a rapid immune response [1]. In 
fact, PRRs are so integral to innate immunity that the discovery of toll-like receptors (TLRs), 
an important class of PRR, won the 2011 Nobel Prize in Physiology or Medicine. The cellular 
constituents of the innate immune system are varied and numerous, all of which carry 
distinct yet synergistic functionality.  
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 Macrophages for example, are a broad group of phagocytic cells present in every 
tissue in the human body. These cells are crucial to innate immunity and mainly derive host 
protection via phagocytosis—which is the process of engulfing compromised cells or 
pathogens [3]. The process of phagocytosis results in the production of a phagosome that 
progressively becomes more acidic. Additionally, reactive oxygen and nitrogen 
intermediates are employed, synergising with the acidic environment to destroy engulfed 
material [4]. To complement phagocytosis, macrophages produce a large array of 
inflammatory cytokines and chemokines to recruit additional leukocytes. Two commonly 
recruited innate leukocytes are the granulocytes—eosinophils, basophils, and neutrophils—
and natural killer (NK) cells.  
NK cells possess diverse functionality such as anti-tumour, anti-pathogen, and 
immune regulatory capabilities [5]. NK cells are present throughout lymphoid and non-
lymphoid tissues; however, they only represent a small fraction of total lymphocytes—
ranging from 2–18% of peripheral blood lymphocytes. Despite being few in number, these 
cells have important immunological roles as demonstrated by their killer cell 
immunoglobulin-like receptors (KIRs) [5]. KIRs are receptors that recognise human 
leukocyte antigen class I (HLA-I). Therefore, KIRs allow NK cells to monitor the expression 
levels of HLA-I on healthy and diseased tissues [5]. An important function given that HLA-I 
is often down-regulated in malignant tumours as a mechanism of immune escape [6]. Thus, 
alongside their traditional roles in innate immunity NK cells serve important functions in 
tumour immunology. 
 
1.1.2 Adaptive Immunity 
Adaptive immunity designates an arm of the immune system, which utilises antigen-specific 
receptors and provides durable responses referred to as immunological memory. In fact, 
immunological memory is the basis behind vaccination, whereby subsequent challenge with 
a pathogen is met with a heightened response and reduced response delay. Further division 
of the adaptive immune system on the basis of effector function yields two categories. The 
first category termed the humoral system utilises soluble antigen-specific proteins termed 
antibodies (Abs). Produced by activated B-cells, Abs provide host defence by ligating 
cognate antigen and imparting an opsonising effect or a neutralising function. Additionally, 
ligation of Abs with cognate antigen may evoke antibody-dependent cell cytotoxicity. In this 
case, Abs coating a pathogen serve as anchor points for Fc receptor-expressing leukocytes, 
which subsequently mediate their destruction.  
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The second category of the adaptive immune system is designated cell mediated immunity. 
This division employs T-cells—a subset of leukocytes matured within the thymus, to protect 
against pathogenic infection and disease. T-cells and cell mediated immunity are arguably 
the most important leukocyte subset in the control of intracellular pathogens, such as viruses 
and neoplastic malignancies. 
 
1.1.3 Cell Mediated Immunity 
Cell mediated immunity is a function of thymus matured T-cells of which there are two broad 
groups. These groups are designated on the basis of cluster of differentiation (CD) molecule 
expression, which in turn relates to phenotypic function. The first division are CD4+ T-cells 
that may also be referred to as T-helper (Th) cells. Th cells are a diverse subset of 
leukocytes with functions extending into humoral immunity and immune regulation. The 
second division consists of cytotoxic T-lymphocytes (CTLs), which are CD8+ T-cells. CTLs 
are crucial to cell mediated immunity and display numerous mechanisms of cytotoxicity. T-
cells derive antigen specificity through their T-cell receptor (TCR) a molecule borne through 
genetic recombination events catalysed by the recombinase encoded by recombination 
activating gene (RAG). The RAG gene product functions to reorganise the highly variable 
gene segments within the TCR locus. Additionally, the act of genetic reorganisation creates 
novel gene sequences at the joints between variable gene segments. Hence, both the highly 
variable nature of gene segments within the TCR locus and novel joining sequences gives 
rise to a highly specific TCR. Indeed, this variability can produce some 1018 unique TCRs 
[7]. A highly diverse and therefore specific TCR is only half the equation with the other half 
provided by HLA molecules, which present antigen and allows TCR recognition.  
 
1.1.4 Antigen Presentation 
HLA molecules are a group of diverse immunological molecules whose function is to present 
antigen to surveying leukocytes. Two classes of HLA molecules exist with HLA-I found on 
the surface of all nucleated cells and presenting intracellular antigen to CD8+ T-cells. HLA 
class II (HLA-II) on the other hand have a more restricted expression pattern and are found 
on the surface of professional antigen presentation cells (APCs). HLA-II complements the 
function of HLA-I and therefore is responsible for presenting extracellular antigen to CD4+ 
T-cells. In healthy people both HLA-I and HLA-II present endogenously derived self 
peptides; however, following pathogenic challenge foreign peptides will be presented [8]. 
This process allows surveying T-cells to mediate an appropriate response upon encounter 
with cognate peptide loaded HLA (pHLA). 
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The HLA-I molecule is a heterodimer of a variable type I membrane glycoprotein 
heavy chain and an invariant β2-microglobulin (β2M) [9]. β2M primarily functions to provide 
structural support for the HLA-I complex and does not interact with the TCR. It is the HLA-I 
heavy chain that confers antigen specificity and mediates pHLA-TCR interactions. This is 
achieved through the peptide binding groove created between domains α1 and α2 while the 
third domain (α3) interacts with the CD8α subunit [8]. Presentation of antigen by HLA-I 
represents the end point of a complex pathway termed antigen processing and presentation 
(AP&P). AP&P in the context of HLA-I is initiated by the proteosomal degradation of 
intracellular proteins into short peptides. These peptides are shuttled into the endoplasmic 
reticulum (ER) by transporter associated with antigen processing (TAP) molecules. Once 
inside the ER numerous chaperones facilitate a peptide loading and editing process [10, 
11]. This culminates in a HLA-I loaded with a peptide between 8–13 amino acids (AAs), 
which is subsequently transported to the cell surface where surveying immune cells can 
recognise the complex [12].  
The HLA complex is a highly polymorphic polypeptide. This polymorphism allows the 
HLA to impart exquisite specificity for both epitope and recipient TCR. HLA-I comes in three 
different classical forms, designated HLA-A, -B, and -C. Similarly, the HLA-II dimer comes 
in three major forms (HLA-DP, -DQ, and -DR). Further adding to the polymorphism, of these 
three subtypes, individuals will have at 2 alleles. Thus, an individual has the potential for six 
different HLA-I classical molecules. The nomenclature designation of HLA subtypes is as 
follows. Each subtype is specified by the “HLA” prefix followed by locus indicator i.e (HLA-A 
or HLA-B). Subsequently, the locus indicator is followed by the allele group (as in HLA-A*02 
or HLA-B*35). Allele groups can be further described by a numerical designation of protein 
type (as in HLA-A*02:01 and HLA-A*02:05). These highly defined subtypes can be (although 
rarely required) further described by their synonoymous mutations inside or outside of the 
coding region—using prefix of “:” followed by a numeric value. Finally, the established HLA 
nomenclature allows for the addition of expression values within the molecule naming 
structure [13]. In all, the HLA protein complex provides refined selection for an epitope and 
a conjugate TCR. Therefore, when specificity is met TCR-pHLA-I ligation sets in motion a 
cascade of intracellular signalling events that can ultimately stimulate effector function. 
However, the activation fate of a naïve T-cell is largely dictated by accessory molecule 
signalling alongside TCR-pHLA-I binding.  
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1.2 T-cell receptor 
1.2.1 TCR rearrangement and structure 
The TCR is an extremely diverse molecule with some 1018 unique TCRs theoretically 
possible [7]. However, realised diversity is significantly restrained following the biological 
process of thymic selection. Nevertheless, TCR diversity allows T-cells to recognise 
numerous epitopes and thus survey a host from infection and disease. The structure of the 
TCR locus provides the necessary elements to develop such diversity. In brief, a TCR 
molecule is comprised of two chains α, and β. There exists a second set of chains, 
designated the γ, and δ chains. These constitute the less abundant γδ-TCR which defines 
γδ-T-cells. Conventional T-cells; however, are comprised of the α, and β chains. It is these 
chains that will be discussed further, although numerous parallels exist between the locus 
structures of all chains. The α chain locus consists of variable (V), joining (J), and constant 
(C) gene segments; which combine to form a functional α chain gene. The β locus contains 
an additional gene, the diversity (D) gene segment which sits between the V and J 
segments. Thus, the β chain has a V, D, J, C structure. There exists ~70 and 52 V genes 
within the α and β loci respectively. Only two D genes exist, whereas, 61 and 13 different J 
genes exists for the α and β loci, respectively. There are only three C genes, one Cα and 
two Cβ, which do not differ in any known functional aspect [7].  
Gene rearrangement occurs with the use of RAG recombinase and recombination signal 
sequences, similar to immunoglobulin gene rearrangement. It is the unique rearrangement 
that defines Ag specificity of a TCR. Structurally, it is the complementarity-determining 
regions (CDR) that comprise the Ag binding segments of a TCR. CDR1 and CDR2 loops 
are encoded by the V gene segments of both α and β chains and are primarily involved in 
peripheral MHC binding, whereas, the CDR3 is primarily involved in peptide binding within 
the MHC grove. The CDR3 is encoded by the V(D)J junctional region of both α and β chains 
[14]. Hence, TCR analysis can largely focus on the CDR3 as this is the primary epitope 
specificity-determining region of a TCR.  
 
1.2.2 TCR Signalling 
TCR signalling instigates T-cell differentiation and effector function. However, the short 
cytoplasmic domains of the TCR chains are incapable of intrinsic signalling and therefore 
signalling is facilitated by the association with the CD3 complex. The CD3 complex is 
comprised of ε-, δ-, γ-, and ζ-chains with all chains containing immunoreceptor tyrosine-
based activation motifs (ITAMs). ITAMs are critical to signalling as they are phosphorylated 
by the Src kinase leukocyte-specific tyrosine kinase (Lck) [15]. It is thought that via a 
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conformational change, TCR engagement with pHLA promotes Lck-mediated CD3 
phosphorylation [16, 17]. Once phosphorylated, ITAMs serve as docking sites for Syk family 
kinase Zeta-activated protein 70 kDa (Zap70). This interaction is facilitated by a Src-
homology-2 (SH2)-domain contained within Zap70. After Zap70 has been recruited to the 
TCR/CD3 complex, Zap70 may promote the phosphorylation of downstream signalling 
proteins. One such protein is the membrane-associated scaffold linker for the activation of 
T-cells (LAT) [18]. LAT together with another scaffolding protein, the SH2-domain-containing 
leukocyte protein of 76 kDa (Slp76), function as binding sites for numerous signalling 
proteins. One notable protein that is recruited to the LAT-Slp76 complex is phospholipaseC-
γ (PLCγ) [19]. Upon recruitment PLCγ transduces TCR signalling via catabolism of 
membrane phospholipids, which ultimately results in mitogen-activating protein kinase 
(MAPK) activation [16]. Additional to induction of signalling cascades, TCR ligation induces 
conformational changes and accumulation of TCR complexes within the immunological 
synapse. These processes are thought to facilitate receptor signalling. Specifically, TCR 
accumulation appears important for transducing signals from low affinity TCR interactions 
[20]. 
To circumvent the induction of autoimmunity Bretscher and Cohn [21] proposed a two 
signal model. Whereby the first signal is facilitated by TCR signalling and a second signal is 
derived from co-signalling molecules. This model has been expanded upon and it is now 
widely accepted that co-signalling is critical to the final activation state of a T-cell. More 
recently, experimentation by Richard, Lun [22], set out to address the intuitive notion that 
TCR signalling strength impacts T-cell cytolytic capacity. However, the authors 
demonstrated that T-cell cytolytic capacity is not dependent upon epitope potency. Their 
observations reveal that TCR signalling strength merely modulates T-cell proliferation and 
rate of activation but not the overall activation capacity.  
 
1.2.3 TCR gene sequencing technology 
Advances in sequencing technology have enabled unprecedented access to profile the TCR 
repertoire of a sample. Where, TCR repertoire refers to the sum of all TCRs within the 
sample. Thus, TCR gene sequencing (TCRseq) has given unique insight into disease 
pathology and clinical responses following treatment. The ability to sequence the TCR 
repertoire is itself a great technological achievement, given the diversity is estimated at 
some 1013 unique clones [23]. Previously, monoclonal TCR V-chain subgroup antibodies 
allowed interrogation of TCR usage; however, this was a low-resolution analysis of TCR 
repertoire [24]. Indeed, the application of next gene sequencing (NGS) technology to TCR 
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profiling has revealed the majority of TCRs are rare [25, 26]. Therefore, high-resolution 
TCRseq is necessary to allow informative assessment of the TCR repertoire. In recent 
years, numerous studies have established the utility of TCRseq. For example, recent 
investigation by Scheper, Kelderman [27] suggests the majority of tumour infiltrating 
lymphocytes (TILs) have low anti-tumour reactivity. This has broad implications on the 
development of novel cancer therapeutics. This study represents one of many recent 
publications applying TCRseq technology to understanding disease mechanisms and 
treatment effects [28-32]. From a bioinformatics and analytics stand point, the field has seen 
a rapid expansion in tools available to researchers for analysis of TCRseq data [33-40]. In 
fact, analytical tools have allowed repurpose of RNA sequencing data for TCR repertoire 
profiling [41-43].  
 Experimentally, varied methods for TCRseq are currently in use. Decisions must be 
made for starting material (genomic DNA or RNA), bulk or single cell, library preparation, 
target enrichment, sequencing platform, and sequencing depth [44-46]. As input, TCRseq 
piplines can usually accept either genomic DNA (gDNA) or RNA. Both gDNA and RNA have 
particular advantages and disadvantages. A critical difference between the input material is 
the relative copy number and thus inference of clone abundance. Present at a single 
template per cell, gDNA is better suited for the quantification of a single TCR clone [47]. 
Conversely, RNA allows assessment of TCR expression level [48]. Additional benefits of 
gDNA include increased stability. However, gDNA can have errors induced by intronic 
regions or off-target-priming [44]. Additionally, selection of input material can be forced by 
other experimental factors; such as, availability of material, processing requirements, etc.  
 
1.3 Co-signalling 
Experimentation by Mueller, Jenkins [49] demonstrated that TCR signalling alone did not 
result in T-cell activation and instead resulted in anergy. This result validated Bretscher and 
Cohn [21] proposed two signal model for successful T-cell activation; which was further 
demonstrated around the same time by Lafferty and Jones [50] using allogenic graft 
rejection models [51]. In vitro analysis suggested CD28 as an important co-stimulatory 
receptor as experimentation had linked CD28 engagement with elevated interleukin (IL)-2 
production [52, 53]. Indeed, it has since become widely accepted that CD28 provides a 
secondary activation signal through interaction with B7 family members: CD80 and CD86 
[54]. Since the identification of CD28 a myriad of co-stimulatory receptors has been 
described, most of which function post-TCR/CD3 signalling to modulate T-cell activation, 
effector function, proliferation, and survival [55-57]. Some notable co-stimulatory receptors 
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include CD40, inducible co-stimulatory molecule (ICOS), and OX-40, which influence T-cell 
function via interactions with their ligands: CD154, B7h, and OX-40L respectively. 
Juxtaposing co-stimulatory receptors are the co-inhibitory receptors, which are tasked with 
impeding T-cell effector functions. Recent years have seen a spike in the research of co-
inhibitory receptors due to their therapeutic potential. 
 Around the same time that CD28 was being investigated, genetic analysis revealed 
the presence of a CD28 homologue—cytotoxic T-lymphocyte antigen-4 (CTLA-4) [58]. 
CTLA-4 shares both ligands CD80 and CD86 with CD28; however, CTLA-4 is not expressed 
in naïve T-cells unlike constitutively expressed CD28 [59]. In fact, early experiments by 
Brunet, Denizot [58] found CTLA-4 mRNA to increase upon T-cell activation. Additionally, 
CTLA-4 was observed to have a significantly higher affinity for CD80 and CD86—
approximately 100–1000 fold, when compared with CD28 [60, 61]. Subsequent 
experimentation suggested CTLA-4 binding of CD80 or CD86 transduced inhibitory signals 
[62-64]. Given a heightened binding affinity it is no surprise that at least one modality of 
CTLA-4’s inhibitory functionality is derived from competitive binding; with remaining 
inhibitory processes owing to the induction of opposing intracellular signalling cascades. 
Hence, co-inhibitory receptors have also been described as immune-checkpoint or simply 
just inhibitory receptors (IRs). CTLA-4 gives an interesting insight into immune regulation as 
its ligation with ostensibly stimulatory ligands produces an inhibitory response. This 
suggests that understanding co-inhibitory receptors in isolation is moot without a thorough 
appreciation for differential signalling produced via different ligands.  
 
1.4 Co-inhibitory Signalling 
The prevailing notion is that IRs exist to regulate immune responses and enforce self-
tolerance. These suggested immune regulatory functions are inline with the expression 
pattern of CTLA-4, whereby only activated T-cells show expression. Therefore, following 
initial T-cell activation, expression of CTLA-4 is induced to subsequently reduce stimulatory 
signalling and preventing immunopathology. This concept is dramatically illustrated in 
CTLA-4-deficient mice, which fail to reach maturity and succumb to a fatal 
lymphoproliferative disorder after 18–28 days of life [65, 66]. Thus, IRs are critical to both 
the impediment of autoimmunity and mitigation against immunopathology. The importance 
of IRs in these two protective functions is echoed in studies of other IRs. For example, 
experimentation has shown that an absence of the IR programmed cell death-1 (PD-1) 
results in spontaneous autoimmunity [67]. Furthermore, it has been found that defects in the 
PD-1 signalling pathway lead to increased viral-mediated immunopathology [68, 69]. 
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Therefore, effective immunity results from a finely balanced equilibrium between immune 
activation and inhibition. Attesting to this notion is the observation that IR expression is 
tightly linked to T-cell differentiation.  
 T-cells develop and differentiate in response to antigen and co-signalling in order to 
gain required immune functions. In other words, upon antigen recognition—given 
appropriate co-stimulatory signalling, T-cells will differentiate towards effector cells with 
increased host defence capabilities. Analysis by Legat, Speiser [70] supports the perception 
that IRs have evolved to limit immunopathology and autoimmunity. The authors 
demonstrated that a myriad of IRs are up-regulated as T-cells acquire effector capabilities. 
The findings essentially mirroring earlier investigations that revealed expression of IRs in 
viral-specific CD8+ T-cell is associated with their differentiation state [71]. More specifically 
Baitsch, Legat [72] observed that the IRs 2B4 (CD244), killer cell lectin-like receptor 
subfamily G member 1 (KLRG-1), PD-1, T-cell immunoglobulin and mucin protein 3 (TIM-
3), and CD160 peaked in highly cytotoxic effector T-cells. Tight association between iR 
expression and differentiation status clearly supports the axiom that IRs evolved as a 
mechanism to counter T-cell activation and maintain homeostatic balance [70]. Given typical 
immune challenges IRs effectively provide temporally regulated negative feedback allowing 
a successful immune response to be mounted with minimal off-target effects. Unfortunately, 
under chronic immune challenge—neoplasmic malignancies or latent viral infections, this 
feedback mechanism is dysregulated [73]. Under these conditions a T-cell may progress 
towards an exhausted phenotype, this is a cellular state defined by elevated IR expression 
and importantly limited effector functionality [74]. To properly understand T-cell exhaustion 
an appreciation of the typical T-cell differentiation pathway is required. Essentially because 
exhaustion represents yet another cellular state in T-cell differentiation and it can be useful 
to view exhaustion in such a light.   
 
1.5 T-cell Differentiation and Development 
A T-cell’s differentiation state is defined based on proliferative ability and effector function. 
Commonly, T-cell subsets are categorised into naïve (TN), central memory (TCM), effector 
memory (TEM), and effector memory CD45RA+ (TEMRA) (Figure 1.5.1) [75]. Experimentally, 
classification is achieved using surface markers that denote antigen experience and tissue 
homing. For example, TN cells are CCR7+, CD62L+, and CD45RA+ reflecting their 
requirement to migrate through high endothelial venules (HEV) and deposit into secondary 
lymphoid organs. TCM cells are also CCR7+ and CD62L+ given a similar need to migrate to 
secondary lymphoid organs via HEV. Contrasting the naive subset, TCM are CD45RA- and 
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are more responsive to antigenic stimulation producing IL-2. Classically, TEM cells lack 
expression of CCR7-, CD62L-, and CD45RA-; however, a CD62L+ TEM subset has been 
described [76]. TEM demonstrate effective migration to inflamed tissue where they secrete 
effector molecules such as IFN-γ, IL-4, and IL-5 [75]. Finally, TEMRA cells are often described 
as terminally differentiated effector cells carrying high levels of perforin and IFN-γ. These 
cells are characterised by their acquisition of CD45RA+ while retaining a CCR7- and CD62L- 
phenotype. However, studies by Carrasco, Godelaine [77] imply that TEMRA cells are not 
terminally differentiated in the classical sense and retain the ability to proliferate. 
Furthermore, the authors noted that TEMRA cells lost CD45RA and transiently gained CCR7 
expression following antigenic stimulation. This observation highlights the caution that must 
be taken when classifying T-cell subsets using surface markers. For example, antigenic 
stimulation results in the acquisition of CCR7 in TEM and the loss of CD62L in TCM. Therefore, 
identification of subsets with these markers is only valid in resting cells not currently engaged 
in an antigen response [75]. 
 
Figure 1.5.1 Linear T-cell differentiation model. A linear model of T-cell differentiation 
where T-cells progress from a naïve (TN) state, through central memory (TCM), effector 
memory (TEM), and finally effector memory CD45RA+ (TEMRA). Molecules indicate classical 
markers of each cellular differentiation state. Figure illustrated by Susanna Ng. 
 
A number of models have been proposed to describe the path of T-cell differentiation. 
Wherry, Teichgraber [78] advocate a linear, step-wise progression that proceeds as TN–
effector–TEM–TCM. Unfortunately, the Wherry, Teichgraber [78] model fails to consider the 
TEMRA subset. This oversight is due to their experimentation utilising murine models, which 
lack a TEMRA subset [79]. A model suggested by Koch, Larbi [80] retains the notion of linear 
progression; however, implies that TN differentiate to TCM before progressing through 
multiple effector stages (Figure 1.5.1). Yet another model has been proposed by Sallusto, 
Geginat [75], which contradicts the preceding models by implying that T-cell differentiation 
is dependent upon signal strength. Under this model, strong antigenic stimulation results in 
TEM generation, while suboptimal signalling produces a TCM phenotype. In line with Sallusto, 
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Geginat [75] increasing evidence points towards the importance of TCR signal strength in 
T-cell differentiation [81, 82]. Furthermore, experimentation by groups such as Crompton, 
Narayanan [83] demonstrate a linear relationship between cell differentiation states and the 
methylation status of histones associated with key transcription factors. Additionally, the 
asymmetric cell division model proposes cell fate is decided by the asymmetrical partitioning 
of transcription factors and regulatory molecules during cell division. This model also 
suggests a progenies fate is determined by environmental cues as well as intrinsic cell 
factors. Thus, this model advocates a framework whereby one daughter may retain self-
renewal capacity and a memory phenotype; whereas, the other daughter cell is fated for an 
effector lineage [84]. These models need not be mutually exclusive. For example, unification 
of these models presents a description of T-cell differentiation whereby, cell fate is 
determined by TCR signalling strength. Which progresses via the linear aggregation of 
epigenetic marks along a linear differentiation trajectory. However, mechanistically this may 
be the function of asymmetric cell division, that may be biased by TCR signal strength 
towards a particular trajectory.  
 
1.6 T-cell anergy and senescence 
T-cell development is a complex multifaceted process. Following thymic selection, T-cells 
face numerous developmental fates ranging from effector subsets to memory subsets. 
Alternatively, T-cells may undergo tolerogenic processes. Dependent upon antigenic 
recognition and co-signalling, T-cells can progress into anergy, senescence, or exhaustion 
states. Although these states are unique, they share a large overlap of surface and 
functional markers. Hence, anergy, senescence, and exhaustion are all functionally defined 
as hyporesponsive T-cell states with differing degrees of effector function loss. Anergy is 
arguably the best understood tolerogenic T-cell fate, with majority of experimentation 
performed on the CD4+ T-cell compartment. The axiom of anergic development relies upon 
TCR signalling in the absence of co-stimulatory or elevated co-inhibitory signalling. A classic 
application of this concept is in the case of naïve APC presentation of self-antigen, which is 
recognised by cognate T-cells. As the APC is in an inactivated state there is a key absence 
of co-stimulatory signalling. Ultimately, this drives cognate T-cells to progress towards 
anergy. In this scenario it is evident why anergy has evolved and how this tolerogenic state 
mediates against autoimmunity. Phenotypically anergic cells can be identified by low IL-2 
production and elevated TIM-3, PD-1, and CTLA-4 expression [85]. In comparison to anergy, 
the tolerogenic state of senescence is less understood and probably arises as the result of 
aging and DNA damage. Hence, telomeric shortening, cell cycle arrest, and loss of CD28 
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expression identify these cells. Additional markers associated with senescence include TIM-
3 and CD57 in human or KLRG-I in mouse [85-87]. Although aging is often attributed to 
senescence, immune challenge has the potential to push a senescence fate. This is evident 
by the identification of senescent T-cells in young patients suffering viral infection, chronic 
tumour burden or autoimmunity [85, 88]. Indeed, senescent T-cells have been found in 
patients with multiple cancer types and there is growing evidence that suggests tumours 
can induce T-cell senescence [89]. Interestingly, tumour induced senescence has been 
linked with the acquisition of immune inhibitory functions [90]. Thus, both anergy and 
senescence represent T-cell fates that are important considerations for host defence under 
conditions of chronic antigenic challenge. 
 
1.7 T-cell Exhaustion 
The third tolerogenic T-cell state, exhaustion, is far less understood than anergy or 
senescence. Additionally, where studies on anergy have focused on the CD4+ T-cell lineage, 
studies on exhaustion have centred on the CD8+ T-cell compartment. This complicates 
direct inferences between the two data sets. Regardless, both anergy and exhaustion are 
known to influence the CD4+ and the CD8+ T-cell compartments. Anergy and exhaustion 
are very similar T-cell states; however, where anergy is often seen as a naturally occurring 
hyporesponsive state, exhaustion is considered as T-cell dysfunction. This terminology is 
misleading as it implies the T-cell has become defective which is disparate from a T-cell fate 
that has developed to mitigate immunopathology. As with senescence and anergy, 
exhaustion is hypothesised to represent a host protection mechanism, which may become 
counter-productive in certain disease or infection states. In other words, T-cells progressing 
towards exhaustion is physiologically essential; however, dysregulation of exhaustion 
initiation and maintenance may exacerbate disease or infection. The functionality and 
phenotype of exhausted T-cells overlaps considerably with anergic and senescent T-cells. 
Although, analysis by Wherry, Ha [91] using a Lymphocytic choriomeningitis virus (LCMV) 
murine model demonstrated that exhaustion is transcriptionally distinct from anergy, 
effector, and memory states. The mRNA expression data from this investigation revealed 
unique alterations in chemotaxis, adhesion, and migration gene expression. Additionally, 
the authors noted exhausted T-cells transcribe a distinct set of transcription factors and have 
significant deficiencies in the expression of key metabolic and bioenergetics genes [91].  
Originally it was experimentation by Zajac, Blattman [92] and Gallimore, Glithero [93] 
that first described exhaustion as a hyporesponsive state resulting from chronic antigenic 
stimulation. These studies followed work by Moskophidis, Lechner [94], which described 
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exhaustion of effector cells in immunocompetent mice following murine LCMV infection. The 
authors of these studies observed that prolonged antigenic stimulation during LCMV 
infection resulted in the deletion of anti-viral T-cells with remaining anti-viral T-cells 
demonstrating drastically reduced effector functions.  
Exhausted cells are primarily characterised by the co-expression of multiple IRs, loss 
of effector function, and decreased proliferative potential [74, 95, 96]. For example, 
exhausted cells commonly express elevated levels of PD-1, CTLA-4, TIM-3, and LAG-3 
(Figure 1.7.1). Contrasting anergy, in which unresponsiveness occurs rapidly as a result of 
TCR signalling without adequate co-stimulation, hyporesponsiveness occurs progressively 
in exhaustion [73]. In fact, the exhaustion phenotype develops in a hierarchical manner with 
IL-2 production and cytotoxic functions first to be lost. This is followed by the loss of TNF-a 
and subsequently IFN-g production (Figure 1.7.1). Interestingly, it appears as though IFN-g 
production is relatively resistant to exhaustion and loss is evident only in severe exhaustion 
[97]. Temporally, exhaustion can develop within two weeks post-infection or disease 
emergence [98]. This relatively rapid developmental timeline impedes protective intervention 
and instead forces investigations towards methods of exhaustion reversal. Indeed, 
advancements in tumour immunology have produced promising strategies to reinvigorate 
T-cell function and reverse the exhaustive state.  
 
 
Figure 1.7.1 Prototypical presentation of CD8+ T-cell exhaustion. This figure is a 
diagrammatic representation of the hierarchal progression of CD8+ T-cell exhaustion. It 
delineates phenotypical and functional changes that occur as T-cells become progressively 
more exhausted (from left to right). Additionally, this figure highlights key exogenous 
influences of T-cell exhaustion such as CD4+ T-cell help and Antigen exposure. This figure 
was adapted from [73]. Figure illustrated by Susanna Ng. 
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Certain factors that influence the development of exhaustion have been known since 
the dysfunctional state was originally observed. For example, CD4+ T-cell help is known to 
be an important variable in T-cell exhaustion (Figure 1.7.1) [92, 99, 100]. These observations 
on CD4+ help have also been demonstrated in similar experimental analysis following 
murine gammaherpesvirus infection, Friend virus, and following adoptive transfer of CMV-
specific CD8+ T-cells [101-103]. More recently, CD4+ T-cell help has been implicated in the 
early stages of exhaustion development [104]. Aside from CD4+ T-cell help, the sustained 
elevated antigen load that occurs during chronic infections or disease states has been 
identified as an integral driver of exhaustion (Figure 1.7.1) [97, 105]. Hence, repeated and 
sustained TCR/CD3 signalling appears to be a key driver of exhaustion. It is likely that 
TCR/CD3 signalling stimulates the expression of IRs which subsequently starts feedback 
loops enforcing IR expression. Additionally, IR engagement serves to initiate signalling 
cascades that lead to deeper molecular changes such as, metabolic and epigenetic 
alterations that establish the exhaustion phenotype [106-110]. In fact, the epigenetic 
landscape of exhausted T-cells is postulated to limit reinvigoration efforts of terminally 
exhausted cells [111]. Further complicating the model, experimentation has demonstrated 
that exhaustion can develop in the genetic absence of PD-1 [112]. Indicating that T-cell 
exhaustion is a complex multi-faceted process with numerous redundancies.  
 
1.8 EBV and Associated Diseases 
With a 172kb DNA genome Epstein-Barr virus (EBV) is a gamma-herpesvirus, a 
subclassification of the herpesviridae family [113]. There are approximately 130 different 
herpesviruses identified from mammal, reptile, insect, and amphibian species [114]. Major 
features of the herpesvirus family are their ability to infect lymphoid tissue or nervous tissue, 
double stranded DNA genomes, and their potential for latency [114]. EBV primarily infects 
resting B-lymphocytes; often taking the form of a latent infection persisting for the lifetime of 
the host. In fact, EBV can be found in upwards of 90% of the world’s population with primary 
infection principally occurring during youth [115, 116]. Usually EBV infection remains latent 
and asymptomatic; however, in rare circumstances the virus may induce pathogenesis. 
Commonly this occurs during the primary infection of B-cells, facilitated by complement 
receptor 2 (CD21), which induces short term B-cell proliferation [117]. Immunocompetent 
hosts successfully control acute B-cell proliferation; however, the resultant response can 
consist of up to 50% of circulating T-cells. Such large EBV-specific T-cell numbers 
subsequently gives rise to the clinical symptoms associated with infectious mononucleosis 
(IM), also known as glandular fever [113]. Succeeding primary infection, EBV infected B-
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cells progress towards a memory phenotype where they persist in latency for years. 
Periodically EBV is shed, through a poorly understood mechanism, into the saliva to infect 
new hosts [113]. In rare circumstances EBV may become reactivated and associate with 
neoplastic diseases. Indeed, given EBVs prevalence, the virus is estimated to be associated 
with approximately 1% of the global cancer burden [118]. Examples of which are burkitt’s 
lymphoma (BL), T-cell lymphoma, Hodgkin’s disease (HD), and Nasopharyngeal carcinoma 
(NPC).  
Epidemiological observations by Denis Burkitt lead him to propose a viral etiology for 
African BL. Burkitt’s hypothesis coincided with electromicroscopy performed by Epstein and 
colleagues who identified viral particles in a BL derived cell line in 1964 [119, 120]. Since 
the discovery of EBV, numerous T-cell antigens have been identified originating from both 
the latent and lytic cycles of the viral life cycle. EBV-associated malignancies can be defined 
in terms of viral antigen expression and doing so delineates three latency types.  
Malignancies of latency type I, an example of which is BL, express a restricted EBV 
antigen repertoire consisting of only EBV-encoded nuclear antigen (EBNA)-1. 
Phenotypically the cells under infection demonstrate resting cellular qualities [121]. Due to 
the restricted viral expression, malignancies of latency type I are highly non-immunogenic 
and poorly recognised by EBV-specific CD8+ T-cells [122]. NPC and HD are two 
malignancies that demonstrate latency type II viral antigen expression. Latency type II is 
defined by expression of only EBNA1 and the two latent membrane proteins (LMP) 1 and 2 
[121]. Finally, malignancies of latency type III classification express the full complement of 
EBV-latent antigens. This includes LMP1, LMP2, EBNA1, EBNA2, and the immunodominant 
EBNA3, EBNA4, and EBNA6 antigens. An example of a latency type III malignancy is post-
transplant lymphoproliferative disease (PTLD)—a disease that arises from uncontrolled 
EBV-infected B-cell proliferation. To prevent transplant rejection, transplantation often 
occurs with concurrent immunosuppressive treatment. The immunosuppressive treatment 
is widely accepted as a major risk factor for PTLD development. Hence, the severity and 
relative risk of presenting with PTLD is highly associated with the immunosuppression given. 
Additionally, the patients EBV status prior to transplantation serves as a good indicator of 
relative risk. For instance, EBV seronegative recipients carry a higher risk of PTLD than EBV 
seropositive recipients, given that most donor samples are from EBV seropositive patients 
[123]. 
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1.9 Cancer treatment 
Chronic disease and infection represent considerable global health burdens affecting both 
developed and developing nations alike. For example, cancer is one of the largest public 
health issues with recent estimates attributing 1/4th of deaths in the United States of America 
(USA) to the disease [124]. A similar story is echoed in Australia where cancer is a major 
cause of illness surpassed only by cardiovascular disease [125]. The figures of cancer 
incidence are staggering with males and females having a 1 in 2 or 1 in 3 risk of diagnosis 
before age 85, respectively [125]. Treatment options and prognosis for cancer have 
improved in recent years given our increasing understanding of both disease biology and 
technological advancements. An example of which is the advent of rapid next generation 
sequencing technologies, which has facilitated the identification of numerous disease 
promoting genetic variants. Identification of genetic risk variants provides useful information 
for determining prognosis and assessing patient risks; furthermore, identification serves as 
the starting point for understanding disease biology at a functional level. On this front, 
numerous technological advancements have aided in furthering researchers’ 
understandings of cancer pathology. A notable example would be the recent 
CRISPER/Cas9 technology for gene manipulation. These technological advancements and 
sustained effort in understanding basic disease biology with a focus on clinical translation 
have led to a number of novel cancer therapeutics.  
Four broad categories of cancer treatment can be defined, surgical, non-specific, 
small molecule inhibitors, and immunotherapies. Surgical intervention is often employed and 
remains a principle cancer treatment option for macro-neoplasms. Despite surgery offering 
great patient benefit, frequently mechanical intervention is not feasible. Take for example 
late stage metastatic disease where micro-tumours are systemically disseminated. Hence, 
surgery offers the ability to lessen tumour burden but does not provide a practical stand-
alone treatment option. Current standard of care therefore, couples surgery with non-
specific therapeutics such as chemotherapy or radiotherapy. These treatment options are 
considered non-specific as they broadly attack tissue and/or proliferation as a marker for 
disease. Hence, these treatments are riddled with side effects that may themselves 
ultimately contribute to the demise of patients. It is therefore, quite unfortunate that these 
treatment options are still a staple of cancer therapy despite our increased understanding of 
disease biology. Small molecule inhibitors on the other hand are more targeted and exploit 
fundamental aspects of cancer biology.  
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1.9.1 Small molecule inhibitors 
Small molecule inhibitors are epitomised by mitogen-activated protein kinase (MAPK) 
pathway inhibitors, a pathway which is often dysregulated in malignancy. Notably, BRAF 
inhibitors (BRAFi) have shown significant improvements in late stage metastatic melanoma 
patients across copious clinical trials [126, 127]. Despite enhancements in patient outcome 
criteria, BRAFi are associated with a myriad of side effects. Side effects arise from limited 
specificity, as the pathways targeted are often ubiquitous cellular signalling pathways [128, 
129]. Although the inhibitors are designed or selected for specific interaction with only 
aberrant pathway variants there is inevitably leakage and side effects ensue. Although 
arguably the greatest challenge that impedes BRAFi is the emergence of drug resistance 
and subsequent relapse [129]. Additionally, these drugs battle a significant delivery 
conundrum. The most efficacious delivery methodology being direct injection into a tumour 
mass; however, this has limited feasibility with late stage metastatic disease. Hence, a 
systemic delivery mechanism is required, which subsequently increases the potential of 
undesired toxicities and heightens dose requirements.  
 
1.10 Immunotherapy 
Chronic diseases such as cancer have classically been treated with non-specific therapies 
such as surgical resection, radio-, and chemotherapy. Being non-specific both radio- and 
chemotherapy are rife with side effects. Unfortunately, these treatments currently represent 
the standard treatment for most cancer types. This does not accurately reflect our ever-
increasing knowledge of disease pathology and physiology. Hence, modern medicine is 
largely focused on immunotherapeutics as an approach to treat chronic disease—with the 
aim to harness the immune system’s ability to provide durable, systemic and potent anti-
tumour responses.  
Broadly, immunotherapy can either act upon endogenous leukocytes and/or 
pathways or alternatively, via in vitro methodologies, provide renewed and/or expanded 
leukocytes. Examples of the former include early immunotherapeutic iterations such as IL-
2 infusion and more recently, immune-checkpoint blockade [130-132]. The latter 
immunotherapy modality represents the field of cellular immunotherapeutics. These include 
adoptive T-cell transfer (ACT), which supplement the endogenous tumour-specific T-cell 
population via in vitro expansion and subsequent reinfusion. Both immunotherapy modalities 
experience their own unique challenges and benefits. 
 
 
18 
 
1.10.1 Checkpoint-blockade immunotherapy 
Immunotherapy blocking IRs has propelled the field into the public space by achieving 
promising results with limited adverse events. IR blockade utilises the dogma that IRs in 
healthy patients are involved in peripheral tolerance and preventing immunopathology. 
However, within a chronic disease setting IRs facilitate immune escape and evasion. Hence, 
blocking signalling via these pathways may reinvigorate natural immunity and prevent 
immune escape. Supporting this notion is the observation by Gros, Robbins [133] that IR 
expression is so strongly associated with anti-tumour CD8+ T-cells that it can be used as an 
accurate marker for tumour reactive cells. Indeed, early immunotherapy studies utilised 
murine models and showed that inhibition of IR signalling could enhance anti-tumour 
immunity. These investigations are exemplified by anti-CTLA-4 and anti-PD-1 mAb 
treatment (Figure 1.10.1.1). For example, Hurwitz, Foster [134] showed that CTLA-4 
blockade resulted in significantly lower tumour incidence—15% versus 75% in control 
mice—in transgenic prostate cancer mice.  
 
 
Figure 1.10.1.1 Checkpoint-blockade immunotherapy. Diagram shows the central 
concept of checkpoint-blockade immunotherapy with anti-PD-1 (Left) or anti-CTLA4 (Right). 
Figure illustrated by Susanna Ng. 
 
Unfortunately, as revealed by Mokyr, Kalinichenko [135], CTLA-4 blockade alone is 
not always sufficient to enhance anti-tumour immunity. In their model Mokyr and colleagues 
found that additional treatment with a chemotherapeutic was required. The authors 
suggested that their sub-therapeutic dose of chemotherapy augmented anti-CTLA-4 
treatment by increasing the immunogenicity of target tissue. This observation highlights a 
critical consideration for immunotherapy, namely that IR blockade will only prove efficacious 
if the tumour is immunogenic. This notion is supported by investigations by Demaria, 
Kawashima [136] in which the poorly immunogenic murine breast cancer 4T1 was 
unaffected by anti-CTLA-4 treatment. However, when anti-CTLA-4 treatment was combined 
with local ionising radiation therapy a significant survival advantage was observed. 
Combining IR blockade with additional immunotherapy approaches has produced promising 
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clinical results in human trials. For example, in a phase I/II trial of anti-CTLA-4 Ab treatment 
in combination with immune stimulation via IL-2 in metastatic melanoma patients, 22% (n = 
8) experienced objective tumour responses [137]. Similar results have been obtained using 
melanoma-associated antigens in conjunction with anti-CTLA-4 Ab treatment [138]. 
Investigations by Yuan, Gnjatic [139] show that anti-CTLA-4 treatment works by increasing 
T-cell polyfunctionality. The authors reported that patients on anti-CTLA-4 treatment had an 
enhanced ability to produce effector molecules such as IFN-γ and TNF-α from tumour-
specific T-cell [139]. 
Despite the promising results of anti-CTLA-4 treatment, this immunotherapy 
approach has been plagued with immune-related adverse events (IAEs). For example, 
Phan, Yang [138] reported 43% of patients developed grade III/IV IAEs. Similarly, grade 
III/IV IAEs were reported in the Maker, Phan [137] study. A more recent trial performed by 
Hodi, O'Day [140] demonstrated complementary results, with the authors reporting 
improvements in survival of late stage metastatic melanoma suffers but at the cost of IAEs 
[140]. These side effects have led to increased focus on other IRs as immunotherapeutic 
targets. 
 
1.10.1.1 PD-1 checkpoint-blockade therapy 
Immunotherapies against IRs was paved by anti-CTLA-4 mAb treatment; however, lack of 
efficacy against poorly immunogenic tumours and IAEs have sidelined the therapeutic 
potential [141]. Fortunately, PD-1 blockade has provided partial reprieve from anti-CTLA-4’s 
treatment issues (Figure 1.10.1.1). Early and pioneering investigations described the 
therapeutic potential of PD-1 in viral models [68, 142, 143]. Within the cancer space, Iwai, 
Terawaki [144] employed mice to demonstrate that poorly immunogenic B16 melanoma 
showed greater control of metastasis when PD-1 was knocked out. Additionally, the authors 
measured T-cell proliferation and cytokine production and found that PD-1 deficient mice 
had greater effector functions following tumour challenge than their wild-type littermates 
[144]. These results translated into human trials; which, showed clinical benefits across a 
number of disease [145-151]. Although, anti-PD-1 therapy is better tolerated, treatment is 
not without IAEs [152-156].  
 
1.10.1.2 Novel checkpoint-blockade targets 
Aside from CTLA-4 and PD-1, several IRs have been identified and studied (Figure 
1.10.1.2.1). Given the success of anti-PD-1 treatment, research is actively exploring 
antagonists against other IRs or pathways. For example, anti-LAG-3 agonists have begun 
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early phase trials in melanoma and metastatic solid malignancies [157] (NCT02460224). 
The receptor TIM-3 is known to regulate T-cell proliferation and cytokine production [158]. 
Currently a single anti-TIM-3 antagonist is under investigation in a phase I-II trial for 
advanced malignancies (NCT02608268), results are expected mid 2019. Another 
interesting target for antagonist therapy is the T-cell immunoglobulin and ITIM domain 
(TIGIT) receptor. TIGIT has two ligands, CD155, which it shares with CD96 and CD112, 
which, it shares with CD226 [159]. This complex regulatory network has been intensively 
investigated in murine models and early phase clinical trials are underway [160-162]. 
Additionally, approaches to inhibit signalling from B and T-cell lymphocyte attenuator 
(BTLA), transforming growth factor (TGF)-β, V-domain Ig suppressor of T-cell activation 
(VISTA), CD73/A2aR, and many more, are at various stages of development [163-168].  
 
 
 
 
 
Figure 1.10.1.2.1 Immunoinhibitory and 
co-stimulatory receptors. List of 
immunoinhibitory and co-stimulatory 
receptors that have or could be targeted 
with antagonist and agonist antibodies. 
Figure illustrated by Susanna Ng 
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1.10.2 Cellular immunotherapies 
Cellular immunotherapy refers to the branch of immunotherapeutics aimed at inducing anti-
tumour immune responses via transfer of cells. Cells employed in this therapeutic modality 
can be derived from a number of sources; furthermore, they can be genetically engineered. 
Cellular immunotherapy therefore, encapsulates treatments such as ACT, chimeric antigen 
receptor T-cell (CAR-T), transgenic TCR, NK cell, and dendritic cell vaccines, just to name 
a few. CAR-T therapy is possibly the most successful variant of cellular immunotherapy. 
CAR-T therapy involves any treatment in which, a chimeric antigen receptor (CAR) is 
genetically introduced into a T-cell. The CAR element is hybrid receptor consisting of an 
extracellular antigen binding domain and intracellular signalling moieties. The extracellular 
domain is usually derived from Fab fragment of antibodies. Thus, CAR-Ts recognise 
proteins expressed on the surface of target cells, in a non-MHC restricted manner. First 
developed in 1989, CAR design has undergone many iterations [169]. Initial CAR design 
used sole CD3ζ-chain for signal transduction; however, this was subsequently found to 
produce suboptimal activation [170]. Second- and third-generation CARs added one or two 
co-stimulatory domains, respectively. A number of co-stimulatory signalling domains and 
combinations have been tested; however, research has largely focused on CD28, CD137, 
and CD134 [171].  
 CAR-T therapy has earnt its reputation through haematological malignancies. 
Namely, B-cell malignancies, which have seen complete remission rates of up to 94% [172]. 
B-cell acute lymphoblastoid leukemia has had the greatest success from CAR-T treatment 
[173-175]. Success in haematological malignancies is in part due to the easy targetability of 
disease. Majority of CAR-T designs target CD19 or similar B-cell marker. Thus, in this 
iteration the CAR-T therapy is not directed against the malignancy per se, but instead the 
cell type. This notion has hampered therapeutic transition of CAR-T to solid malignancies 
[176-179]. Although outside the scope of this thesis, a number of early phase trials have 
been performed to deploy CAR-T therapy in solid malignancies. These CAR-T constructs 
largely target tumour-associated antigens (see below for description). One such target is 
epidermal growth factor receptor and its type III variant; which, has been targeted in 
numerous malignancies. Myriad other targets such as; CD133, human epidermal growth 
factor receptors 1 and 2, erythropoietin producing hepatocellular carcinoma A2 and 
epithelial cell adhesion molecule are among those that have been trialled as antigenic 
targets for CAR-T therapy. However, these trials have largely shown sub-par results and 
thus, solid malignancies represent a significant impediment to CAR-T immunotherapy [180]. 
Therefore, haematological malignancies epitomise the therapeutic potential of CAR-T 
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immunotherapy. However, patients treated with CAR-T immunotherapy for haematological 
malignancies are at risk of cytokine-release syndrome (CRS) and other IAEs. Therefore, 
these side-effects present a significant safety hurdle that must be overcome for CAR-T 
immunotherapy to progress within the clinic [181, 182].  
 
1.10.3 Tumour antigens 
A challenge faced by immunotherapy is the identification of viable tumour-specific targets. 
Two broad classes of tumour antigens have been defined. Tumour-associated antigens 
(TAAs) and tumour-specific antigens (TSA), also known as neoantigens. TAAs are peptides 
derived from normal proteins, which are dysregulated within a malignancy. For example, 
numerous proteins are up-regulated in malignant cells and as a consequence immune 
presentation of these healthy proteins is increased [183]. Alternatively, proteins such as the 
cancer/testis antigens, which display stringent tissue restriction, can be aberrantly 
expressed in a number of malignancies [184]. Hence, immunotherapies are able to target 
TAAs as a marker for disease through either increased presentation or atypical tissue 
expression. TAAs have demonstrated to be effective in directing immunotherapeutic 
treatments; however, their limited specificity is associated with a number of undesired 
toxicities. Although these side effects are less common in cancer/testis antigen-specific 
immunotherapies, they still have hampered clinical benefit. Thus, TSAs or neoantigens, 
which have increased tumour-specificity, are preferred targets for immunotherapy.  
Neoantigens are peptide fragments that contain within them non-synonymous 
genetic mutations that have arisen as a product of malignancy. In fact, investigations by 
Lennerz, Fatho [185] has suggested that neoantigens are the dominant antigen recognised 
by anti-tumour CD8+ T-cells [186, 187]. The existence of such antigens is often correlated 
with more favourable prognosis, thus demonstrating their immunogenic benefit [188, 189]. 
Interestingly, recent analysis suggests the vast majority of neoantigens are derived from 
traditionally non-coding regions [190]. Such drastic aberrant gene expression therefore 
provides a highly targetable and tumour-specific selection of epitopes. Unfortunately, the 
specificity of neoantigens is both a positive and negative attribute, as neoantigens are 
patient and tumour specific. Hence, their patient-specificity demands individualised 
identification and production of tailored therapeutics, both of which limit experimental 
procedures. Interestingly, public neoantigens have begun to be described [191], although, 
it is unclear what role these will play in future disease treatment. Fortunately, in certain 
cancer types an additional antigenic source exists in the form of viral-derived peptides.  
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Viral peptides may be ideal immunotherapy antigens in virus-associated 
malignancies as they provide specificity without the need to identify a patient’s individual 
mutanome. EBV and cytomegalovirus (CMV) are two viruses that are highly associated with 
a number of chronic malignancies [121, 192]. Targeting EBV or CMV antigens in 
immunotherapeutic approaches may garner similar specificity as TSAs, while capitalising on 
similar benefits afforded to TAAs—namely the ubiquitous nature and hence the easy 
identification of these antigens. Indeed, promising results have been obtained from clinical 
trials exploiting EBV or CMV antigens as targets for immunotherapy [193-198]. Largely, 
these trials have demonstrated a positive safety profile with minimal adverse events. EBV 
and CMV are not the only viruses associated with malignant disease. Immunotherapy 
targeting viral-derived antigens for a number of other viruses has also shown promising 
clinical results [199-201]. Hence, there is evidence that demonstrates targeting viral-derived 
antigens is an efficacious and a safe immunotherapy option.  
 
1.10.4 Adoptive T-cell transfer 
As the name implies, Adoptive T-cell transfer (ACT) involves the therapeutic transfer of T-
cells to treat disease (Figure 1.10.4.1). ACT has been used extensively to treat malignancies 
as well as viral complications. T-cells can either be derived from TILs or via antigen-specific 
in vitro expansion. TILs are naturally enriched for tumour-antigen specific T-cells and are a 
great starting material for ACT [202]. Indeed, Steven Rosenberg pioneered ACT around 
1988 using interleukin-2 (IL-2) expansion of TILs [203-205]. These early trials failed to 
produce durable responses. It was only after lymphodepletion regimes were implemented 
that TIL-based ACT resulted in objective response rates of up to 72% in metastatic 
melanoma patients [206]. Subsequently, it has been shown that neoantigen-reactive T-cells 
can be found in infused TIL-derived T-cells [207-209]. This may explain why TIL-based ACT 
has underperformed in low-mutational burden tumour types; such as, breast, ovary, and 
gastrointestinal [188, 189]. An additional challenge for TIL-based ACT is the availability of 
ample tumour material. This, in part explains why melanoma has been the pioneering 
malady in TIL-based ACT.  
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As previously stated, ACT can use antigen-specific in vitro expansion to derive a 
treatment product. This approach leverages the observation that cancer antigen-specific T-
cells can be detected in peripheral blood of patients [210-212]. ACT using expanded 
antigen-specific T-cells is safe and efficacious [213-215]. However, this method of ACT is 
highly dependent on prior knowledge of a viable target. As with most cancer 
immunotherapies, target antigen can have a significant impact on adverse events and 
treatment efficacy [216]. Given the technical challenges in identifying patient-specific 
neoantigens, ACT derived from in vitro expanded cells has largely been confined to TAAs 
and TSAs. To increase tumour-specificity other approaches or targets must be considered.  
 
1.10.5 Virus-specific adoptive T-cell transfer 
Virus-associated diseases provide a good target for the development of ACT using in vitro 
expanded cells. Virus-associated malignancies express viral peptides; which, offers 
exquisite specificity without the personalised nature of neoantigens. Perhaps unsurprisingly, 
ACT against virus-associated malignancies has propelled the field. As with the development 
of TIL-based ACT, early iterations of virus-specific ACT used rudimentary protocols. Proof 
of principle came in the form of infusing unmodified donor derived T-cells to treat EBV-
associated lymphoma [217]. Thus, demonstrating the potential of ACT in the treatment of 
virus-associated malignancies. Further work, pioneered by Cliona Roony and Helen Heslop 
focused on the treatment of EBV-associated PTLD in hematopoietic stem cell transplant 
(HSCT) recipients [218]. The approach was quickly applied to a solid organ transplant (SOT) 
recipient who developed PTLD [219]. More recently, virus-specific T-cells have be used to 
treat a range of EBV-associated diseases with high tolerability and few IAEs [193, 196, 220-
228]. EBV is not unique in its association with disease. Indeed, many other viruses are 
Figure 1.10.4.1 Adoptive T-
cell therapy. A schematic 
detailing the key tenets of 
Adoptive T-cell therapy. Cells 
are acquired from the patient 
and expanded in culture 
before reinfusion. Figure 
illustrated by Susanna Ng. 
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known to cause or be associated with a range of debilitating maladies. It is estimated that 
as much as 15% of malignancies have a causative viral association [229]. 
One such virus is CMV; which, is associated with both GBM and post-transplant 
diseases—particularly in SOT patients. CMV disease in SOT patients is associated with the 
immunosuppressive treatment required to prevent graft rejection. Standard treatment 
involves anti-viral drug treatment; however, patients can develop drug-resistance. Despite 
initial safety concerns, subsequent trials using virus-specific ACT treatment for CMV disease 
were greatly tolerated, with no serious IAEs [230-232]. A phase I trial demonstrated CMV-
specific ACT was coincident with improved disease symptoms and reduced CMV DNAemia 
in 84% of patients [197]. CMV is also associated with highly aggressive GBM; which, has a 
median survival of 6 months [233, 234]. Indeed, anti-CMV ACT has shown great efficacy in 
GBM patients [194]. Similar results have been seen for virus-specific ACT treatment of BK 
virus, Human Herpesvirus 6, Adenovirus, and Human Papillomavirus maladies [199, 200, 
235-239]. 
 
1.10.6 Adoptive T-cell transfer manufacture methodologies 
Methods to manufacture T-cells for ACT therapy are varied and diverse. Currently, no 
consensus exists within the immunotherapy community as to the best approach to culture 
ACT products. This is perhaps because each method has its own unique benefits and 
disadvantages. The earliest methods to expand T-cells for therapy were largely non-specific. 
This is seen in the early ACT studies; which, used IL-2 stimulation to expand TILs [203-205]. 
However, the benefit of providing TILs with co-stimulatory signalling was realised early in 
cellular immunotherapy development [240-242]. More recently, a combination of CD3/28 co-
stimulation, provided via monoclonal antibodies, and IL-2 stimulation are routinely used 
[243-248]. Although, some groups still use IL-2 stimulation alone [249-251]. Interestingly, 
artificial APCs have also been used to expand T-cells by providing co-stimulatory signalling 
[252, 253]. 
In contrast, protocols for antigen-driven expansion of T-cells have been developed, 
and extensively used (Figure 1.10.6.1). However, these protocols are extremely varied. 
Expansion methods differ by numerous key variables; namely, antigen source, stimulation 
dose, repeated stimulation, and culture duration. Antigen source can be broken down into 
those that require explicit knowledge of stimulatory antigens and those that do not. The latter 
category includes stimulation with bulk tumour material or tumour lysate-pulsed dendritic 
cells (DC) [254]. These antigen sources are usually employed when the target antigen 
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sequence is not known or a polyclonal T-cell population is desired. Use is somewhat limited 
as they can induce non-specific T-cell clones; which, can have undesired side-effects.  
When the target antigen is explicitly known and a more targeted T-cell population is 
desired, other expansion methods are utilised. Namely, peptide-pulsed cells or genetically 
modified stimulator cells (Figure 1.10.6.1). Using peptide-pulsed cells as an antigen source, 
involves coating a cell subtype with the target antigen peptide/s. The cell subtype typically 
used is a DC; however, PBMCs and other APCs such as EBV-transformed lymphoblastoid 
cell lines (EBV-LCL) can be used [197, 231, 255-259]. Alternatively, genetic constructs can 
be used to force expression and presentation of tumour or viral antigens in APCs or PBMCs. 
For example, genetic constructs for the expression of tumour antigens can be electroporated 
into DCs and used as an antigen stimulation source [260]. More commonly, replication-
incompetent adenovirus is used as a vector to transduce the genetic element into stimulator 
cells. This method has successfully expanded specific T-cell for myriad studies [196, 197, 
226, 261].  
 
 
Figure 1.10.6.1 Different stimulation and antigen sources for T-cell expansion. This 
schematic, details three common sources of antigen used in the expansion of antigen-
specific T-cells for adoptive T-cell therapy. Figure illustrated by Susanna Ng.  
 
The expansion of virus-specific T-cells for ACT and more particularly, EBV-specific 
T-cells, has been performed by most methods previously described. Predominantly, EBV-
specific T-cells have been stimulated and expanded using peptide-pulsed cells, adenovirus 
transduced stimulator cells, and EBV-LCLs. The use of EBV-LCLs as an antigen source has 
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only briefly been discussed. However, EBV-LCLs represent a major stimulation method for 
the expansion of EBV-specific T-cells [220, 222-224, 262]. EBV-LCLs are EBV immortalised 
B-cells and thus, have APC properties. This makes EBV-LCLs a unique antigen source for 
EBV-specific T-cell expansion. Although, their utility is not limited to expansion of EBV-
specific T-cells. Indeed, EBV-LCLs represent an easily manufactured, obtainable, and 
sustainable APC source. DCs can be laborious and time costly to manufacture; hence, EBV-
LCLs have been utilised in expansion of non-EBV-specific T-cell populations [261, 263, 
264].  
 Aside from the antigen source, there is a large amount of variability in the stimulation 
dose and regime used in expanding T-cells for ACT. For example, virus-specific T-cells were 
previously expanded using multiple stimulations with initial responder to stimulator (R:S) 
ratios of between 25:1 and 40:1 [219, 265]. More recently, virus-specific T-cells have been 
expanded using a single-stimulation with a R:S ratio of 2:1 [226, 231, 255]. Whereas, other 
groups use a varied stimulation regime with multiple-stimulations ranging from a R:S ratio 
of 40:1 to 4:1 [196, 220, 222, 266]. Further still, HIV-specific T-cells have been expanded 
using an initial R:S ratio of 10:1 followed by multiple stimulations at a 4:1 ratio [267, 268]. 
This highlights some of the variability in expansion protocols currently employed in the 
manufacture of virus-specific T-cells. The ultimate impact this has on in vivo T-cell efficacy 
and clinical outcomes is poorly understood. It is known that elevated antigen dose can drive 
T-cells towards a dysfunctional state [105, 269]. Additionally, extended culture can push a 
terminal effector phenotype; which, is known to have poor in vivo persistence [270]. 
Therefore, the expansion protocol used in the manufacture of ACT products is a critical and 
underappreciated aspect of immunotherapy development.  
 
1.10.7 Allogeneic immunotherapy 
Autologous therapy is ideal with regards to the potential for graft-versus-host disease 
(GvHD) and product rejection [271]. Although the autologous modality sacrifices scalability, 
deployment time, and is simply not feasibly for a subset of patients [272]. Most notably, 
autologous ACT is reliant upon the existence of a memory T-cell population in either the 
tumour infiltrate or in the peripheral blood. Quite evidently, there is a subset of patients 
whose tumour is not accessible and thus, not amendable to TIL-based immunotherapy. 
Further, a large subset of patients eligible for immunotherapeutic intervention are heavily 
immunosuppressed. A cellular product may therefore be a challenge to produce and further 
still, the resultant product may be sub-optimal due to the immunosuppressive pre-treatment. 
Additional, challenges confront patients of primary infection or those who suffer from genetic 
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immunodeficiency [273, 274]. These patients are not amendable to autologous 
immunotherapy and thus, a different strategy is required. 
Allogeneic T-cells therapies are an attractive therapeutic option for numerous 
reasons. One obvious benefit allogeneic T-cells have over autologous therapies is the rapid 
deployment and treatment potential [275, 276]. In theory, the largest deployment delays are 
transport logistics and patient HLA typing. Additionally, as previously mentioned, an 
autologous therapeutic approach is challenging or not viable for numerous patients, 
particularly those under immunosuppressive regimes, genetically immunocompromised, or 
suffering from primary infection. Thus, an allogeneic therapy may yield better clinical 
outcomes or be the only viable option. 
 A major concern about the use of third-party T-cells is the potential for GvHD. In 
practise, partial HLA-matched third-party T-cells have been shown by numerous groups to 
be safe, with low levels of GvHD observed [277-280]. An additional concern is the in vivo 
persistence of allogeneic T-cells. Autologous T-cells have been detected up to 9 years post-
infusion, in contrast, allogeneic T-cells have only been detected up to 90 days post-infusion 
[224, 278]. However, in vivo persistence may not be necessary for efficacious treatment. A 
number of studies have shown modest infusion engraftment while still demonstrating 
significant clinical responses [281-283]. These observations have supported development 
of allogeneic multi-virus-specific ACT products [200]. These multi-virus-specific ACT 
products have largely demonstrated great efficacy with a low incidence of IAEs or GvHD 
complications [199].  
 
1.10.8 Novel cellular immunotherapies 
Immunotherapy is developing at a profound rate, technological innovations and novel 
therapeutic modalities are constantly emerging. One such therapeutic innovation is the 
notion of switch therapy in third-party T-cell ACT. Yet to be comprehensively published, 
switch therapy leverages an allogeneic T-cell bank to maximise treatment efficacy. 
Following initial treatment, a patient’s therapy product may be switched for one of a different 
HLA-restriction. Thus, minimising the possibility of epitope escape while releasing another 
subset of epitopes to be targeted [284].  
 NK cells are quickly becoming a promising target for immunotherapeutic modulation. 
Unlike T-cells, NK cells are part of the innate immune system and therefore are not 
dependent on antigen presentation for anti-tumour function [285, 286]. A number of studies 
have highlighted the anti-tumour functions and clinical utility of NK cells [287-289]. Indeed, 
adoptive transfer of allogeneic NK cells has demonstrated safety and efficacy for this 
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immunotherapy approach [290, 291]. Furthermore, CAR NK cells have recently been 
developed and begun clinical testing. Preliminary data has been promising in terms of both 
safety and anti-tumour efficacy [292-295]. Mounting data is suggesting NK cells will play a 
larger role in the cellular immunotherapy space, moving forward.  
 
1.11  Project significance  
ACT immunotherapy is valuable therapeutic modality and has shown success across 
numerous disease types [196, 197, 222, 226, 235]. A central process within the manufacture 
of ACT immunotherapy products involves the stimulation and expansion of T-cells in vitro. 
To date, the field of ACT immunotherapy has largely employed expansion strategies that 
prioritise cell yield. This sole focus however, neglects the impact that in vitro T-cell 
stimulation and expansion has on the functional efficacy of the resultant ACT drug product. 
Existing research has demonstrated that T-cell culture conditions can have a profound effect 
on their phenotype and functional profiles [296-298].  
 The requirement for increased cell yield has driven ACT immunotherapy 
manufacturing methods towards high dose and repeated dose stimulation strategies [197, 
220, 226, 231]. However, data published more than two decades ago suggests that this may 
have a detrimental impact on T-cell quality [299]. More recently, elevated and persistent 
antigen stimulation has been heavily implicated in the development of T-cell exhaustion [73, 
269]. In vivo experimentation has further demonstrated the effects of stimulation dose on 
vaccine responses [300, 301]. These data therefore suggest that the choice of in vitro T-cell 
stimulation and expansion method used in ACT drug product manufacture is important. More 
specifically, this study aims to contribute to the growing evidence ACT drug product quality 
is influenced by the stimulation and expansion method used. This study aims to characterize 
the transcriptional and protein level changes driven by various ACT drug product 
manufacturing strategies. Additionally, this study aims to investigate the impact ACT drug 
product manufacture has upon the resultant TCR repertoire.  
Comprehensive analysis employed within this project is seldom performed within the 
ACT immunotherapy field. It is envisioned that data acquired will demonstrate the validity of 
such detailed ACT drug product assessment. Furthermore, analytical methods described 
within this study will help refine the metrics of importance in determining ACT drug product 
quality. Therefore, data acquired during the course of this project can establish a precedent 
for comprehensive ACT drug product assessment. Routine acquisition of such data will 
serve to inform ACT drug product development methods towards the production of more 
efficacious products.  
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2.0 Aim and scope of thesis 
The overall aim of this PhD project was to investigate the impact different expansion 
strategies have upon a T-cell drug product. Information which can subsequently be used to 
improve manufacturing strategies in T-cell immunotherapy.  
 
2.1 Hypothesis 
The functional and molecular profile of in vitro expanded T-cells for adoptive immunotherapy 
is significantly determined by the strategies used for their stimulation and expansion.  
 
2.2 Aims 
• To assess the impact of antigen stimulation dose and strategy on in vitro expansion 
of CD4+ and CD8+ T-cells 
• To assess impact of antigen stimulation dose and strategy on in vitro functional and 
phenotypic profile of expanded T-cells 
• To assess the impact of antigen stimulation dose and strategy on the molecular 
profile of expanded T-cells 
• To assess the impact of antigen stimulation dose on the T-cell receptor repertoire 
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3.0 Materials and methods 
3.1 List of equipment 
Table 3.1.1 List of equipment 
DESCRIPTION COMPANY 
Autoclave, Tomy ES-315 Tomy,  
Katsushika, Tokyo, Japan 
Bench top centrifuge, Sigma D-37520 Sigma-Aldrich,  
St.Louis, MO, U.S.A 
Biosafety cabinet  Thermo Fisher Scientific,  
Waltham, MA, U.S.A 
Cell counting microscope, Olympus, CX41 Olympus,  
Shinjuku, Tokyo, Japan 
CO2 incubator-Steri-Cult 200 Thermo Fisher Scientific 
Cryo 1°C freezing container Nalgene, NalgeNunc,  
Rochester, NY, U.S.A 
Dry Block heater, Ratek DBH10 Ratek Instruments,  
Melbourne, VIC, Australia 
FACS ARIA III cell sorter – 70μm nosel  Becton Dickinson,  
Franklin Lakes, NJ, U.S.A 
Flow Cytometer, FACS LSR fortessa Becton Dickinson 
Freezer -80°C Thermo Fisher Scientific 
Haemocytometer Hausser Scientific,  
Horsham, PA, U.S.A 
Haemocytometer coverslips Menzel-Glaser,  
Menzel, Germany 
Inverted microscope, Olympus CK40 Olympus 
Microcentrifuge, Eppendorf 5415D Eppendorf,  
Hamburg, Germany 
Milli-Q water supply MiliporeSigma,  
Burlington, MA, U.S.A 
Vortex mixer Ratek Instruments 
Water bath Grant Instruments,  
Shepreth, Royston, UK 
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3.1 Venepuncture 
Venepuncture was performed by trained and certified phlebotomists using a 21G 
Vacutainer® Safety-Lok™ blood collection set (Becton Dickinson, Franklin Lakes, NJ, 
U.S.A, catalogue (cat)# 367282). Blood was collected into 9ml sodium heparin 
VACUETTE® Greiner Bio-One tubes (Interpath, VIC, Australia, cat# 455051).  
 
3.1 Donor screening 
HLA typing: Sample containing >5μg of gDNA at 50ng/μl was sent to Beijing Genomics 
Institute (Yantian District, Shenzhen, China) for HLA class I typing on locus A, B, and C.  
 
EBV serology: Serology was performed by collecting 5ml of whole blood in VACUETTE® 
Z Serum Separator Clot Activator tubes (Interpath, cat# 456071). Samples were left for 30–
60 minutes at room temperature to allow clot formation. Subsequently, tubes were 
centrifuged at room temperature at 1,000g for 10 minutes. Samples were then submitted to 
Pathology Queensland (Herston, Australia) for EBV serology profiling. 
 
3.1 Peripheral blood mononuclear cells isolation 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from healthy donor blood by 
initially diluting blood 1:2 with Roswell Park Memorial Institute 1640 (RPMI; Media services, 
QIMR Berghofer Medical Research Institute (QIMRB), Herston, QLD, Australia) and 
overlaying diluted mixture on 10ml of Ficoll-Hypaque (Sigma-Aldrich, St.Louis, MO, U.S.A). 
Blood was separated via centrifugation at 450g for 30 minutes with acceleration = 2 and 
deceleration = 1. The buffy coat was harvested using a transfer pipette and washed with 
RPMI using a 400g for 10 minutes centrifugation. Supernatant was discarded and cells 
washed once more with RPMI using a 400g for 5 minutes centrifugation (wash spin). 
Supernatant was discarded and cells washed with RPMI with 10% heat-inactivated (56°C 
for 60 min) foetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, U.S.A) using 
a wash spin. Supernatant was discarded and cells were resuspended in RPMI with 10% 
FBS for haemocytometer counting. 
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3.1 Haemocytometer cell count 
Sample was diluted in an appropriate volume of 0.4% Trypan blue (ICN Biochemicals, NSW, 
Australia). From this, 10μl was applied to a bright line haemocytometer (Hausser Scientific, 
Horsham, PA, U.S.A) and viewed using an inverted light microscope (Olympus CK41, 
Shinjuku, Tokyo, Japan) at 100X magnification. 
 
3.2 EBV stocks 
EBV stocks were prepared for both B95.8 and Wil virus strains as follows. Relevant B-cell 
line was cultured and expanded to desired volume. Once culture volume was achieved cells 
were left for approx. 1 week without feeding to allow high density and lytic cycle induction. 
Cells were harvested and pelleted using a 335g for 15 minutes centrifugation. Supernatant 
was discarded leaving ~10ml above cell pellet. This supernatant was transferred and stored 
at 4°C. Remaining cell pellets were pooled and flash frozen by rapid agitation in a dry ice 
slurry. Dry ice slurry was created by filling a 500ml plastic beaker with 300ml of dry ice and 
mixing in 100ml absolute ethanol (Sigma-Aldrich) until a slushy-like consistency is reached. 
Once frozen, tube was thawed by rapid agitation in a 37°C water bath. Freeze-thaw cycle 
was repeated for a total of up to 3 cycles. Lysed cells were centrifuged at 335g for 10 mins 
at 4°C. Lysate supernatant was combined with previously harvested cell free supernatant 
and aliquoted for immediate storage in liquid nitrogen.  
 
3.3 Lymphoblastoid cell line generation 
EBV lymphoblastoid cell lines (EBV-LCLs) were generated by infecting 2–5e6 PBMCs in 
500μl RPMI with 500μl RPMI containing 100–500 infectious units of EBV Wil or B95.9 strain, 
for 1 hour at 37°C with a 5% CO2 atmosphere. Following incubation cells were washed with 
9ml of RPMI with 10% FBS and 2% penicillin (10,000IU/ml Penicillin, Gibco, Grand Island, 
U.S.A) and streptomycin (10,000μg/ml Streptomycin, Gibco) cocktail (R10) and centrifuged 
at 335g for 5 minutes. Supernatant was discarded and cells were resuspended in R10 with 
10μg/ml of Cyclosporin A (Sigma-Aldrich). Cells were subsequently two-fold serially diluted 
in a 24-well plate 6–8 times. Infected cells were cultured for up to 4 weeks with media 
replenished weekly with R10 Cyclosporin A media. After 4 weeks culture, the lowest dilution 
with EBV-LCL colony formation was harvested and expanded in R10.  
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3.4 Cell culture 
Human cells were cultured in Roswell Park Memorial Institute 1640 (RPMI, QIMRB) medium 
supplemented with 10% heat-inactivated (56°C for 60 min) foetal bovine serum (FBS, 
Thermo Fisher Scientific) and 2% penicillin and streptomycin (Penstrep) cocktail 
(10,000IU/ml Penicillin and 10,000μg/ml Streptomycin from Gibco) referred to as R10 media 
solution. Cells were cultured in an incubator at 37°C with a 5% CO2 atmosphere.  
Cell freezing medium consisted of RPMI 1640 supplemented with 10% FBS, 2% Penstrep, 
and 10% Dimethyl sulfoxide (DMSO, Sigma-Aldrich). 
 
3.5 Quality control 
Short tandem repeat (STR) profiling: STR profiling was performed by the DNA 
Sequencing and Genotyping facility at QIMRB. 
 
Mycoplasma testing: Media was aspirated and centrifuged at 650g for 5 mins. Cell free 
supernatant (1ml) was sent to Media services at QIMRB for mycoplasma testing via a 
luciferase bioluminescence assay (MycoAlert™ mycoplasma detection kit by Lonza, Basel, 
Switzerland). Results were reported electronically as a test certificate.  
 
3.6 Cell sorting 
Cell sorting was performed using markers Cell Trace™ Violet, LIVE/DEAD™ Fixable Near-
IR, anti-CD3 APC, anti-CD4 AF700, anti-CD8 PerCP-Cy5.5, and anti-CD19 PE-Cy5 (See 
table 4.2.6.1). Cells were stained for surface markers and filtered through a 40μm filter 
(Corning®, NY, U.S.A) and resuspended in Phosphate-buffered saline (PBS) at 
approximately 10–20e6 cells/ml. Cells were then sorted using a 70μm nosel on a FACS Aria 
IIIu (Becton Dickinson). 
 
3.7 Human ethics 
Studies on the healthy volunteers were approved by the Human research ethics committee 
at QIMRB under ethics approval numbers P1210 and P2282. All study participates provided 
written consent for sample usage.  
 
3.8 Statistics 
GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, U.S.A). 
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3.9 Computer specifications 
Majority of analysis was performed on a late 2013 iMac running macOS High Sierra (Version 
10.13.4) with 3.1 GHz Intel Core i7 processor, 16GB 1600 MHz DDR3 RAM module, and a 
NVIDIA GeForce GT 750M 1024 MB graphics card. 
 
3.10 R analysis 
R version 3.4.3 “Kite-Eating Tree” or newer was used for analysis [302]. Run within RStudio 
version 1.1.423 IDE or newer [303]. See table 3.10.1 for packages used in analysis. 
 
Table 3.10.1 R packages used 
Package Reference 
alakazam Gupta, Vander Heiden [304] 
ape Paradis, Claude [305], Paradis and Schliep 
[306], Popescu, Huber [307] 
calibrate Graffelman [308] 
cluster Maechler [309] 
corrplot Wei and Simko [310] 
edgeR Robinson, McCarthy [311], McCarthy, Chen 
[312] 
Factoextra Kassambara and Mundt [313] 
FactoMineR Le, Josse [314] 
dplyr Wickham, Francois [315] 
plyr Wickham [316] 
gplots R. Warnes, Bolker [317] 
ggplot2 Wickham [318] 
PerformanceAnalytics Peterson and Carl [319] 
Hmisc Harrell Jr and Dupont [320] 
knitr Xie [321], Xie [322], Xie [323] 
RColorBrewer Neuwirth [324] 
sjPlot Lüdecke [325] 
TCGAbiolinks Colaprico, Silva [326] 
List of R packages used for analysis 
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3.11 Additional software 
Thesis was written using Microsoft® office 365 Version 16.11 (Microsoft Corporation, 
Redmond, WA, USA) and Endnote X8.2 (Clarivate Analytics, Philadelphia, PA, U.S.A). 
Figures compiled using Adobe illustrator Creative Cloud 2017, Version 21.1.0 (Adobe 
Systems, San Jose, CA, U.S.A). Cytoscape version 3.4.0 was used for network visualisation 
[327].  
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4.0 Impact of antigen stimulation dose and source on in vitro 
expansion of CD4+ and CD8+ T-cells for adoptive 
immunotherapy 
4.1 Introduction 
Immunotherapeutic intervention is poised to become the modern standard of care for 
numerous maladies. ACT represents a particularly promising modality of immunotherapy. 
Myriad trials have shown clinical benefit from patients accessing ACT immunotherapy, for 
both viral and non-viral associated malignancies [193, 194, 197, 206, 207, 218, 223, 226, 
232, 328]. A central tenet of ACT is the in vitro T-cell stimulation and expansion steps. 
Currently, numerous stimulation and expansion methods are used; however, focus and 
assessment of viable expansion protocols is largely focused on the ability to generate 
sufficient cell yield. This focus is driven in part due to research that has demonstrated that 
the number of cells transferred in ACT strongly correlates with the magnitude of in vivo 
tumour regression [329-331]. Furthermore, a large cell yield is critical as ACT 
immunotherapy progresses towards third-party (allogeneic) treatment [199, 332-334]. 
However, this focus on cell yield has neglected the important role that stimulation and 
expansion plays in shaping a T-cells therapeutic potential. Research has demonstrated that 
culture conditions can significantly alter a T-cells function, differentiation, and ultimately 
therapeutic potential [105, 296, 300, 335]. Furthermore, comprehensive analysis of an ACT 
drug product is rarely performed. Instead, researchers rely on basic phenotyping and 
function assessment to gauge ACT drug product quality. 
 Commonly, one or a combination of EBV-transformed lymphoblastoid cell (EBV-
LCLs), peptide-pulsed APCs, or adenoviral vector-infected APCs, are employed to stimulate 
and expand antigen-specific cells to generate an ACT drug product [194, 222-224, 226, 231, 
262]. Given the requirement for large cell yield, frequently these stimulation methods are 
applied at a high dose to ensure maximum stimulation and drive the greatest proliferation 
[226, 231, 255]. Indeed, often multiple rounds of stimulation are used to maintain 
proliferation and promote a large cell yield [196, 220, 222, 266]. However, minimal ACT drug 
product assessment and research has elucidated how the ACT manufacturing method 
impacts final drug product quality [299, 336]. Given the importance ACT immunotherapy will 
play in future disease management, we thought it prudent to revisit this central and 
overlooked aspect of ACT drug product development. Furthermore, our investigations serve 
to demonstrate the significance of comprehensive ACT drug product assessment.  
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4.2 Material and Methods 
4.2.1 AdE1-LMPpoly vector 
The AdE1-LMPpoly vector (herein referred to as AdE1-LMPpoly) used within this thesis has 
been previously described [193, 337]. In brief, the AdE1-LMPpoly vector contains 39 HLA-
restricted LMP1&2, and EBNA1 epitopes (Table 4.2.1) [228]. The AdE1-LMPpoly vector was 
created on the Ad5/F35 backbone as described in Yotnda, Onishi [338].   
 
Table 4.2.1 List of EBV epitopes found in AdE1-LMPpoly vector 
Epitope HLA Restriction Antigen Amino acid 
position 
PYLFWLAAI HLA-A*23:01 
HLA-A*24:02/03 
LMP2 131–139 
SSCSSCPLSKI HLA-A*11:01 LMP2 340–350 
TYGPVFMCL HLA-A*24:02 
HLA-A*23:01 
LMP2 419–427 
RRRWRRLTV HLA-
B*27:02/04/05/06/09 
LMP2 117–125 
LLSAWILTA HLA-A*02:03 LMP2 328–336 
LTAGFLIFL HLA-A*02:06 LMP2 334–342 
CLGGLLTMV HLA-A*02:01 LMP2 426–434 
VMSNTLLSAW HLA-A*25 
HLA-A*26 
LMP2 323–332 
MSNTLLSAW HLA-B*58 LMP2 324–332 
IEDPPFNSL HLA-B*40:01 LMP2 200-208 
YLLEMLWRL  HLA-A*02:01 LMP1 125–133 
YLQQNWWTL HLA-A*02:01 LMP1 159–167 
ALLVLYSFA HLA-A*02:01 LMP1 51–59 
IALYLQQNW HLA-B*57 
HLA-B*58 
LMP1 156–164 
FLYALALLL HLA-A*02:01 LMP2 356–364 
CPLSKILL HLA-B*08:01 LMP2 226–233 
HPVGEADYFEY HLA-B*35 EBNA1 407–417 
RPQKRPSCIGC HLA-B*07:02 EBNA1 72–85 
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IPQCRLTPL HLA-B*07:02 EBNA1 528–536 
LSRLPFGMA HLA-B*57:01 EBNA1 536–544 
YNLRRGTAL HLA-B*08:01 EBNA1 518–526 
VLKDAIKDL HLA-A*02:03 EBNA1 574–582 
FVYGGSKTSL Cw3 EBNA1 508–517 
FVYGGSKTSLY HLA-A*26 EBNA1 508–518 
LQTHIFAEV HLA-A*02:06 EBNA1 566–574 
HPVGEADYF HLA-B*53 EBNA1 407–415 
FMVFLQTHI HLA-A*02:01 EBNA1 562–570 
YNLRRGTALAIPQ HLA-DP3 EBNA1 518–530 
VFLQTHIFAEVLKDAIKDL HLA-DP5 EBNA1 564–582 
PPWFPPMVEGAAA HLA-DQ2 EBNA1 607–619 
IAEGLRALLARSHVERTTDE HLA-DQ2/3 EBNA1 481–500 
ENIAEGLRVLLARSHVERTT HLA-DQ7 EBNA1 479–498 
TSLYNLRRGTALAI HLA-DR1 EBNA1 515–528 
PGPLRESIVCYFMVFLQTHI HLA-DR1 EBNA1 551–570 
VYGGSKTSLYNLRRGTALAI HLA-DR11 EBNA1 509–528 
YFMVFLQTHIFAE HLA-DR11/12/13 EBNA1 561–573 
AIPQCRLTPLSRLPF HLA-DR13 EBNA1 527–541 
PQCRLTPLSRLPFGM HLA-DR14 EBNA1 529–543 
MVFLQTHIFAEVLKD HLA-DR15 EBNA1 563–577 
List of the 39 EBV epitopes found within AdE1-LMPpoly vector and the associated HLA 
restriction 
 
4.2.2 EBV-Pepmix 
EBV-Pepmix refers to a custom peptide pool (JPT Peptide Technologies, Berlin, Germany) 
of 22 EBV epitopes derived from LMP1&2 and EBNA restricted to HLA-I and HLA-II (Table 
4.2.2) 
 
Table 4.2.2 List of EBV epitopes found in EBV-Pepmix 
Epitope HLA Restriction Antigen Amino acid 
position 
CLGGLLTMV HLA-A*02:01 LMP2 426–434 
YLQQNWWTL HLA-A*02:01 LMP1 159–167 
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FLYALALLL HLA-A*02:01 LMP2 356–364 
SSCSSCPLSKI HLA-A*11:01 LMP2 340–350 
AVFDRKSDAK HLA-A*11:01 EBNA3B 399–408 
PYLFWLAAI HLA-A*23:01 
HLA-A*24:02 
HLA-A*23:02 
LMP2 131–139 
TYGPVFMCL HLA-A*24:02 LMP2 419–427 
VMSNTLLSAW HLA-A*25:01 
HLA-B*58:01 
LMP2 323–332 
FVYGGSKTSLY HLA-A*26:01 
HLA-A*68:02 
HLA-C*03:03 
HLA-C*03:04 
EBNA1 508–518 
RPPIFIRRL HLA-B*07:02 EBNA3A 379–387 
SPQPRAPIRPI HLA-B*07:02 EBNA3C 879–889 
FLRGRAYGL HLA-B*08:01 EBNA3A 325–333 
RRIYDLIEL HLA-B*27:02 
HLA-B*27:04 
HLA-B*27:05 
EBNA3C 258–266 
RRRWRRLTV HLA-B*27:02 
HLA-B*27:04 
HLA-B*27:05 
HLA- B*27:06 
HLA-B*27:09 
LMP2 117–125 
YPLHEQHGM HLA-B*35:01 
HLA-B*35:02 
HLA-B*35:03 
EBNA3A 458–466 
HPVGEADYFEY HLA-B*35:01 
HLA-B*35:08 
EBNA1 407–417 
IEDPPFNSL HLA-B*40:01 LMP2 200–208 
VEITPYKPTW HLA-B*44:02 EBNA3B 657–666 
EENLLDFVRF HLA-B*44:02 
HLA-B*44:03 
HLA-B*44:05 
EBNA3C 281–290 
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EGGVGWRHW HLA-B*44:03 EBNA3C 163–171 
VSFIEFVGW HLA-B*57:01 
HLA-B*58:01 
EBNA3B 279–287 
PRSPTVFYNIPPMPLPPSQL HLA-DR52/DQ2/7, DR7 EBNA2 276–295 
List of the 22 EBV epitopes found within EBV-Pepmix and the associated HLA restriction 
 
4.2.3 Expansion of EBV-specific T-cells 
T-cell cultures were generated using the following protocol. Healthy EBV-seropositive donor 
PBMC was thawed from liquid nitrogen storage and rested for at least 1 hour in R10 media 
with 1μl DNAse (Sigma-Aldrich). PBMCs were subsequently counted and plated at 2e6 
cells/well in a 24-well plate—unless a large cell number was required, in which case G-Rex® 
culture vessels were used as outlined in section 4.2.4. Plated PBMCs were then stimulated 
with 2:1, 25:1, 50:1, or 100:1 (Responder:Stimulator ratio) of autologous irradiated (80Gy) 
EBV-LCLs, irradiated (25Gy) EBV-Pepmix-pulsed stimulator cells, or irradiated (25Gy) 
AdE1-LMPpoly infected stimulator cells. Stimulator cells for EBV-Pepmix- or AdE1-
LMPpoly-based treatments were generated via incubation of PBMCs for 1 hour at 37°C with 
1μg/ml or 10pfu/cell of EBV-Pepmix or AdE1-LMPpoly vector, respectively. For cultures 
intended to extend beyond 10 days IL-2 (Charles River Laboratories, Wilmington, MA, 
U.S.A) was added to culture media from the second day of culture at a concentration of 
120IU/ml. Subsequently, IL-2 media was replenished on days 5, 8, 11, 14, 17, and 20 of 
culture.  
 
4.2.4 G-Rex® density splitting  
For some experiment’s cells were cultured in G-Rex® culture vessels (Wilson Wolf 
Manufacturing, St Paul MN, U.S.A). With culture progressing via density splitting regime as 
presented in table 4.2.4.1. 
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Table 4.2.4.1 G-Rex® density splitting regime 
Timepoint 
(Days) 
Density 
(cells/cm2) 
Day 0 ~2e6  
Day 8 ~2e6 
Day 11 ~2e6 
Day 14 ~2.5e6 
Day 17 ~2e6 
Cultures were split based on heamocytometer counts to maintain above cellular densities at 
given timepoints. 
 
4.2.5 CellTrace™ Violet staining 
Where indicated, PBMCs were stained with CellTrace™ Violet (CTV; Thermo Fisher 
Scientific) prior to stimulation and culture. PBMCs were stained by initially washing with PBS 
and resuspension at 1e6 cells/ml in PBS. CTV stock was made by diluting reagent vial in 
20μl DMSO (5mM). PBMCs were stained with 0.2μl/ml (1μM) for 20 minutes at room 
temperature protected from light. After incubation, PBMCs were washed with R10 at 5x the 
original staining volume. PBMCs were subsequently resuspended in R10 and rested for at 
least 10 minutes in a 37°C with a 5% CO2 atmosphere incubator. 
 
4.2.6 Flow cytometry 
TBNK: At specified time points 50μl of culture was sampled and stained for 15 mins at room 
temperature with 2.5μl 6-colour TBNK reagent (Becton Dickinson), within TruCount tubes 
(Becton Dickinson). Following staining, samples were diluted in 450μl FACS fix (Becton 
Dickinson) and incubated for 15 mins at room temperature before acquisition. 
 
Surface staining: Surface staining was performed by plating approx. 5e5 cells/well into a 
96-well V-bottom plate (See table 4.2.6.1). Cells were subsequently washed twice with PBS 
containing 2% FBS (PBS2%F) and resuspended in 50μl/well of staining mix diluted in 
PBS2%F. Staining was performed at 4°C for 30 mins protected from light. Following staining, 
cells were washed twice with PBS2%F and diluted to desired concentration before 
acquisition. 
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Recall intracellular staining: Cultured cells were aliquoted into 96-well U-bottom plates at 
5e5 cells/well. Autologous EBV-LCLs were used to recall response using a responder to 
stimulator ratio of 10:1. Stimulation was performed at 37°C, 6.5% CO2 controlled incubator 
in a final volume of 200μl/well of stimulation media for 6 hours. Stimulation media consisted 
of R10 with 2μg/ml Brefeldin A (GolgiPlug Protein Transport Inhibitor; BD Pharmingen™, 
San Diego, CA, U.S.A), 2.8μg/ml Monensin (GolgiStop; BD Pharmingen™), and 50μl/ml 
anti-CD107a-FITC (Becton Dickinson). Following incubation, cells were pelleted and 
washed twice with 200μl/well of PBS2%F. Cells were subsequently stained for surface 
markers (See table 4.2.6.1) in 50μl staining volume of PBS2%F for 30 mins at 4°C. Following 
which, cells were washed twice with 200μl/well PBS2%F and incubated with 50μl/well of a 
fixation and permeabilisation solution (Cytofix/Cytoperm; BD Pharmingen™) for 20 mins at 
4°C. Cells were subsequently washed twice with 200μl/well 1X BD Pharmingen’s™ 
Perm/Wash solution and stained with intracellular antibodies (See table 4.2.6.1) diluted in 
Perm/Wash (final 50 μl/well staining volume) for 30 mins at 4°C. Stained cells were washed 
twice with 200μl/well Perm/Wash buffer and resuspended in 50–100μl/well PBS containing 
1% paraformaldehyde (Sigma Aldrich) and subsequently acquired on a BD LSRFortessa™. 
All staining was performed protected from light. 
 
Intranuclear staining: Staining was performed as outlined in intracellular staining protocol 
with deviation occurring post-surface staining. Whereby, cells were washed twice with 
200μl/well PBS2%F then resuspended in 100μl/well transcription factor permeabilisation 
buffer (Becton Dickinson) for 1 hour at 4°C. Cells were subsequently washed twice with 
200μl/well transcription factor wash buffer (Becton Dickinson) and resuspended in 50μl/well 
intracellular staining antibodies (see table 4.2.6.1) diluted in transcription factor wash buffer 
for 30 mins at 4°C. Following staining cells were washed twice with 200μl/well transcription 
factor wash buffer and resuspended in 50–100μl/well PBS containing 1% paraformaldehyde 
and subsequently acquired on a BD LSRFortessa™. All staining was performed protected 
from light. 
 
MHC-peptide multimer staining: For staining involving multimer reagents, cultured cells 
were aliquoted into 96-well U-bottom plates at 5e5 cells/well. Cells were stained for specific 
MHC-peptide multimers (see table 4.3.4.1) at 4°C for 20 mins in 50μl/well staining volume, 
using PBS2%F as diluent. Subsequently, cells were washed once with 200μl/well PBS2%F 
and stained for surface markers for 30 mins at 4°C. Intracellular or intranuclear staining was 
then performed as previously described.  
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Acquisition: BD LSRFortessa™ (special order research product) using BD FACSDiva™ 
V8.0 (Both by Becton Dickinson). Data was analysed using FlowJo v10.4.2 OSX (Tree Star, 
Inc., Ashland, OR, U.S.A) 
 
Table 4.2.6.1 List of antibodies and fluorescent markers 
Antigen Fluorochrome Clone Company Catalogue # 
CD103 FITC Ber-ACT8 BD 561677 
CD107a FITC H4A3 BD 555800 
CD14 APC-Cy7 HCD14 BL 325620 
CD160 AF488 BY55 BD 562351 
CD19 APC-Cy7 HIB19 BL 302218 
CD19 PE-Cy5 HIB19 BD 555414 
CD195 
(CCR5) 
PE eBioI21/8 eBio 12-1957 
CD223 
(LAG-3) 
PE-ef610 3DS223H eBio 61-2239-42 
CD223 
(LAG-3) 
PE - R&D FAB2319P 
CD25 
(IL2RA) 
PE 2A3 BD 341009 
CD278 BV711 DX29 BD 563833 
CD279 
(PD-1) 
BV786 EH12.1 BD 563789 
CD3 APC SK7 BD 340440 
CD3 PE-Cy7 SK7 BD 341091 
CD3 BUV395 SK7 BD 564001 
CD38 FITC HIT2 CALTAG MHCD3801 
CD39 BV711 A1 BL 328228 
CD4 AF700 RPA-T4 BD 557922 
CD4 BV786 SK3 BD 563881 
CD4 BUV496 SK3 BD 564651 
CD45R0 APC UCHL1 BD 559865 
CD45RA FITC HI100 BD 555488 
CD56 BV650 NCAM16.2 BD 564057 
CD57 Biotin HNK-1 BD 347391 
CD62L APC DREG-56 BD 559772 
CD8 AF700 RPA-T8 BD 557945 
CD8 BUV805 SK1 BD 564912 
CD8 PerCP-Cy5.5 RPA-T8 eBio 45-0088-42 
CD96 
(TACTILE) 
PE NK92.39 BL 338406 
Cell Trace™ Violet - Invitrogen C34557 
FoxP3 AF488 236A/E7 eBio 53-4777 
GATA-3 PerCP-ef710 TWAJ eBio 46-9966 
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Granzyme A FITC CB9 BD 557449 
Granzyme B AF700 GB11 BD 560213 
IFNy AF700 B27 BD 557995 
IL-10 APC JES3-19F1 BL 506804 
IL-2 PE MQ1-
17H12 
BD 554566 
LIVE/DEAD™ 
Fixable 
Near-IR - Invitrogen L10119 
Perforin PE dG9 eBio 12-9994 
PLZF AF647 R17-809 BD 563490 
Streptavidin  BV711 - BL 405241 
TIGIT PE-Cy7 MBSA43 eBio 25-9500-41 
TIGIT PerCP-ef710 MBSA43 eBio 46-9500-42 
TIM-3 PE-Cy7 F38-2E2 BL 345013 
TNF APC MAb11 BD 554514 
TNF BV605 MAb11 BD 563915 
Near-Infrared (Near-IR), Allophycocyanin (APC), Fluorescein isothiocyanate (FITC), Alexa 
Fluor (AF), Phycoerythrin (PE), Cyanine (Cy), eFluor (ef), Peridinin-chlorophyll proteins 
(PerCP), Brilliant Violet™ (BV), Brilliant™ Ultraviolet (BUV). Companies abbreviated as 
follows; BioLegend (BL), eBiosciences (eBio), Becton Dickinson (BD), R&D Systems (R&D). 
Catalogue number (Catalogue #). 
 
4.2.7 t-Distributed stochastic neighbor embedding 
Unless otherwise stated, t-Distributed stochastic neighbor embedding (tSNE) was 
performed following linage gating by first downsampling and concatenating samples to give 
a final event count of ~200,000. Clustering parameters were as follows; iterations = 1,000, 
perplexity = 30, Eta = 200, Theta = 0.5. All tSNE clustering performed using Flowjo software 
plugins.  
 
4.2.8 Metabolism assays 
qPCR array: Preliminary analysis of mitochondrial metabolism was assayed with the RT2 
Profiler PCR Array for Human Mitochondrial Energy Metabolism Cat. No. 330231 PAHS-
008ZA (QIAGEN®, Hilden, Germany) kit using ~250ng input RNA (see section 5.2.1), as 
per manufactures instructions. 
 
Seahorse assays: Mitochondrial metabolism was assayed using both the Agilent Seahorse 
XFp Cell Energy Phenotype kit (cat# 103275-100) and the Agilent Seahorse XF Glycolysis 
Stress Test Kit (cat# 103020-100, Agilent Technologies, Santa Clara, CA, U.S.A). Both kits 
were used as per manufactures instructions and defaults. In brief, cells were cultured and 
sorted using Dynabeads® Untouched™ Human CD8 T-cell kit (Invitrogen, Carlsbad, CA, 
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U.S.A, cat# 11348D) as per manufactures instructions and rested overnight. On the day of 
the assay, cells were seeded at a density of 3e5 cells per well using Corning® Cell-Tak™ at 
a concentration of 22.4μg/ml (Thermo Fisher Scientific) as an adherence medium. Final 
concentrations for reagents used are as follows; FCCP = 0.5μM, Oligomycin = 1μM, Glucose 
= 10μΜ, 2-deoxy-glucose = 50μΜ. Where possible, samples were run in technical triplicate. 
 
MitoTracker® and MitoSOX™ staining: MitoTracker® orange (Life Technologies, 
Carlsbad, CA, U.S.A, cat# M-7511) and MitoSOX™ Red (Life Technologies, cat# M36008) 
staining was performed as per company recommendations. In brief, 5e5cells were stained 
using 200nM of MitoTracker® Orange or 5μM of MitoSOX™ Red at 37°C for 30 mins 
followed by surface staining for lineage markers at 4°C.   
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4.3 Results 
4.3.1 Differential doses of EBV-LCL stimulation impacts on qualitative and 
quantitative profile of in vitro expanded T-cells 
In the first set of experiments, PBMC from healthy EBV seropositive donors pre-stained with 
CellTrace™ Violet (CTV) (Supplementary figure 9.1.1A), were stimulated with autologous 
EBV-LCLs and then assessed for their phenotypic and functional profile at different time 
points (days 7, 10, and 12). As evident in Figure 4.3.1.1, exposure of PBMCs to a higher 
dose of EBV-LCL stimulation (referred to as a responder to stimulator ratio, R:S of 2:1) drove 
rapid proliferation (Figure 4.3.1.1A, Top panel and Supplementary figure 9.1.1B), while 
PBMC stimulated with a lower dose of EBV-LCL stimulation (referred to as a R:S ratio of 
100:1) showed much slower proliferation of T-cells. Additionally, PBMC stimulated with high-
dose EBV-LCL drove significantly lower expansion of CD3+ and CD8+ T-cells when 
compared to the T-cells stimulated with EBV-LCLs at a low dose (Figure 4.3.1.1A, Middle 
and lower panels). Furthermore, T-cells expanded following R:S 2:1 stimulation showed 
reduced production of key cytokines upon recall when compared with T-cells expanded with 
low-dose antigen stimulation (Figure 4.3.1.1C). Importantly, multivariate visualisation using 
a t-Distributed Stochastic Neighbor Embedding (tSNE) algorithm revealed polyfunctionality 
differences between treatment conditions. tSNE plots allow visualisation of multiple 
expression parameters on a single plot. Cells are represented as dots on the plots and gene 
expression is overlayed. Using this visualisation technique, it was observed that T-cells 
stimulated with a higher dose of EBV-LCL stimulation had reduced polyfunctionality as 
evident by the decrease in events visualised in Figure 4.3.1.1B, lower panel.  
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Figure 4.3.1.1 High-dose EBV-LCL stimulation drives greater cell yield but lower T-
cell functionality. Expansion dynamics and functionality of T-cells grown against 
autologous lymphoblastoid cell line (EBV-LCL) for 7, 10 or 12 days with either a responder 
to stimulator ratio of 2:1 (red circles; high dose) or 100:1 (blue squares; low dose). (A) Total 
cell counts (top panel), percentage of CD4+ T-cells (middle panel), percentage of CD8+ T-
cells (bottom panel). (B) t-Distributed Stochastic Neighbor Embedding plots of day 10 
treatment groups with CD4+ T-cells (red, top panel), CD8+ T-cells (orange, top panel), CD3- 
cells (blue, middle panel), and polyfunctional cells (CD107a+IFNγ+TNF+, blue, bottom panel) 
overlayed. (downsample = 66,000 events, gated on lymphocytes, live cells, CD19- cells, 
clustered on CD3, CD4, and CD8, perplexity = 60). (C) Percentage of CD8+ T-cells positive 
for effector markers CD107a, IFNγ, or TNF. Data representative of three independent 
experiments with a total n ≥ 11, p values derived from paired on-tailed students T-test where 
α = 0.05, NS = Non-significant. Error bars represent mean ± SEM. 
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4.3.2 High-dose EBV-LCL stimulation drives expansion of NK cells 
When expanding cells for use as an immunotherapeutic, it is important to derive a large 
number of effector cells and hence the cell yield and subtype composition are important 
considerations. To more accurately dissect the cellular composition and yield of T-cell drug 
products derived following high or low R:S ratio stimulation, an immune lineage marker panel 
was utilised. This panel termed TBNK for its detection of T-cells, B cells, and NK cells, was 
coupled with BD’s Trucount™ cell counting tubes to allow estimation of the absolute number 
of cells within each lineage. To visualise the overall structure of the cellular product, tSNE 
algorithm was applied to flow cytometry data (Figure 4.3.2.1A). Visualised in this manner it 
is evident that cultures stimulated with a higher dose of EBV-LCLs drove large expansion of 
NK cell population (Figure 4.3.2.1A, Blue population). While high EBV-LCLs R:S ratio limited 
T-cell expansion, the same stimulation condition significantly increases cell yield. Therefore, 
in terms of absolute cell numbers, this results in an almost equivalent number of CD8+ T-
cells across various R:S ratios. However, both CD4+ T-cells and NK cells are significantly 
different across antigen conditions (Figure 4.3.2.1B). Specifically, CD4+ T-cells are 
decreased while NK cells are increased following high Ag dose stimulation.  
 
Figure 4.3.2.1 High-dose EBV-LCL stimulation increases NK cell and decreases CD4+ 
T-cell expansion. Cells cultured using various responder to stimulator (R:S) ratios of 
lymphoblastoid cell line (EBV-LCL)-based stimulation for 10-days were stained to identify 
cell subsets. (A) t-Distributed Stochastic Neighbor Embedding plots across various R:S 
ratios with cell subsets overlayed. (downsample = 30,000 events, gated on lymphocytes, 
single cells, CD45+ cells, clustered on CD3, CD4, CD8, CD19, and CD16/56, perplexity = 
60). (B) Graphs represent absolute counts of cell sub-populations (Total = black triangles, 
CTV+ = red circles, CTV- = blue squares) with bars showing mean ± S.E.M. p values derived 
from a repeated measures two-way ANOVA; n = 11 biological replicates from three 
independent experiments.  
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4.3.3 High-dose EBV-LCL stimulation drives increased inhibitory receptor 
expression and decreases polyfunctionality of T-cells 
To further characterise the impact of antigen stimulation dose on phenotypic differences 
driven by Ag dose the expression of immune inhibitory and stimulatory receptors was 
assayed. Interestingly, it was found that multiple receptors were influenced by the dose of 
EBV-LCL stimulation. For example, the co-stimulatory receptor inducible T-cell 
costimulatory (ICOS) was found to be up-regulated on both CD4+ and CD8+ T-cells following 
higher dose EBV-LCL stimulation (R:S ratio of 2:1) (Figure 4.3.3.1). Additionally, both the 
inhibitory receptors (IRs) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and 
lymphocyte-activation gene 3 (LAG-3) were increased following high-dose EBV-LCL 
stimulation (Figure 4.3.3.1). Interestingly, tSNE plots revealed that the greatest expression 
of TIM-3 and LAG-3 occurred in the non-T-cell compartment. As per previous data presented 
within this chapter, NK cells constitute a large proportion of this population. The expression 
of programmed cell death protein (PD-1) was observed to be significantly increased in low 
Ag dose (100:1) stimulated CD4+ T-cells. Although, not statistically significant, PD-1 
expression in CD8+ T-cells showed a similar trend (p = 0.0647).  
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Figure 4.3.3.1 High-dose EBV-LCL stimulation increases the expression of inhibitory 
receptors. T-cells cultured for 10-days following a high- (2:1) or low- (100:1) dose EBV-LCL 
stimulation were stained for various immunoinhibitory receptors. (A) t-Distributed Stochastic 
Neighbor Embedding plots showing high-dose (2:1, left panels) and low-dose (100:1, right 
panels) stimulated cells. (downsample = 55,000 events, gated on lymphocytes, live cells, 
CD19- cells, clustered on CD4, CD8, and cell trace violet, perplexity = 60). (B) Graphs 
quantifying cell subtype frequencies and levels of inhibitory receptor expression in CD8+ T-
cells (left) and CD4+ T-cells (right) following high-dose (2:1, red) and low-dose (100:1, blue) 
stimulation. p values derived from a repeated measures two-way ANOVA and subsequent 
Sidak’s multiple comparison test, where α = 0.05; n = 11 biological replicates from 5 
independent experiments. 
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 Co-expression of multiple IRs is a known marker for T-cell dysfunction [91, 96]. 
Therefore, the co-expression (also referred to as Boolean expression) profile of IRs and 
functional markers were assessed following differential Ag dose stimulation. As evident in 
figure 4.3.3.2, high Ag dose stimulated CD8+ T-cells are less polyfunctional and have 
increased co-expression of multiple IRs. A phenotype which is consistent with T-cell 
dysfunction [95]. An intriguing observation is the elevation of PD-1 single-positive cells 
following low Ag stimulation (Figure 4.3.3.2C). These PD-1 single-positive cells can be found 
in both the CD8+ and CD4+ T-cell compartments (Figure 4.3.3.2B). 
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Figure 4.3.3.2 Co-expression of inhibitory receptors is increased and 
polyfunctionality is decreased following high-dose EBV-LCL stimulation. Cells 
stimulated for 10-days with a high- (2:1) or low- (100:1) dose EBV-LCL stimulation were 
assayed for co-expression of inhibitory receptors or functional markers. Analysis was 
performed on divided (cell trace violet negative) CD8+ T-cells. (A) Co-expression of PD-1, 
TIM-3, and LAG-3 as a percentage of proliferating (Cell trace violet negative; CTV-) CD8+ 
T-cells. Co-expression profiles were summarised as positive for 3+ (green), 2+ (yellow), 1+ 
(blue) or negative for all three inhibitory receptors (0+, red). (B) t-Distributed Stochastic 
Neighbor Embedding plots with PD-1 single-positive population overlayed in blue. 
(downsample = 55,000 events, gated on lymphocytes, live cells, CD19- cells, clustered on 
CD4, CD8, and CTV, perplexity = 60). (C) Heatmap showing inhibitory receptor expression 
profile. Scaling was performed for columns and colouring has been constrained between a 
Z-score of -1 and 1. (D) Co-expression of Granzyme A, Granzyme B, and Perforin on CD8+ 
CTV- T-cells. (E) Co-expression of CD107a, IFNγ, and IL-2 on CD8+ CTV- T-cells. p values 
derived from a repeated measures two-way ANOVA and subsequent Sidak’s multiple 
comparison test, where α = 0.05; n = 11 biological replicates from 5 independent 
experiments, bars represent mean ± 95% CI. 
 
 Due to limitations in polychromatic flowcytometry, IR and functional markers were run 
across different staining panels. Therefore, to visualise the overall phenotype induced by 
differential Ag dose stimulation in CTV- CD8+ T-cells, multivariate analytics were employed. 
Using the geometric mean fluorescence expression value for each marker assayed for, the 
multiple flow staining panels could be correlated and visualised together. Figure 4.3.3.3, 
shows the overall protein expression profile of CTV- CD8+ T-cells after a 10-day culture 
period. As expected, functional markers largely correlate with one another and show 
negative correlation with IRs (Figure 4.3.3.3A). Broadly speaking, the same applied for IRs, 
whereby, IRs showed strong positive correlations between themselves and negative 
correlations with functional markers. Deviations from these trends are observed for ICOS 
and PD-1. ICOS a co-stimulatory molecule was found to be negatively correlated with 
effector molecules and positively correlated with IR expression. Conversely, PD-1 shows 
positive correlation with effector molecule expression. Expression of IRs and effector 
molecules was sufficient to split samples by antigen stimulation regime in multi-dimensional 
reduction analysis—principle component analysis (PCA) with K-means clustering (Figure 
4.3.3.3B). Dimension 1 (Dim1, x-axis) contained 40.5% of variability and is responsible for 
separation of samples by Ag dose stimulation. Consistent with previous analysis, high Ag 
dose stimulated samples were largely enriched for IRs; while, low Ag dose samples were 
enriched for effector molecules. Notable exceptions to this broad conclusion is ICOS, PD-1, 
and TIGIT expression (Figure 4.3.3.3B). 
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Figure 4.3.3.3 Expression of immune inhibitory receptors and functional markers 
separates CD8+ T-cells expanded using high- or low-dose EBV-LCL stimulation. 
Proliferating CD8+ T-cells were stained for an array of immune relevant proteins and 
assayed via flow cytometry following 10-days of culture after high- (2:1) or low- (100:1) dose 
EBV-LCL stimulation. Geometric mean of fluorescence intensity was used to perform cluster 
and correlation analysis. (A) Correlation analysis of each marker across both conditions (2:1 
and 100:1) at 10 days post-stimulation. Circles show statistically significant correlations 
where size and colour reflect spearman correlation values ranging from +1 (blue) to -1 (red). 
(B) Supervised K-means clustering (k = 2) with samples (left panels) and associated variable 
plot indicating the direction and strength of each immune marker in cluster separation (right 
panels). n = 11 biological replicates from 5 independent experiments. 
  
55 
 
4.3.4 High-dose EBV-LCL stimulation impacts the phenotype of EBV-specific 
T-cells 
In the next set of experiments, I used EBV-specific MHC-peptide multimers to assess the 
phenotypic and functional impact of EBV-LCL stimulation dose on EBV-specific T-cells 
(Table 4.3.4.1). For each biological donor, all HLA-matched multimers were used. 
Therefore, in most instances the results below describe the staining for one or two multimers 
for each biological donor.  
 
Table 4.3.4.1 List of Epstein–Barr virus epitopes assayed for in multimer-specific 
analysis 
Antigen Epitope sequence Allele 
EBNA1 HPVGEADYFEY HLA*B35.01 
EBNA3A RPPIFIRRL HLA*B07 
FLRGRAYGL HLA*B08 
LMP2 FLYALALLL HLA*A02 
Table of antigen, epitope sequence, and allele for multimers used in antigen-specific T-cell 
analysis. 
 
Whist the frequency of MHC-peptide multimer+ cells was unchanged following 
differential doses of EBV-LCL stimulation (Figure 4.3.4.1A), significant phenotypic 
differences were observed. The effect of Ag stimulation dose on Multimer+ T-cell phenotype 
is illustrated by tSNE plots whereby, high-dose EBV-LCL stimulation (R:S ratio of 2:1) are 
almost entirely separate from T-cells stimulated at a R:S ratio of 100:1 (Figure 4.3.4.1B). T-
cells stimulated with a higher dose of EBV-LCLs showed an elevated frequency and 
geometric mean expression of ICOS, LAG-3, and TIM-3 (Figure 4.3.4.1C and 
Supplementary figure 9.1.2). This observation thus validates previous analysis on the 
divided population and demonstrates that antigen load has a pivotal impact on cells of the 
same antigen specificity (Supplementary figure 9.1.2A).  
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To garner a better understanding of the phenotype induced by differential dose EBV-
LCL stimulation, multivariate analytics were used. Mutlivariate analysis of EBV multimer-
specific CD8+ T-cells mirrors results previously described for the overall CTV- CD8+ T-cell 
population. Namely, high-dose EBV-LCL stimulation drives an increase in IR expression and 
a decrease in effector molecule production in the Multimer+ population (Figure 4.3.4.2A). 
Notably, the expression of cytotoxic molecules GzmA and GzmB are both significantly 
decreased in high-dose EBV-LCL stimulated Multimer+ cells (Figure 4.3.4.2B). This result, 
mirrors the expression pattern of Multimer- cells. Additionally, the frequency of both GzmA+ 
and IL2+ Multimer+ cells mirrors previous observations in CTV- CD8+ population 
(Supplementary figure 9.1.3). Interestingly, the Multimer+ population does not show the 
treatment effects observed within Multimer- cells with respect to the expression of CD107a+, 
and IFNγ+ cells (Supplementary figure 9.1.3). This indicates that the CTV- population does 
not entirely recapitulate the observations of multimer-specific cells.  
Figure 4.3.4.1 EBV-specific CD8+ 
T-cells are impacted by EBV-LCL 
stimulation dose. EBV-LCL 
stimulation dose has a significant 
impact on receptor expression 
pattern of EBV multimer-specific 
CD8+ T-cells after 10 days of 
culture. (A) Frequency of EBV-
specific (Multimer+) CD8+ T-cells 
after high- (2:1, red circles) or low- 
(100:1, blue squares) dose EBV-
LCL stimulation. (B) t-Distributed 
Stochastic Neighbor Embedding 
plot of EBV-specific CD8+ T-cells 
clustered on PD-1, ICOS, LAG-3, 
and TIM-3 expression. (C) 
Expression of receptors ICOS, 
LAG-3, and TIM-3 within multimer-
specific (left panels) or remaining 
population (right panels). n ≥ 6 
biological donors from 3 
independent experiments. p value 
derived from two-tailed paired 
students T-test. 
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Figure 4.3.4.2 High-dose EBV-LCL stimulated EBV-specific CD8+ T-cells show an 
inhibitory phenotype. A high-dose EBV-LCL stimulation drives EBV multimer-specific 
CD8+ T-cells (Multimer+) towards an inhibitory phenotype. (A) Heatmap of the geometric 
mean expression values for inhibitory and effector molecules in high- (2:1) or low- (100:1) 
dose EBV-LCL stimulated Multimer+ CD8+ T-cells. White = missing data. (B) Geometric 
mean expression of GzmA and GzmB in Multimer+ (left panel) or Multimer- (right panel) 
populations. n ≥ 6 biological donors from 3 independent experiments. p value derived from 
two-tailed paired students T-test. 
 
Phenotypically, high-dose EBV-LCL stimulated Multimer+ cells showed a greater 
enrichment for co-expression of IRs (Figure 4.3.4.3A). Conversely, low-dose EBV-LCL 
stimulated Multimer+ cells show greater single IR positivity or absence of IR expression 
(Figure 4.3.4.3B). The observation of increased single-positive IR expression was largely 
due to the increase in PD-1 single-positive expression following low-dose EBV-LCL 
stimulation (Figure 4.3.4.3E). Functionally, low-dose EBV-LCL stimulated Multimer+ cells 
are enriched for co-expression of multiple cytotoxic molecules (Figure 4.3.4.3C). 
Interestingly, high-dose EBV-LCL stimulated Multimer+ cells show an increase in the 
frequency of GzmB+Prf+ double-positive and GzmB+ single-positive cells (Figure 4.3.4.3C). 
This data largely mimics the previous results of CTV- CD8+ T-cells indicating that analysis 
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of the dividing population provides a good approximation for EBV multimer-specific cells. 
Further, this data demonstrates that antigen dose has a significant impact on the phenotype 
and function of EBV multimer-specific CD8+ T-cells. This statement is strikingly visualised 
by Figure 4.3.4.3D whereby, samples are easily separated using multi-dimensional analysis 
using the co-expression of functional markers, and IRs.  
 
 
Figure 4.3.4.3 High-dose EBV-LCL stimulated EBV-specific CD8+ T-cells are less 
polyfunctional and express multiple inhibitory receptors. High-dose EBV-LCL 
stimulation drives EBV multimer-specific (Multimer+) CD8+ T-cells to express multiple 
inhibitory receptors and inhibits polyfunctionality. (A) Heatmap of the boolean expression of 
inhibitory receptors in high- (2:1) or low- (100:1) dose EBV-LCL stimulated Multimer+ CD8+ 
T-cells. (B) Frequency of Multimer+ CD8+ T-cells positive for 4, 3, 2, 1, or 0 immune inhibitory 
receptors (IR). (C) Cytotoxic function of Multimer+ CD8+ T-cells. (D) K-means cluster using 
boolean expression values from cytotoxic, effector function, and IR staining. (E) Frequency 
of boolean expression for IR. n = 8 biological donors from 3 independent experiments. p 
value derived from repeated measures Two-way ANOVA. 
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4.3.5 AdE1-LMPpoly stimulation dose has a marginal impact on T-cell 
phenotype and function 
We investigated the impact other stimulation regimes have on the qualitative profile of 
expanded T-cells. Using a recombinant viral vector encoding EBV epitopes, is a viable 
method for stimulating antigen-specific T-cells [226, 227]. To investigate this stimulation 
method, we used a previously published EBV-specific polyepitope vector, referred to as 
AdE1-LMPpoly vector (see methods 4.2.1) [228, 337]. AdE1-LMPpoly contains epitopes 
spanning both HLA-I and HLA-II from LMP1&2 and EBNA1. Compared to EBV-LCL-based 
stimulation, AdE1-LMPpoly infected APC cells had a marginal impact on the expansion of 
different cell subsets. Regardless of the dose, using AdE1-LMPpoly stimulation 
preferentially expanded T-cells (Figure 4.3.5.1A). Within the T-cell compartment, there is a 
bias towards CD4+ T-cells (Figure 4.3.5.1B).  
 Analysis of the T-cell compartment revealed that varying dose of AdE1-LMPpoly 
stimulation has minimal impact on function or phenotype. Only two measures showed 
statistically significant differences. Specifically, the frequency of TIGIT+ CD8+ CTV- T-cells 
were found to be increased when a low-dose (R:S ratio of 100:1) AdE1-LMPpoly APC was 
used (Figure 4.3.5.1C). Additionally, the frequency of CD107a+ cells were also increased 
following low-dose AdE1-LMPpoly APC stimulation (Figure 4.3.5.1C). Interestingly, 
geometric mean expression of TIGIT was observed to follow a dose relationship and was 
confined to the CTV- population (Figure 4.3.5.1D).  
 Analysis of the CD4+ T-cell compartment revealed some phenotypic impact of 
differential AdE1-LMPpoly APC dose stimulation. Specifically, the frequency of TIGIT+, TIM-
3+, and CD96+ CD4+ CTV- T-cells were significantly increased after low-dose AdE1-LMPpoly 
APC stimulation (Figure 4.3.5.1E). Interestingly, this effect was only observed for the 
frequency of expression and not for intensity (AKA geometric mean) of expression (Figure 
4.3.5.1F).  
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Figure 4.3.5.1 AdE1-LMPpoly APC stimulation dose has minimal impact on qualitative 
profile of T-cells. PBMCs cultured for up to 10 days after differential (responder to 
stimulator ratio) dose AdE1-LMPpoly APC stimulation. (A) Graph showing the cell subsets 
and their proportion within the final culture product. (B) Graph showing T-cell subset 
proportions. (C) Percent of CD8+ CTV- T-cells positive for various markers. (D) Geometric 
mean fluorescent intensity of TIGIT in CD8+ T-cell. (E) Percent of CD4+ CTV- T-cells positive 
for various markers. (F) Geometric mean fluorescent intensity of various markers in CD4+ 
CTV- T-cell. n ≤ 7 biological donors per treatment from two independent experiments, p 
values derived from two-way ANOVA where α = 0.05. Error bars represent mean ± SEM. 
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4.3.6 EBV-Pepmix-pulsed APC stimulation dose has a marginal impact upon 
T-cell phenotype and function 
Stimulation and expansion of antigen-specific T-cells can be achieved via other stimulation 
methods. Namely, peptide-pulsed APC represent a viable method to induce antigen-specific 
T-cell proliferation [194, 197]. To investigate this stimulation method and its impact on T-cell 
qualitative profile, a custom pool of EBV-specific epitopes was designed. Herein referred to 
as EBV-Pepmix, this peptide pool was used to coat stimulator APCs for stimulation and 
expansion of antigen-specific T-cells. EBV-Pepmix contains 22 EBV epitopes spanning 
HLA-I and HLA-II derived from LMP1&2 and EBNA1 (See methods 4.2.2). It was observed 
that stimulation with EBV-Pepmix-pulsed APCs preferentially expanded T-cells (Figure 
4.3.6.1A). Interestingly, a bias towards expansion of CD4+ T-cells was observed within the 
T-cell compartment (Figure 4.3.6.1B). Both of these observations were not influence by the 
dose of EBV-Pepmix APCs.  
 Within the CD4+ T-cell compartment, phenotypic differences were induced by 
differential doses. Specifically, an increase in the frequency of TIGIT+, TIM-3+, and CD96+ 
CD4+ CTV- T-cells was observed following high (2:1) dose EBV-Pepmix APC stimulation 
(Figure 4.3.6.1C). Dose had a smaller impact on the qualitative profile of the CD8+ T-cell 
compartment. The frequency of TIGIT+ and CD107a+ CD8+ CTV- T-cells was significantly 
increased after stimulation with high-dose EBV-Pepmix APC (Figure 4.3.6.1D).  
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Figure 4.3.6.1 EBV-Pepmix APC stimulation dose has minimal impact on qualitative 
profile of T-cells. A summary of the impact high- (2:1) or low- (100:1) dose EBV-Pepmix 
APC stimulation has on T-cells after 10 days of culture.. (A) Frequency of cell subsets after 
10 days of culture with a responder to stimulator (R:S) ratio of 2:1 (red circles), or 100:1 
(blue squares). (B) Frequency of CD4+ and CD8+ T-cells. (C & D) Frequency of CD4+ and 
CD8+ CTV- T-cells (respectively) expressing immune receptors and effector molecules. p 
value derived from repeated measures two-way ANOVA. n = 4 biological replicates. Dot 
plots show mean ± S.E.M. 
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4.3.7 High-dose EBV-LCL stimulation preferentially favours expansion of TCM 
CD8+ T-cells 
The cellular differentiation status of an ACT product can have a large impact on therapeutic 
potential [339, 340]. It was observed that EBV-LCL stimulation bias CD8+ T-cells towards a 
T-cell effector memory (TEM; CD45RA-CD62L-) phenotype (Figure 4.3.7.1B). However, high-
dose EBV-LCL stimulation significantly increased the frequency of central memory (TCM; 
CD45RA-CD62L+) CD8+ T-cells (Figure 4.3.7.1B). Conversely, low-dose EBV-LCL 
stimulation enriched the CD8+ T-cell compartment for TEM cells. Further, PCA analysis with 
K-means clustering using differentiation markers (CD45RA, CD62L, CCR7, CD27, and 
CD57), can distinguish between samples cultured with high- (2:1) or low- (100:1) dose EBV-
LCL stimulation (Figure 4.3.7.1A). This demonstrates a clear impact of stimulation dose on 
CD8+ T-cell differentiation and memory status.  
 
 
Figure 4.3.7.1 High-dose EBV-LCL stimulation bias expansion of central memory 
CD8+ T-cells. Expression of markers of T-cell differentiation on CD8+ CTV- T-cells following 
10 days of culture after high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) Supervised 
(k = 2) K-means cluster analysis using geometric mean expression of CCR7, CD27, CD57, 
CD45RA, and CD62L. (B) Percentage of memory subsets within the CD8+ CTV- T-cells 
population. n = 4 biological replicates per treatment; p values derived from repeated 
measures two-way ANOVA and Sidak’s multiple comparisons test where α = 0.05.  
  
64 
 
4.3.8 High-dose EBV-LCL stimulation impacts the metabolic function of CD8+ 
T-cells  
We investigated the metabolic consequence of differential dose EBV-LCL stimulation on T-
cells. Firstly, a preliminary quantitative PCR (qPCR) experiment was performed to broadly 
consider if metabolic pathways had been altered by EBV-LCL stimulation dose. Indeed, a 
qPCR array of mitochondrial energy metabolism genes, revealed a robust difference 
between different EBV-LCL dose treated CTV- CD8+ T-cells (Figure 4.3.8.1A & 
Supplementary figure 9.1.4 & 9.1.5).  
 Further experimentation revealed that high-dose EBV-LCL stimulated cells had a 
greater oxygen consumption rate (OCR) capacity (Figure 4.3.8.1B & C). Furthermore, high-
dose EBV-LCL stimulation lead to a significant increase of both baseline and stressed 
extracellular acidification rate (ECAR) (Figure 4.3.8.1D). Analysis of a prolonged 21-day 
culture with IL-2 supplemented culture media revealed no metabolic differences 
(Supplementary figure 9.1.6).  
 
Figure 4.3.8.1 High-dose EBV-LCL stimulation alters T-cell mitochondrial metabolism. 
The mitochondrial metabolism of CD8+ T-cells following culture for 10-days after high- (2:1) 
or low- (100:1) dose EBV-LCL stimulation. (A) Dendrogram of gene expression values from 
a qPCR array of mitochondrial metabolism genes, shows samples are easily separated by 
EBV-LCL dose. n = 2 biological replicates, Euclidean distance and Ward.D clustering, one 
independent experiment. (B) Oxygen Consumption Rate (OCR) profile of 10-day cultured 
CD8+ T-cells. (C) Overview of OCR before and after stressor addition in 10-day CD8+ T-
cells. (D) Overview of Extracellular Acidification Rate (ECAR) before and after stressor 
addition in 10-day CD8+ T-cells. p values derived from repeated measures two-way ANOVA 
with Uncorrected Fisher’s LSD post-hoc analysis. n = 5 biological replicates. Error bars 
represent mean ± S.E.M. 
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Measures of OCR and ECAR may reflect altered mitochondrial function or 
alternatively, may indicate changes in mitochondrial biomass. Indeed, staining revealed that 
low-dose EBV-LCL stimulated CTV- CD8+ T-cells had a significant increase in mitochondrial 
biomass (Figure 4.3.8.2). Whereas the CD4+ T-cell compartment was unchanged. Additional 
analysis using a superoxide (O2-) dye revealed a statistically significant increase in low-dose 
EBV-LCL stimulated cells after 10-days of culture (Figure 4.3.8.3). Significance was 
observed for CD8+ and CD4+ T-cells, specifically within the CTV- population. This 
demonstrates a clear link to cell proliferation.  
 
 
Figure 4.3.8.2 EBV-LCL stimulation dose impacts CTV- CD8+ mitochondrial size. T-
cells (CD8+ and CD4+) were assayed for mitochondrial biomass by staining with 
MitoTracker® reagent following a 10-day culture after high- (2:1) or low- (100:1) dose EBV-
LCL stimulation. Representative figure from two independent experiments. n = 5 biological 
donors. p value derived from repeated-measures two-way ANOVA with Sidak’s multiple 
comparison correction.  
 
 
Figure 4.3.8.3 High-dose EBV-LCL stimulation decreases frequency of superoxide 
positive cells. T-cells (CD8+ and CD4+) were assayed for superoxide (O2-) expression 
following 10-day culture after high- (2:1) or low- (100:1) dose EBV-LCL stimulation. 
Representative figure from two independent experiments. n = 5 biological donors. p value 
derived from repeated-measures two-way ANOVA with Sidak’s multiple comparison 
correction.  
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4.3.9 High-dose EBV-LCL stimulation impacts qualitative profile of cultures 
after prolonged culture  
Large cell yields are required for autologous and allogeneic ACT treatments alike. To reach 
required cell yields, culture duration is usually extended. Prolonged cultures require IL-2 
cytokine support to maintain T-cell proliferation and survival. We tested how a prolonged 
(21-day) culture with IL-2 supplemented media faired, with respect to T-cell qualitative 
profile. High (2:1) dose EBV-LCL stimulation significantly increased the frequency of NK 
(CD3- CD56+) cells (Figure 4.3.9.1A). However, the status of NK cells—in terms of CD56 
expression—was unchanged by dose of EBV-LCL used (Figure 4.3.9.1D). Conversely, low 
(100:1) dose EBV-LCL stimulation significantly increased the frequency of T-cells (Figure 
4.3.9.1A). Within the T-cell compartment, strong bias towards CD8+ T-cells was observed 
after a high-dose EBV-LCL stimulation (Figure 4.3.9.1C). In fact, CD8+ T-cell bias was so 
substantial that high-dose EBV-LCL stimulated cultures contained minimal CD4+ T-cells 
(Figure 4.3.9.1B). 
 
 
Figure 4.3.9.1 High-dose EBV-LCL stimulation increases NK cell and limits CD4+ T-
cell expansion after 21-day culture. Cultures were grown for 21-days with IL-2 
supplemented media after high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) The 
frequency of different cell subtypes following 21-days of culture. (B) t-Distributed Stochastic 
Neighbor Embedding plots with cellular subsets overlayed. (C) Frequency of CD8+ and CD4+ 
T-cell subsets. (D) Frequency of CD56High and CD56Low NK cells. p values derived from a 
repeated measures two-way ANOVA; n = 7 biological replicates from one independent 
experiment. 
CD3-CD56- NK cells NKT cells T cells
0
20
40
60
80
100
%
 o
f l
iv
e,
 s
in
gl
e 
ce
ll,
 ly
m
ph
oc
yt
es
2:1
100:1
<0.0001 <0.0001
Cell Subsets
CD8+ T-cells CD4+ T-cells
0
20
40
60
80
100
%
 o
f C
D
3+
 C
el
ls
0.0016 0.0056
T-cell Subsets
A
C D
CD4+
CD8+
CD56+
-19
0
20
2:1
tSNE-X
-19
0
20
-19 0 20
100:1
tS
NE
-Y
B
CD56High CD56Low
0
20
40
60
80
100
%
 o
f C
D
56
+  
C
el
ls 0.7773
0.8077
NK Cells
67 
 
Analysis of the phenotypic impact the EBV-LCL stimulation dose has on prolonged 
21-day culture revealed some common themes. For example, the frequency of TIGIT+ CD8+ 
T-cells and NK cells was increased after high-dose EBV-LCL stimulation (Figure 4.3.9.2A). 
Specifically, within the CD8+ T-cell compartment, the IRs TIM-3 and CD96 were also 
increased in frequency after high-dose EBV-LCL stimulation. Unexpectedly, the CD4+ T-cell 
compartment showed a decrease in TIM-3 expression after a high-dose EBV-LCL 
stimulation. Interestingly, the expression of the receptors, ICOS, PD-1, and LAG-3 were 
substantially lower than at the earlier 10-day timepoint. tSNE visualisation revealed clear 
differences in the abundance of CD96+ or TIM-3+ NK cells across different EBV-LCL dose 
stimulation treatments (Figure 4.3.9.2B).  
 
 
Figure 4.3.9.2 High-dose EBV-LCL stimulated cultures are enriched for TIGIT+, TIM-3+, 
and CD96+ CD8+ T-cells following 21 day culture. Cultures were grown for 21-days with 
IL-2 supplemented media after high- (2:1) or low- (100:1) dose EBV-LCL stimulation. At 
conclusion of culture, phenotype profile was assayed in different cell subsets. (A) Expression 
of receptors within CD4+ T-cell (top graph), CD8+ T-cell (middle graph), or NK cell (bottom 
graph) subsets. (B) Representative t-Distributed Stochastic Neighbor Embedding plots 
showing distribution of TIGIT+, TIM-3+, and CD96+ cells. p values derived from a repeated 
measures two-way ANOVA; n = 7 biological replicates from one independent experiment. 
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4.3.10 AdE1-LMPpoly APC dose has a minimal effect of T-cell qualitative profile 
following a prolonged (21-day) culture duration. 
We investigated the impact a prolonged culture (21-days with IL-2 supplementation) had on 
ACT drug product culture in the context of varied doses of AdE1-LMPpoly infected APC 
stimulation. AdE1-LMPpoly ACT stimulation preferentially expanded T-cells (Figure 
4.3.10.1A). This was not impacted by dose variation. Furthermore, the frequency of NK T-
cells were significantly increased after high (2:1) dose AdE1-LMPpoly APC stimulation 
(Figure 4.3.10.1A). Within the T-cell compartment a large bias towards CD4+ T-cells was 
noted (Figure 4.3.10.1B). No statistically significant differences were observed in the 
phenotype or function of CD8+ CTV- T-cells following various doses of stimulation (Figure 
4.3.10.1C). However, within the CD4+ CTV- T-cell compartment, the frequency of both 
ICOS+ and CD96+ cells were significantly altered (Figure 4.3.10.1D). Specifically, high-dose 
AdE1-LMPpoly APC stimulation resulted in an increase in ICOS+ and a decrease in CD96+ 
cells.  
 
Figure 4.3.10.1 AdE1-LMPpoly APC stimulation dose has a minimal impact on ACT 
drug product culture. PBMCs cultured for up to 21-days with a high- (2:1) or low- (100:1) 
dose AdE1-LMPpoly APC stimulation stained with inhibitory and cell subset markers. (A) 
Graph showing the cell subsets and their proportion within the final culture product. (B) 
Graph showing T-cell subset proportions. (C) Percent of CD8+ CTV- T-cells positive for 
various markers. (D) Percent of CD4+ CTV- T-cells positive for various markers. n = 4 
biological donors per treatment from one independent experiments, p values derived from 
two-way ANOVA where α = 0.05. Error bars represent mean ± SEM. 
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4.3.11 EBV-Pepmix APC dose has a minimal impact on T-cell phenotype and 
function following a prolonged (21-day) culture duration. 
ACT culture duration is usually extended to achieve required cell yield. Hence, we 
investigated how differential EBV-Pepmix APC dose stimulation impacted cell phenotype 
and function following a 21-day culture (with IL-2 supplementation). EBV-Pepmix APC 
stimulation preferentially expanded T-cells (Figure 4.3.11.1A). However, non-T or NK cells 
were also observed in the culture. Within the T-cell compartment, a bias towards CD4+ T-
cells was observed (Figure 4.3.11.1B). Stimulation dose had a minimal impact on the 
phenotype of the CD4+ CTV- T-cell compartment (Figure 4.3.11.1C). Specifically, only the 
frequency of TIGIT+ and ICOS+ cells were significantly altered by differing stimulation dose. 
Explicitly, TIGIT+ cells increased while ICOS+ cells decreased in frequency after a high (2:1) 
dose EBV-Pepmix APC stimulation. Within the CD8+ CTV- T-cell compartment high-dose 
EBV-Pepmix APC stimulation increased the frequency of TNF+ cells (Figure 4.3.11.1D).  
 
 
Figure 4.3.11.1 EBV-Pepmix APC stimulation dose has a marginal impact on ACT drug 
product culture. Phenotypic and functional staining of cells following 21-day (with IL-2 
supplementation) culture after high- (2:1) or low- (100:1) dose EBV-Pepmix APC stimulation. 
(A) Graph showing the cell subsets and their proportion within the final culture product. (B) 
Graph showing T-cell subset proportions. (C) Percent of CD4+ CTV- T-cells positive for 
various markers. (D) Percent of CD8+ CTV- T-cells positive for various markers. n = 4 
biological donors per treatment from one independent experiments, p values derived from 
two-way ANOVA where α = 0.05. Error bars represent mean ± SEM.   
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4.4 Discussion 
ACT immunotherapy is a promising approach to treat multiple viral and non-viral diseases. 
A key component of ACT immunotherapy is the stimulation and subsequent expansion of 
viable antigen-specific T-cells. Myriad methods to achieve T-cell stimulation and expansion 
have been reported. Three common methods of stimulation are EBV-LCLs, peptide-pulsed 
APCs, and adenoviral vector-infected APCs [193, 194, 199]. In recent years, often a high 
dose and multiple stimulation rounds are used to expand T-cells for ACT [197, 220, 226, 
231]. Previous research has demonstrated that antigen dose can significantly modulate T-
cell function [299, 341, 342]. Therefore, it is important to investigate how stimulation and 
expansion methods shape a T-cell drug product.  
Out of aforementioned antigen sources, EBV-LCLs represents a diverse and heavily 
utilised stimulation method. EBV-LCLs are routinely used to expand EBV-specific T-cells 
and as APCs to stimulate and expand T-cells of other specificities [263, 264]. Therefore, 
EBV-LCL-based stimulation was a particular focus within this body of work. Indeed, our 
experimentation has demonstrated that both antigen source and stimulation dose can have 
a significant impact on the resultant T-cell drug product. Within EBV-LCL-based stimulation, 
it was observed that high-dose stimulation resulted in up-regulation of IRs and down-
regulation of effector molecules. IR expression is strongly correlated with T-cell 
differentiation [343]; however, co-expression of multiple IRs is associated with T-cell 
dysfunction [74, 96]. Indeed, it was observed that high-dose stimulation increased co-
expression of IRs on CD8+ T-cells. Within the immunotherapy setting, cells with this 
phenotype are often refractory to checkpoint blockade therapy [106, 344]. Additionally, high-
dose EBV-LCL stimulated cultures resulted in CD8+ T-cells with less polyfunctionality. Taken 
together—co-expression of IR and reduced polyfunctionality—these data demonstrate T-
cells manufactured with high-dose stimulation share hallmarks of exhausted T-cells [73, 91]. 
An interesting observation worth noting is the loss of PD-1 positivity in CD8+ T-cells following 
long-term stimulation. Such an observation may be the result of PD-1 down-regulation or 
biased PD-1- T-cell proliferation/survival. Indeed, experimentation has shown increased T-
cell proliferation following PD-1 blockade [345, 346]. Thus, suggesting PD-1+ T-cells would 
have inhibited proliferative potential and may be outgrown within this in vitro culture. 
Regardless, results from short-term culture fit with current literature demonstrating antigen 
dose is a significant driver of T-cell exhaustion [105, 269]. Therefore, these results suggest 
low-dose EBV-LCL stimulation produces a T-cell drug product with improved therapeutic 
potential. 
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 It was unclear whether the observed T-cell dysfunction induced by high-dose EBV-
LCL stimulation was intrinsic to T-cells or via expansion of alternative epitope specificities. 
To address this question, EBV-specific multimers were used to delineate T-cells with the 
same epitope-specificity. Results demonstrated that EBV-LCL stimulation dose had no 
impact on the frequency of expanded EBV-specific T-cells. However, phenotypic and 
functional dysfunction was observed following a high-dose EBV-LCL stimulation. Broadly, 
these results mirrored those observed for bulk divided CD8+ T-cells. Therefore, these results 
demonstrate that restricting analysis to the divided population is a suitable approximation 
for antigen-responsive T-cells. Additionally, these results demonstrate that stimulation dose 
can significantly alter the phenotype and functional profile of T-cells with the same epitope-
specificity.  
 In addition to EBV-LCL stimulation dose altering the phenotype and functional profiles 
of CD8+ T-cells, there was a significant impact on the overall expansion of cellular subsets. 
Explicitly, high-dose EBV-LCL stimulation resulted in a significant increase in NK cells. 
Indeed, EBV-LCL stimulation has been reported as a method to expand and culture NK cells 
for both experimental and clinical use [347-350]. In contrast, the final drug product generated 
from both EBV-Pepmix-pulsed APCs or AdE1-LMPpoly-infected APCs stimulations were 
dominated by T-cells, with minimal non-T-cell subsets. In addition to the outgrowth of NK 
cells, EBV-LCL stimulation dose was also found to have a significant impact on the relative 
frequencies of T-cell subsets. This is most profound following a long-term (21-day) culture 
in which high-dose EBV-LCL stimulated cultures have almost no CD4+ T-cells. In contrast, 
low-dose EBV-LCL stimulation resulted in a mixed T-cell population with both CD4+ and 
CD8+ subsets. Similarly, both EBV-Pepmix and AdE1-LMPpoly stimulation biased the T-cell 
compartment towards CD4+ T-cells. Studies have demonstrated the critical role CD4+ T-
cells play in potentiating and sustaining CD8+ T-cells in the immunotherapy setting [100, 
351, 352]. Thus, CD4+ T-cells are an important cellular subset that should be included as 
part of an efficacious ACT drug product [352]. These data demonstrate that high-dose EBV-
LCL stimulation drives the expansion of NK cells while limiting the expansion of CD4+ T-
cells and therefore, reiterates the notion that high-dose EBV-LCL stimulation is undesirable 
for the manufacture of an efficacious ACT drug product. In contrast, low-dose EBV-LCL 
stimulation, EBV-Pepmix, or AdE1-LMPpoly stimulation drives the expansion of a mixed T-
cell drug product; which, has been shown to be preferred for ACT immunotherapy [353-355].  
 The cellular differentiation status is an important variable in developing an effective 
ACT drug product. Both human and murine research has reported that less differentiated 
memory subsets show improved engraftment, persistence, and anti-tumour responses [331, 
72 
 
339, 340, 356]. Hence, these subsets are superior and preferential for immunotherapy. Our 
experimentation demonstrated that high-dose EBV-LCL stimulation biased the CD8+ T-cell 
population towards an TCM phenotype. In contrast, a low-dose EBV-LCL stimulation 
preferentially promoted TEM cells. This biased in T-cell differentiation status may explain the 
up-regulation of PD-1 single-positive cells observed following a low-dose EBV-LCL 
stimulation. Specifically, due to the fact that TEM cells are known to express more PD-1 [343]. 
This data is somewhat contradictory with the majority of literature suggesting increased 
stimulation drives further T-cell differentiation. However, recently published work proposes 
a dedifferentiation model whereby, a fate-permissive subset of effector T-cells can revert 
into memory T-cells [357]. Regardless, these data suggest high-dose EBV-LCL stimulation 
may be ideal in the expansion of T-cell memory subsets; which, are favourable for 
immunotherapeutic use.  
 Furthermore, EBV-LCL stimulation dose was seen to have a significant impact on 
CD8+ T-cell metabolism. It is known that activation and effector function of T-cells is tightly 
associated with their metabolic state and fitness [358-362]. Interestingly, it was observed 
that a high-dose EBV-LCL stimulation resulted in CD8+ T-cells with increased OXPHOS and 
ECAR functions. However, this result was only observed for a short-term culture and dose 
dependent differences were not observed following a prolonged culture. This suggests 
stimulation dose either has a transient metabolic effect or prolonged culture with IL-2 is able 
to rescue any metabolic impairment [363, 364]. Furthermore, O2- was found to be increased 
in low-dose EBV-LCL stimulated cultures. This is interesting as TCR signalling is known to 
induce O2- production; which, suggests heightened TCR signalling in low-dose stimulated 
T-cells [365]. It is hypothesised that high-dose EBV-LCL stimulated T-cells are refractory to 
TCR signalling by this time point and thus, have decreased TCR signalling intermediates 
[366]. Further experimentation is required to properly explore this observation and 
hypothesis.  
 These results demonstrate that the T-cell expansion strategy used can have a 
significant impact on the resultant ACT drug product. Of the methods tested, EBV-LCL 
stimulation dose had the most substantial impact on T-cell measures. In contrast, both EBV-
Pepmix and AdE1-LMPpoly stimulation dose had a marginal effect on T-cell measures and 
resulted in a T-cell dominant drug product. It is likely the contrasting influence of antigen 
stimulation sources is driven through differences in accessory co-stimulatory and co-
inhibitory signals between EBV-LCLs and peptide-pulsed or adenoviral infected APCs. This 
notion can be appreciated when the antigenic source is further examined. EBV-LCLs in 
comparison to peptide-pulsed or adenoviral infected APCs are arguable more reflective of 
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viral transformed targets. These immortalised cells have undergone a natural infection, 
albeit in vitro, with an elevated viral dose, respective to physiological levels. However, in 
contrast to peptide-pulsed or adenoviral infected APCs, this methodology generates a more 
recognisable antigenic target. As is evident in the presented data and the remaining data 
found within this thesis. Therefore, it is speculative but grounded in logic to presume that 
enhanced phenotypic and functional differences observed following EBV-LCL stimulation 
are a function of cellular differences present within this stimulation method.  
 In summary, a high-dose EBV-LCL stimulation was observed to have potentially 
therapeutically deleterious effects on the resultant ACT drug product. Namely, high-dose 
EBV-LCL stimulation increased NK cell expansion and significantly limited CD4+ T-cell 
expansion. Additionally, high-dose stimulation increased IR expression and decreased 
effector molecule expression. Taken together, these data suggest a low-dose stimulation 
would generate a superior ACT drug product when employing an EBV-LCL-based 
stimulation. These results are supported by previous studies [298-301, 342]; however, go 
against current trends in ACT immunotherapy; which, use high dose stimulation [218, 220, 
236, 263, 367]. Furthermore, these data reveal the utility of comprehensive ACT drug 
product assessment. The analytical tools used herein present a unique approach to evaluate 
ACT drug product metrics. If adopted by researchers, similar analysis may enable 
improvement of ACT development and subsequently enhance therapeutic outcomes.  
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5.0 Assessment of molecular profile of in vitro expanded T-
cells  
5.1 Introduction 
ACT immunotherapy holds great promise in malignant and non-malignant disease 
treatment. Central to ACT immunotherapy is the in vitro expansion of T-cells. Research has 
explored the use of many different methods for expanding antigen-specific T-cells. A key 
modality has been the use of EBV-LCLs for the expansion of both EBV-specific and T-cells 
of other specificities [220, 222-224, 261-264]. However, other sources of antigen are utilised 
in the expansion of an antigen-specific T-cell population. For example, peptide-pulsed APCs 
or viral vector-infected APCs are two highly utilised sources of antigen [196, 197, 226]. 
Experimentation has demonstrated that T-cells can be significantly shaped by the in vitro 
culture conditions [296, 368]. Although, not much research has investigated how expansion 
regimes impact the resultant T-cell drug product. Additionally, the dose of stimulation has 
been shown to have a substantial influence on T-cell function, differentiation, and 
transcription [299, 336]. Despite early studies suggesting high-dose stimulation is 
undesirable for a T-cell drug product, numerous groups still employ relatively high-dose 
stimulation [196, 220, 222, 226, 231, 255, 266-268]. Our research has already demonstrated 
that T-cells are adversely impacted by a high-dose stimulation, with respect to phenotype, 
differentiation, and function (Chapter 4). Therefore, we interrogated the impact stimulation 
dose and antigen source have on the T-cell transcriptional profile.  
 Previous data has demonstrated that a high-dose EBV-LCL stimulation can drive T-
cells towards an immunoinhibitory phenotype (Chapter 4). This immunoinhibitory phenotype 
shares characteristics associated with T-cell exhaustion [74, 91]. Notably, increased IR co-
expression and decreased polyfunctionality. Thus, to garner a better understanding of the 
molecular mechanisms and processes perturbed by high-dose stimulation we employed 
transcriptional profiling. Furthermore, we endeavoured to evaluate the utility of 
transcriptional profiling in determining an ACT drug products therapeutic fitness. Rarely, is 
such analysis performed on an ACT drug product and thus, this project provides evidence 
for its adoption by the ACT immunotherapy field.  
 We chose to use the relatively novel nanoString™ transcriptional profiling platform. 
This platform allows for absolute measurement of transcript abundance [369]. Furthermore, 
the platform is PCR-free and thus, abstains from associated biases [370, 371]. Additionally, 
aspects of this platform make it extremely amendable to high throughput and is user-friendly. 
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These are both important should such analysis become mainstay in screening ACT drug 
products. A custom designed panel of 131 immunologically relevant genes was designed 
for the nanoString™ platform (Supplementary table 9.2.1). Genes included in the 
nanoString™ panel were selected based upon two criteria. Firstly, a number of genes were 
selected to validate previous phenotypic and functional observations. Additionally, genes 
important in T-cell biology were included to extend upon previous observations and better 
ascertain the transcriptional landscape of cells following differential stimulation. Restricting 
analysis to a curated panel of immunologically relevant genes served downstream analysis 
two-fold. Namely, mitigating against superfluous data and increased analytical complexity, 
two caveats of more broad whole transcriptome profiling [311].  
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5.2 Materials and Methods 
5.2.1 RNA extraction 
Cells were lysed using QIAshredder columns prior to extraction using RNeasy Micro or Mini 
Kit (QIAGEN®) as per manufacturer’s instructions. RNA quality was assayed in random 
samples by using a RNA integrity number (RIN). RIN was obtained using the RNA 6000 
Pico Kit (Agilent Technologies) as per manufacturer’s instructions. 
 
5.2.2 nanoString™ 
Data Acquisition: Gene expression analysis was conducted using the nanoString™ 
nCounter® gene expression platform (nanoString Technologies™, Bio-strategy, Seattle, 
U.S.A). A custom code set was designed to target immunologically important genes. This 
code set consisted of 131 target genes, 5 housekeeping genes (ACTB, B2M, GAPDH, 
HPRT1, RPLP0), 8 spike-in negative controls, and 6 spike-in positive controls. The assay 
was performed as per manufacture recommendations; in brief, the reporter CodeSet was 
resuspended in 70μl hybridisation buffer. For each sample, 8μl of resuspended reporter 
CodeSet mix was combined with 5–10μl of RNA. Immediately prior to incubation, 2μl of 
Capture ProbeSet was added to samples. Samples were then spun down and incubated at 
65°C for 16 hours, after which, samples were kept at 4°C (<12 hours) until run on the 
nanoString™ nCounter® preparation station using the high-sensitivity protocol. Following 
which, the coated nanoString™ cartridge was scanned with the maximum field of views 
settings on the nCounter® Digital Analyzer.  
Analysis: nanoString™ data was analysed by utilising nSolver™ Analysis Software 
V3.0 (nanoString™ Technologies) for quality control (QC), background subtraction, and 
normalisation. Default settings were used for all samples; these values are present in table 
5.2.2.1. In summary, after QC assessment and background subtraction, count values were 
normalised using the geometric mean of housekeeping genes. These normalised count 
values served as input for differential gene expression analysis (DGE) using the “R” package 
edgeR [311, 312]. In brief, a generalised linear model (GLM) was fitted to the data with 
analysis paired where possible. Subsequently, likelihood ratio testing (LRT) was used to 
determine significantly (α = 0.05) differentially expressed genes. 
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Table 5.2.2.1 Table of Quality control and normalisation parameters used in 
nanoString™ analysis 
Variable Value 
Imaging QC FOV registration > 75% 
Binding Density QC 0.05 – 2.25 
Positive Control Linearity QC R2 > 0.95 
Positive Control Limit of Detection QC .5fM positive control > 2 SD above mean 
of negative controls 
Background Subtraction Geometric Mean of Negative Controls 
Positive Control Normalisation Geometric Mean normalisation factor 
within 0.3 – 3 
Housekeeping Normalisation Geometric mean 
Quality control (QC) parameters default in nSolver™ Analysis Software V3.0. Field of view 
(FOV), and standard deviation (SD). 
 
5.2.1 Gene set enrichment analysis 
Geometric mean normalised expression data served as input for gene set enrichment 
analysis [372, 373]. Analysis was run with 1000 gene set permutations as recommended by 
algorithm authors for datasets of <7 samples. Datasets greater than 500 and less than 15 
were excluded (default settings). Genes were ranked using Signal2Noise metric. Analysis 
was performed as 2:1 vs. 100:1. 
 
5.2.2 String database 
Significantly differentially expressed genes false discovery rate (FDR) < 0.05 served as input 
for String database analysis. All analysis was performed with the following settings; network 
edge = confidence, active interaction sources = experimental and databases only, minimum 
required interation score = medium confidence (0.4), max number of interactors to show 1st 
and 2nd shell = no more than 10, remove disconnected nodes [374]. 
 
5.2.3 The cancer genome atlas analysis 
RNA sequencing data was downloaded and processed using relevant functions in the R 
package TCGAbiolinks Colaprico, Silva [326]. In brief raw counts aligned to GRCh38 were 
downloaded and in lane normalised by gene length. Genes with expression mean across all 
samples which fell in the bottom quartile (<25%) were removed. Gene signatures were 
summed within a sample and the samples that fell in the upper quartile of summed 
expression for either the up-regulated genes or down-regulated genes were designated as 
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2:1 or 100:1 signature samples. Samples were removed if they appeared in both signatures. 
Overall survival for selected samples was plotted as Kaplan-Meier curves with p value 
calculated via log-rank test.  
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5.3 Results 
5.3.1 High-dose EBV-LCL stimulation drives a distinct transcriptional 
signature 
Given the novelty of the nanoString™ platform, no gold standard analysis pipeline has been 
developed. Therefore, a pilot experiment was performed to test different analysis algorithms 
and determine a suitable pipeline. The program EdgeR served as a bench mark given its 
wide use in RNA sequencing (RNAseq) analysis Robinson, McCarthy [311], McCarthy, 
Chen [312]. The performance of two newer programs—NanoStringDiff and DataSmart—
were tested against EdgeR [375]. Analysis of the preliminary dataset demonstrated that 
EdgeR performs better than alternative algorithms. This is illustrated by the density plot of 
false discovery rate corrected p values (FDR) (Supplementary figure 9.2.1A). Alternative 
algorithms—NanoStringDiff and DataSmart—result in considerably more significantly (FDR 
< 0.05) differentially expressed genes (DEGs). Additionally, reported log2 fold change 
(log2FC) values derived from NanoStringDiff are dramatically higher than EdgeR 
(Supplementary figure 9.2.1B). Therefore, to reduce false positives, EdgeR was used for all 
further analysis. Furthermore, EdgeR is widely used with the RNAseq community and thus, 
has been comprehensively tested and has detailed documentation [376].  
Initially, a titration experiment was performed to determine the threshold at which 
transcriptional profile is distinct. Gene expression analysis of 10-day EBV-LCL stimulated 
CTV- CD8+ T-cells revealed the number of DEGs was largest in comparisons containing the 
high (2:1) dose treatment (Figure 5.3.1.1A). Dimension reduction analysis demonstrated 
clear clustering of high-dose (2:1) EBV-LCL stimulated cells as a distinct population (Figure 
5.3.1.1B & C).  
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Figure 5.3.1.1 High-dose (2:1) EBV-LCL stimulation drives a distinct transcriptional 
profile. Cells were cultured with varying responder to stimulator ratios and following 10-
days of culture, divided CD8+ T-cells were sorted for transcriptional analysis. (A) Gene sets 
shown as waterfall plots resulting from pairwise analysis, where genes are ordered in terms 
of log2 fold change (logFC). Genes present are significantly differentially expressed as 
defined by p value < 0.05 following Benjamini & Hochberg multiple testings correction. (B) 
Hierarchical clustering using Euclidean distance and ward.D agglomeration. (C) Supervised 
K-means clustering with k = 2 and monte carlo bootstrapping = 100. n = 3 biological 
replicates from one experiment. 
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5.3.2 High-dose EBV-LCL stimulation induces significant transcriptional 
changes in both CD4+ and CD8+ T-cells 
To further investigate observed transcriptional alteration a larger biological (n = 6 donors) 
cohort was used. Analysis derived a number of statistically significant DEGs within both 
CTV- CD4+ and CD8+ T-cell compartments after differential dose EBV-LCL stimulation. 
High-dose EBV-LCL stimulated cells showed an increase in immunoinhibitory transcripts in 
both T-cell populations (Figure 5.3.2.1A & B). Alteration of the transcriptional profile was so 
significant that cells clustered according to stimulation dose (Figure 5.3.2.1C &D). 
Additionally, a number of effector molecules were found to be down-regulated following 
high-dose EBV-LCL stimulation in both T-cell populations (Figure 5.3.2.1E & F). 
 To better understand the transcriptional modulation induced by differential dose 
stimulation, the gene signatures were compared across T-cell compartments (Figure 
5.3.2.2). This overlap derived three gene signatures (Figure 5.3.2.2C). Two signatures 
represented the set of genes unique to CD8+ or CD4+ T-cells (Figure 5.3.2.2A & B). The 
third signature represents the set of genes shared between T-cell subsets (Figure 5.3.2.2D). 
With 38 genes the shared signature was the largest of all three signatures defined. All 
transcripts bar one (PTGDR2), followed the same expression pattern regardless of cell 
subtype (Figure 5.3.2.2D).  
82 
 
 
Figure 5.3.2.1 High-dose EBV-LCL stimulation drives a distinct transcriptional profile 
in CD4+ and CD8+ T-cells. Transcript expression data from proliferating CD4+ or CD8+ T-
cells following 10-days after a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) 
Waterfall plot of differentially expressed genes in CD8+ T-cells; α = 0.05, following Benjamini 
& Hochberg multiple testings correction, ordered by log2 fold change (logFC). (B) Waterfall 
plot for CD4+ T-cells. (C) CD8+ T-cell samples clustered by supervised K-means clustering 
with k = 2 and monte carlo bootstrapping = 100. (D) CD4+ T-cell samples clustered by 
supervised K-means. (E) Volcano plot of CD8+ T-cell genes where genes with a post-false 
discovery rate correction p value < 0.05 and a log2FC greater than 0.5 (fold change of 1.41) 
are highlighted in red (up-regulated in 2:1) or blue (up-regulated in 100:1). (F) Volcano plot 
of CD4+ T-cell genes. All comparisons are relative to gene expression in 100:1 samples. n 
= 6 biological replicates from one experiment.  
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Figure 5.3.2.2 Overlap of differentially expressed genes induced by differential 
antigen dose stimulation in proliferating CD4+ and CD8+ T-cells. Transcript expression 
data from proliferating CD4+ or CD8+ T-cells following 10-days after a high- (2:1) or low- 
(100:1) dose EBV-LCL stimulation. Differentially expressed genes (DEGs) in high vs. low 
dose comparison were overlapped between T-cell subsets to derive three signatures. (A) 
Waterfall plot of CD8+ T-cell specific DEGs that have P values < 0.05 following Benjamini & 
Hochberg multiple testings correction, ordered by log2 fold change (logFC). (B) Waterfall 
plot of CD4+ T-cell specific DEGs. (C) Venn diagram showing the number of DEGs shared 
between CD4+ and CD8+ T-cell populations. (D) Waterfall of DEGs shared between CD4+ 
and CD8+ T-cell populations, genes ordered by CD8+ T-cell values. All comparisons are 
relative to gene expression in 100:1 samples. n = 6 biological replicates from one 
experiment. 
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5.3.3 Low-dose EBV-LCL stimulation enriches CD8+ T-cells for effector gene 
sets  
To better understand the transcriptional signature induced by differential dose EBV-LCL 
stimulation, gene set enrichment analysis (GSEA) was performed. Analysis was performed 
for CD8+ T-cells as this population is of primary interest in ACT drug product development. 
Overall, GSEA revealed that low-dose EBV-LCL stimulated cells are enriched for gene sets 
of effector and memory subsets (Figure 5.3.3.1 & Supplementary figures 9.2.2–3). For 
example, low-dose EBV-LCL stimulated cells are enriched for genes over-represented in 
PD-1high CD8+ T-cells (Figure 5.3.3.1B). An observation which, is consistent with the up-
regulation of PD-1 at both the transcriptional and protein levels.  
 
Figure 5.3.3.1 Low-dose EBV-LCL stimulated CD8+ T-cells are enriched for effector 
and memory gene sets. Gene Set Enrichment Analysis from 10-day cultures of divided 
CD8+ T-cells after high- (2:1) or low- (100:1) dose EBV-LCL stimulation. Gene sets shown 
are significantly enriched within low-dose stimulated cultures. (A) Bar graph showing the 
absolute normalised enrichment score (Abs NES) value for gene sets with FDR ≤ 0.05 
enriched in low-dose stimulated CD8+ T-cells. (B–D) Heatmap showing the gene expression 
pattern of genes from selected enriched gene sets. (B) Gene set based on human 
experimental data. (C & D) Gene sets which are based upon murine data. n = 6 biological 
donors per group, red = increased expression, blue = decreased expression, DN = down-
regulated, UP = up-regulated. 
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As an additional method to interrogate the transcriptional signature derived from 
differential dose stimulation, the String Database was utilised. Analysis demonstrated that 
high-dose EBV-LCL stimulated cells carry a gene signature that is enriched for genes of 
transcription factor activity, inflammation, TCR signalling, cytokine signalling, and immune 
responses, among various others (Supplementary figure 9.2.4). Comparatively, the low-
dose EBV-LCL stimulated cells were enriched for genes related to cytokine receptor activity, 
co-signalling, immune response, inflammation, and cell adhesion, among others 
(Supplementary figure 9.2.5).  
 
5.3.4 Differentially expressed genes are altered at the protein level 
The nanoString™ platform is described as a sensitive gene expression profiling tool [369]. 
However, this platform is relatively novel. Therefore, we sought to validate DEGs at the 
protein level. A number of semi-randomly selected genes were assayed in both CD4+ and 
CD8+ T-cells following high or low-dose EBV-LCL stimulation. In most cases, DEGs 
validated at the protein level. Additionally, differences in expression were largely confined 
to the CTV- population. For example, within the CD8+ T-cell population, up-regulated genes 
FOXP3, GATA3, and ENTPD1 (encodes protein CD39) all showed increased protein 
expression in high-dose EBV-LCL stimulated CTV- CD8+ T-cells (Figure 5.3.4.1A–C). 
Conversely, the down-regulated gene CCR5, was decreased in protein expression in high-
dose stimulated T-cells (Figure 5.3.4.1D). Within the CD4+ T-cell population, the proteins 
CCR5 and CD45RO were both found to be decreased following high-dose stimulation, 
consistent with gene expression data (Figure 5.3.4.2A & B). Additionally, the proteins CD103 
and CD38 validated gene expression data in both frequency of positive cells and fluorescent 
intensity (Geomean) (Figure 5.3.4.3A & B).  
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Figure 5.3.4.1 Protein expression changes validate transcriptional analysis of CD8+ T-
cells. Protein expression of four genes found to be differentially expressed at the transcript 
level in high (2:1) vs. low (100:1) dose EBV-LCL stimulated CD8+ T-cells. Cells were 
assayed via flow cytometry after 10-day culture following EBV-LCL stimulation. (A) 
Geometric mean (Geomean) protein expression of FOXP3. (B) Geomean protein 
expression of GATA3. (C) Geomean protein expression of CD39. (D) Geomean protein 
expression of CCR5. n = 5 biological replicates from one experiment where p values are 
derived from repeated measures two-way ANOVA with Sidak’s multiple comparison testing. 
 
 
Figure 5.3.4.2 Protein expression changes validate transcriptional analysis of CD4+ T-
cells. Protein expression of two genes found to be differentially expressed at the transcript 
level in high (2:1) vs. low (100:1) dose EBV-LCL stimulated CD4+ T-cells. Cells were 
assayed via flow cytometry after 10-day culture following EBV-LCL stimulation. (A) 
Geometric mean (Geomean) protein expression of CCR5. (B) Geomean protein expression 
of CD45RO. n = 5 biological replicates from one experiment where p values are derived 
from repeated measures two-way ANOVA with Sidak’s multiple comparison testing. 
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Figure 5.3.4.3 Protein expression changes validate transcriptional analysis of CD4+ T-
cells. Protein expression of two genes found to be differentially expressed at the transcript 
level in high (2:1) vs. low (100:1) dose EBV-LCL stimulated CD4+ T-cells. Cells were 
assayed via flow cytometry after 10-day culture following EBV-LCL. (A) Protein expression 
of CD103 was decreased in both cell frequency (top) and geometric mean (Geomean) 
fluorescent intensity (bottom) in high-dose treated CD4+ T-cells. (B) Expression of CD38 
was increased in high-dose treated CD4+ T-cells both in terms of frequency (top) and 
geomean fluorescent intensity (bottom). n = 5 biological replicates from one experiment 
where p values are derived from repeated measures two-way ANOVA with Sidak’s multiple 
comparison testing. 
 
Although gene expression was not analysed in NK cells, this cellular subset showed 
similar trends for the expression of CD39, GATA3, and CD38 at the protein level 
(Supplementary figure 9.2.6). Additionally, a number of genes not found to be differentially 
expressed at the transcript level were identified as altered at the protein level 
(Supplementary figure 9.2.7). 
 During the process of validating gene signatures, a number of interesting 
observations were made. Firstly, IL-10 expression was significantly elevated in both CD4+ 
and CD8+ T-cell populations (Figure 5.3.4.4, top and middle panels). A similar observation 
was made for CD3-CD19- cells; which, based on previously presented data are presumed 
to be NK cells (Figure 5.3.4.4, bottom panels). Gene expression data revealed IL2RA was 
up-regulated in both CD4+ and CD8+ T-cells after high-dose EBV-LCL stimulation. Gene 
expression was validated at the protein level with IL-2Rα expression increased in CD4+, 
CD8+ T-cells, and CD3-CD19- cells after high-dose stimulation (Figure 5.3.4.5). Importantly, 
altered expression was only observed for the CTV- population, thus demonstrating a clear 
association with proliferation. 
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Figure 5.3.4.4 High-dose EBV-
LCL stimulation increases 
expression of IL-10. Expression 
of IL-10 protein in different cell 
subsets after 10-days of culture 
after a high- (2:1) or low- (100:1) 
dose EBV-LCL stimulation. (A) 
Frequency of IL-10+ cells in CD8+ 
T-cells (top), CD4+ T-cells 
(middle) or CD3-CD19- (bottom). 
(B) Geometric mean (Geomean) 
of IL-10 fluorescence intensity in 
CD8+ T-cells (top), CD4+ T-cells 
(middle) or CD3-CD19- cells 
(bottom). n = 5 biological 
replicates from one experiment 
where p values are derived from 
repeated measures two-way 
ANOVA with Sidak’s multiple 
comparison testing. 
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Figure 5.3.4.5 High-dose EBV-LCL 
stimulation increases expression 
of IL-2Rα. Expression of IL-2Rα 
protein in different cell subsets after 
10-days of culture after a high- (2:1) 
or low- (100:1) dose EBV-LCL 
stimulation. (Left panels) Frequency 
of IL-2Rα+ cells in CD8+ T-cells (top), 
CD4+ T-cells (middle) or CD3-CD19- 
(bottom). (Right panels) Geometric 
mean (Geomean) of IL-2Rα 
fluorescence intensity in CD8+ T-cells 
(top), CD4+ T-cells (middle) or CD3-
CD19- cells (bottom). n = 5 biological 
replicates from one experiment where 
p values are derived from repeated 
measures two-way ANOVA with 
Sidak’s multiple comparison testing. 
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Gene expression analysis showed a clear up-regulation of ZBTB16 in both CD4+ and 
CD8+ T-cells following high-dose stimulation. Flow cytometric staining of the PLZF protein—
encoded for by the ZBTB16 gene—validated gene expression data (Figure 5.3.4.6). PLZF 
was found to be increased specifically within the CTV- population of CD4+, CD8+ T-cells, 
and CD3-CD19- cells (Figure 5.3.4.6). Furthermore, the highest frequency of PLZF+ cells 
was observed in the CD3-CD19- cell population. Despite observations of differentially 
regulated FOXP3, IL2RA, and IL-2Rα there was no difference in the expansion of regulatory 
CD4+ T-cells (Tregs) (Supplementary figure 9.2.8) [377]. 
 
 
Figure 5.3.4.6 PLZF expression is increased in high antigen stimulated cells. 
Expression of PLZF protein in different cell subsets after 10 days of culture against 
autologous lymphoblastoid cell lines following either a high (2:1) antigen (Ag) or low Ag 
(100:1) dose stimulation. (Left panels) Frequency of PLZF+ cells in CD8+ T-cells (top), CD4+ 
T-cells (middle) or CD3-CD19- (bottom). (Right panels) Geometric mean (Geomean) of 
PLZF fluorescence intensity in CD8+ T-cells (top), CD4+ T-cells (middle) or CD3-CD19- cells 
(bottom). n = 5 biological replicates from one experiment where p values are derived from 
repeated measures two-way ANOVA with Sidak’s multiple comparison testing. 
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5.3.5 EBV-LCL stimulation induces significant changes to CD8+ T-cell 
transcriptional profile 
To better understand the impact expansion has on the transcriptional signature of CD8+ T-
cells, we assessed transcript signatures relative to an unstimulated exvivo CD8+ T-cell 
control (Figure 5.3.5.1). EBV-LCL stimulation induced a large number of transcriptional 
differences in CD8+ T-cells (Figure 5.3.5.1A). Notably, EBV-LCL stimulated cells broadly up-
regulate expression of effector molecules and IRs (Figure 5.3.5.1B & C). Overall, cells from 
stimulated cultures are more transcriptionally related to each other than to exvivo CD8+ T-
cells (Figure 5.3.5.1D). Similar results were obtained for 21-day cultures (Supplementary 
figure 9.2.9) 
 
Figure 5.3.5.1 EBV-LCL stimulation significantly alters the transcriptional landscape 
of CD8+ T-cells. The transcriptional signature of high- (2:1) or low- (100:1) dose EBV-LCL 
stimulated cells after 10-days of culture compared with exvivo CD8+ T-cells. (A) Heatmap of 
all genes measured with unsupervised clustering (Euclidean distance and Ward.D 
clustering), colour scaling is by both column and row. (B) Waterfall plot of significantly 
differentially expressed (FDR < 0.05) genes in Day 10 2:1 vs Exvivo comparison. (C) 
Waterfall plot of differentially expressed genes in Day 10 100:1 vs Exvivo comparison. (D) 
Unrooted dendrogram showing association between samples, clustering was performed 
using Euclidean distance and Ward.D clustering. n = 6 biological samples per treatment/time 
point.  
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5.3.6 EBV-LCL stimulation dose impacts the transcriptional landscape of CD8+ 
T-cells after a prolonged (21-day) culture  
To produce a viable ACT product, a large cell yield is required. Therefore, the transcriptional 
landscape following a prolonged (21 day) culture period with IL-2 supplemented media was 
assayed. Consistent with previous results, the stimulation dose of EBV-LCLs used had a 
measurable impact upon the transcriptional profile (Figure 5.3.6.1). Transcriptionally, EBV-
LCL dose separated samples above background donor variation (Figure 5.3.6.1A). A 
number of DEGs overlapped with those seen after a short-term culture (Figure 5.3.6.1B). 
Therefore, this data suggests that the EBV-LCL stimulation dose can have a long-lasting 
impact on the transcriptional profile of expanded cells.  
 
 
 
5.3.7 Culture duration and EBV-LCL stimulation dose has a significant impact 
on the transcriptional profile of CD8+ T-cells 
Results have demonstrated that EBV-LCL stimulation dose can significant impact the 
transcriptional profile of CD8+ T-cells. Furthermore, experimentation has shown that the 
transcriptional impact of EBV-LCL stimulation can be observed after a prolonged culture 
period. To explore these notions further the datasets for short-term and long-term cultures 
were combined and compared (Figure 5.3.7.1). The DEGs derived from 21-day vs. 10-day 
comparisons for high or low-dose EBV-LCL stimulated cultures are presented as a venn 
Figure 5.3.6.1 EBV-LCL 
stimulation dose impacts the 
transcriptional landscape of 
CD8+ T-cells after a prolonged 
culture. Divided CD8+ T-cells were 
cultured for 21-days following a 
high- (2:1) or low- (100:1) dose 
EBV-LCL stimulation. (A) Principle 
component analysis of the 
transcriptional signature of high- or 
low-dose cells. (B) Waterfall plot 
showing the significantly (FDR < 
0.05) differentially expressed 
genes in high vs. low dose 
comparison. n = 6 biological donors 
per treatment, analysis represents 
pooled data from two independent 
experiments, with batch effects 
removed. 
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diagram (Figure 5.3.7.1). This comparison allows dissection of which genes are temporally 
regulated and which are Ag dose driven. Results reveal 35 DEGs unique to high-dose 
stimulated cells from short- or long-term cultures (Figure 5.3.7.1A). Additionally, 16 DEGs 
were found to be unique to low-dose stimulated cells regardless of timepoint (Figure 
5.3.7.1C). Comparatively, 26 genes were found to be common across differential stimulation 
doses and therefore primarily temporally regulated (Figure 5.3.7.1B). Clustering of all 
samples demonstrates that high and low-dose EBV-LCL stimulated cells are most 
transcriptionally different after 10-days of culture (Figure 5.3.7.1D).  
 
 
Figure 5.3.7.1 Transcriptional signature of CD8+ T-cells is regulated by both culture 
duration and EBV-LCL stimulation dose. Gene expression data of divided CD8+ T-cells 
following 10-day (D10) or 21-day (D21) culture after a high- (2:1) or low- (100:1) dose EBV-
LCL stimulation. Venn diagram represents differentially expressed genes (DEGs) (FDR < 
0.05) from D21 vs. D10 high dose comparison overlapped with DEGs from D21 vs. D10 low 
dose comparison. (A) Heatmap of DEGs unique to D21 vs. D10 high dose comparison. (B) 
Heatmap of DEGs shared between the two comparisons. (C) Heatmap of DEGs unique to 
D21 vs. D10 low dose comparison. (D) Unrooted dendrogram showing overall sample 
relationships. Heatmaps and dendrogram generated using Euclidean distance and Ward.D2 
or Ward.D clustering respectively. n = 6 biological replicates per treatment group and time 
point.  
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5.3.8 AdE1-LMPpoly infected APC stimulation dose impacts CD8+ T-cell 
transcriptional profile 
Data has demonstrated the significant and long-lasting impact EBV-LCL stimulation and 
dose can have on the transcriptional profile of CD8+ T-cells. However, other stimulation and 
expansion methods are commonly used to derive ACT drug products. Therefore, the 
transcriptional consequence of AdE1-LMPpoly infected APCs as a stimulation method was 
evaluated. High (R:S ratio of 2:1) or low (R:S ratio of 100:1) dose AdE1-LMPpoly APC 
stimulation derived two distinct transcriptional profiles after a 10-day culture (Figure 
5.3.8.1A). Analysis of the DEGs induced by differential dose stimulation reveals a number 
of interesting genes (Figure 5.3.8.1B). Comparison of the transcriptional landscape of AdE1-
LMPpoly APC stimulated cells and exvivo CD8+ T-cells reveals large transcriptional changes 
associated with expansion (Supplementary figure 9.2.10). AdE1-LMPpoly APC stimulation 
dose does not result in measurable transcriptional changes following a prolonged (21-day) 
culture (Supplementary figure 9.2.11). However, cells are transcriptional distinct from exvivo 
CD8+ T-cells (Supplementary figure 9.2.12). Suggesting a large temporal influence in this 
experimental set up (Supplementary figure 9.2.13).  
 
 
Figure 5.3.8.1 AdE1-LMPpoly stimulation dose in a short-term culture induces a 
distinct transcriptional profile in CD8+ T-cells. Gene expression of divided CD8+ T-cells 
following 10-day culture after AdE1-LMPpoly-based stimulation. (A) Supervised K-means 
clustering (K = 2) of samples stimulated with either a high- (2:1) or low- (100:1) dose. (B) 
Heatmap of significantly (FDR < 0.05) differently expressed genes between high- and low-
dose stimulated samples. n = 3 biological replicates per treatment. 
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5.3.9 EBV-Pepmix APC stimulation dose has a minimal impact on CD8+ T-cell 
transcriptional profile 
Expanding cells using EBV-Pepmix-pulsed APC stimulation is a valid method for 
manufacturing epitope-specific T-cells [197, 255]. Hence, we investigated the transcriptional 
impact of dose and culture duration using this expansion method. Analysis of the 
transcriptional landscape following this expansion method revealed no measurable 
difference in gene expression between high (R:S ratio of 2:1) or low (R:S ratio of 100:1) 
dose EBV-Pepmix stimulated CTV- CD8+ T-cells (No DEGs detected, data not shown). As 
an alternative expansion method, two differential doses of EBV-Pepmix were added directly 
to culture media. Thus, bypassing traditional step of coating stimulator APCs with EBV-
peptides. Using EBV-Pepmix in this manner resulted in marginal transcriptional differences 
(Figure 5.3.9.1). This result corroborates previous results; which, suggests EBV-Pepmix 
APC stimulation dose has a minimal impact on CD8+ T-cell transcription.  
Similar observations were made for a prolonged (21-day) culture when following 
stimulation with EBV-Pepmix-pulsed APC stimulation (Supplementary figure 9.2.15). Given 
these results, it is unsurprising that culture duration plays a more significant role in shaping 
the transcriptional profile in this setting (Supplementary figure 9.2.17). Interestingly, 
extending culture duration appears to reduce the transcriptional variability across 
differentially stimulated samples (Supplementary figure 9.2.17). This can also be observed 
in exvivo comparisons, whereby day 21 cultured samples cluster more tightly 
(Supplementary figure 9.2.14 & 9.2.16).  
 
 
 
Figure 5.3.9.1 The stimulation 
dose of free-floating EBV-
Pepmix in a short-term culture 
has a marginal effect on the 
transcriptional profile of CD8+ 
T-cells. Gene expression of 
divided CD8+ T-cells following 10-
day culture after stimulation with 
EBV-Pepmix added directly to 
culture. (A) Heatmap of 
differentially expressed genes 
(FDR < 0.05) in comparison of 
1μg vs. 0.01μg stimulated cells. 
(B) Waterfall plot of differentially 
expressed genes. n = 3 biological 
replicates.  
−1 0 1
Row Z−Score
Color Key
K
LR
B
1
HA
VC
R2
CD
27
S
E
LL
-2
-1
0
1
2
3
Lo
g 2
FC
A
B
SELL
KLRB1
HAVCR2
CD27
1μg
0.01μg
95 
 
5.3.10 AdE1-LMPpoly and EBV-Pepmix stimulated CD8+ T-cells are 
transcriptionally similar 
This chapter has revealed the transcriptional impact of differential Ag dose stimulation for 
three broad Ag sources. Furthermore, this chapter has considered how culture duration 
shapes the transcriptional profile for any given Ag source. However, it is informative to 
consider how the different Ag sources impact the CD8+ T-cell transcriptional landscape. As 
seen in figure 5.3.10.1, EBV-Pepmix- and AdE1-LMPpoly-based stimulation regimes 
produce similar transcriptional profiles in CD8+ T-cells. Therefore, demonstrating that LCL-
based stimulation produces the most distinct transcriptional signatures. This observation 
holds true for prolonged (21-day) culture; where, LCL-based stimulation results in a distinct 
transcriptional signature (Supplementary figure 9.2.18). However, it is worth noting that 
prolonged culture does somewhat abrogate the transcriptional differences between 
expansion regimes. 
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Figure 5.3.10.1 EBV-LCL 
stimulation results in a 
distinct transcriptional 
signature in CD8+ T-cells. 
Gene expression of divided 
CD8+ T-cells after a 10-day 
culture with differing antigenic 
stimulants. EBV-Pepmix-
pulsed APCs (Peptide), AdE1-
LMPpoly infected APCs 
(Adeno), or EBV-LCL (LCL) 
were used as antigenic 
stimulants at a high- (2:1) or 
low- (100:1) dose. (A) Top 
graphs demonstrate the results 
of high dose stimulated cultures 
from differing antigenic 
sources. Unrooted dendrogram 
demonstrates overall sample 
relationships and waterfall plots 
reveal the differentially 
expressed genes (FDR < 0.05) 
from all possible comparisons. 
(B) Same as (A) for low-dose 
stimulated cultures. 
Comparisons written as sample 
vs. control. n = 6 LCL, and 3 
Adeno/Peptide, biological 
replicates per treatment. 
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5.3.11 Low-dose EBV-LCL stimulation induces a transcriptional signature 
associated with improved patient survival  
Given the significant impact EBV-LCL stimulation has on the transcriptional landscape of 
CD8+ T-cells, further investigation was done. A bioinformatic approach similar to that 
presented in Bottcher, Bonavita [289] was utilised. This analysis method used publicly 
available RNAseq data from The Cancer Genome Atlas (TCGA) (n = 33 disease 
indications). For all available disease indications, patients were stratified by gene expression 
(see methods 5.2.3). In brief, patients in the TCGA were stratified by the DEG signature of 
CTV- CD8+ T-cells induced after high- (2:1) or low- (100:1) dose EBV-LCL stimulation 
(Figure 5.3.11.1A). Overall, this analysis revealed that patients with a low dose 
transcriptional signature, had a significant increase in overall survival (Figure 5.3.11.1B & C 
and Supplementary figure 9.2.19). This trend was observed in other disease indications; 
however, low sample number post-stratification meant these did not reach statistical 
significance (Data not shown). The transcriptional signature of CTV- CD8+ T-cells after a 
prolonged (21-day) culture, was also associated with improved overall survival across 
various diseases (Supplementary figure 9.2.20).  
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Figure 5.3.11.1 Low-dose EBV-LCL stimulation induces a transcriptional signature in 
CD8+ T-cells associated with improved overall survival. Gene expression data from 
divided CD8+ T-cells stimulated with EBV-LCL for 10-days was used to subset patients in 
The Cancer Genome Atlas (TCGA). RNA sequencing data was used to stratify patients in 
the TCGA as having either a high- (2:1) or low- (100:1) dose signature. (A) The gene 
signature used in TCGA analysis, where up-regulated genes are in red (high dose or 2:1 
signature) and down-regulated genes are in blue (low dose or 100:1 signature). (B & C) 
Kaplan-Meier curves of overall survival in patients with Head and Neck Squamous Cell 
Carcinoma, Lung Squamous Cell Carcinoma, and Sarcoma. p value calculated using log-
rank test. 
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 Similar results are seen when this analysis method is applied to the transcriptional 
signature of CTV- CD4+ T-cells from 10-day cultures (Figure 5.3.11.2). In fact, observations 
were shared across CD4+ and CD8+ T-cell signatures for both head and neck squamous 
cell carcinoma (HNSC) and lung squamous cell carcinoma (LUSC) (Figure 5.3.11.2A & C). 
Furthermore, the low dose transcriptional signature in CD4+ T-cells was found to be 
associated with an improved overall survival in three additional diseases (Figure 5.3.11.2B, 
D, & E).  
 
 
Figure 5.3.11.2 Low-dose EBV-LCL stimulation induces a transcriptional signature in 
CD4+ T-cells associated with improved overall survival. Gene expression data from 
divided CD4+ T-cells after EBV-LCL stimulation for 10-days was used to subset patients in 
The Cancer Genome Atlas (TCGA). RNA sequencing data was used to stratify patients in 
the TCGA as having either a high- (2:1) or low- (100:1) dose EBV-LCL signature. (A–E) 
Kaplan-Meier curves of overall survival in patients with Head and Neck Squamous Cell 
Carcinoma, Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Uterine 
Corpus Endometrial Carcinoma, and Stomach Adenocarcinoma. p value calculated using 
log-rank test. 
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Interestingly, the inverse trend was observed in acute myeloid leukemia (LAML) 
patients. For both CD4+ and CD8+ T-cell signatures at 10-days of culture, high-dose EBV-
LCL stimulation was associated with an increase in overall survival in LAML patients (Figure 
5.3.11.3). Perhaps the haematological nature of LAML provides an explanation for the 
inconsistency in results obtained for solid malignancies.  
 
 
Figure 5.3.11.3 High-dose EBV-LCL stimulation induces a transcriptional signature in 
CD4+ and CD8+ T-cells associated with improved overall survival in acute myeloid 
leukemia. Gene expression data from divided CD4+ or CD8+T-cells after EBV-LCL 
stimulation for 10-days was used to subset patients in The Cancer Genome Atlas (TCGA). 
RNA sequencing data was used to stratify patients in the TCGA as having either a high- 
(2:1) or low- (100:1) dose EBV-LCL signature. (A & B) Kaplan-Meier curves of overall 
survival in patients with acute myeloid leukemia. p value calculated using log-rank test. 
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5.4 Discussion 
ACT immunotherapy is a valuable therapeutic modality and has shown success across 
numerous disease types [215, 249, 250, 378, 379]. Central to ACT immunotherapy is the in 
vitro stimulation and expansion of T-cells. Previously published data has demonstrated that 
T-cell expansion methods can have a significant impact on the quality of a T-cells and impact 
therapeutic outcomes [296, 336]. Indeed, our experimentation has shown that stimulation 
dose, antigen source, and culture duration all have significant influence on the final T-cell 
drug product (Chapter 4). Broadly, it was discovered that EBV-LCL stimulation had the most 
substantial impact on T-cell phenotype and function. More specifically, a high-dose EBV-
LCL stimulation drove an immunoinhibitory profile (Chapter 4). Numerous trials and 
research groups rely on a high-dose EBV-LCL stimulation to derive their therapeutic product 
[196, 220, 282]. Thus, it was prudent to further characterise the impact of differential ACT 
drug product manufacturing methods. 
 T-cell exhaustion is known to have deep molecular roots. For example, a pivotal 
paper by Wherry, Ha [91] found exhausted T-cells to have a unique transcriptional signature, 
disparate from naïve, memory, or effector cells. Thus, to better understand the cellular 
impact of differential ACT drug product manufacturing methods we interrogated the 
transcriptional consequences. Three stimulation and expansion methods were tested for 
their effects on T-cell transcription. Consistent with previous data (Chapter 4), EBV-LCL 
stimulation induced the largest transcriptional changes. Both EBV-Pepmix- and AdE1-
LMPpoly-based stimulation had similar and minimal transcriptional effects. Titration of EBV-
LCL stimulation dose revealed that transcriptional effects were correlated with stimulation 
dose. Further experimentation with an extended cohort showed that high- (2:1) or low- 
(100:1) dose EBV-LCL stimulated CD4+ and CD8+ T-cells had unique transcriptional 
signatures. This demonstrated that ACT manufacturing methodology can have a substantial 
impact on the resultant T-cell drug product. Furthermore, these data demonstrate the utility 
of transcriptional profiling of an ACT drug product. 
 Numerous transcripts encoding IR were up-regulated following high-dose EBV-LCL 
stimulation and concurrently, a number of effector molecules were down-regulated. 
Interestingly, IRF4 was found to be up-regulated following high-dose stimulation. IRF4 has 
been linked with CD8+ T-cell exhaustion during chronic infection [380]. Additionally, IRF4 is 
known to be regulated by TCR signaling strength, suggesting that high-dose EBV-LCL 
stimulation led to increased TCR signaling [381, 382]. In line with this, pathway analysis 
revealed that genes up-regulated following high-dose EBV-LCL stimulation were associated 
with TCR signaling. The connection between TCR signaling and T-cell exhaustion is well 
101 
 
documented [105, 335, 383]. Given the increase in genes associated with TCR signaling, it 
is unsurprising that a high-dose EBV-LCL stimulation promoted a dysfunctional T-cell 
transcriptional landscape. However, it must be noted that a number of genes found to be 
differentially expressed within the high-dose EBV-LCL stimulation were inconsistent with an 
exhaustion signature. One such gene is MAF, which was identified to be down-regulated in 
high-dose EBV-LCL stimulated CD4+ and CD8+ T-cells. MAF expression has been 
implicated as a driver of T-cell exhaustion in murine studies [384]. Nevertheless, the overall 
transcriptional signature induced by high-dose EBV-LCL stimulation reflects immune 
inhibition.  
 GSEA was performed to better understand the gene signature induced by differential 
dose stimulation. This analysis demonstrated that low-dose EBV-LCL-stimulated CD8+ T-
cells were enriched for activation- and memory-associated gene sets. In consideration with 
previous data, this reaffirms the hypothesis that high-dose stimulation drives T-cell 
dysfunction while low-dose stimulation promotes a more functional T-cell drug product. A 
particularly interesting observation in this analysis was the enrichment of PD-1High CD8+ T-
cell and PD-1Low CD8+ T-cell gene sets, which supports the notion that PD-1 transcript and 
protein up-regulation in low-dose EBV-LCL stimulated cultures is associated with T-cell 
differentiation and activation, as opposed to a dysfunction. Indeed, the dataset from which 
these gene signatures were derived, found that PD-1High CD8+ T-cells from healthy human 
subjects were not similar to gene sets related to T-cell exhaustion [385]. Furthermore, the 
authors reported that PD-1High CD8+ T-cells had gene expression reflecting a TEM cell 
phenotype, when compared with TN or TEMRA subsets [385]. These data fit with previous 
observations that low-dose EBV-LCL stimulation preferentially expanded TEM cells (Chapter 
4) [343]. Therefore, PD-1 expression appears to mark T-cell activation within this system. 
Furthermore, GSEA supports the notion that low-dose EBV-LCL stimulation promotes a 
more desirable T-cell therapeutic product.  
 The TCGA database represents a vast resource of patient data. We therefore 
leveraged the publicly-available sequencing data to investigate the in vivo consequence of 
gene signatures driven by high- or low-dose EBV-LCL stimulation. This analysis showed 
that patients with a gene signature similar to that induced by low-dose EBV-LCL stimulation, 
had improved overall survival in numerous oncological settings. This was observed for gene 
signatures from both CD4+ and CD8+ T-cells, and gene signatures from a prolonged (21-
day) culture, altogether demonstrating a robust treatment effect. Interestingly, both EBV-
associated [386] and non-EBV-associated malignancies within the TCGA dataset showed a 
clear overall survival benefit when the gene signature from a low-dose EBV-LCL stimulation 
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was used. This result is important given that EBV-LCLs are routinely used as APCs to derive 
antigen-specific T-cells targeting non-EBV malignancies or diseases [261, 263, 264]. 
Furthermore, a number of studies have reported the use of high-dose and multiple-dose 
EBV-LCL stimulation strategies [226, 231, 255, 267, 268]. An interesting deviation to these 
results was seen in LAML patients; which showed an inverse trend. LAML patients with a 
high-dose EBV-LCL gene signature had improved overall survival. It is postulated that the 
tissue origin of this disease explains these contradictory results. Explicitly, immune gene 
expression within solid malignancies likely represents TILs and their function or phenotype. 
Conversely, immune gene expression within a hematological malignancy may be derived 
from the diseased cells and thus, reflect the phenotype and functional profile of cancerous 
cells. Such a hypothesis will undoubtedly need to be assessed by further experimentation. 
However, overwhelmingly TCGA analysis revealed that low-dose stimulation drives a gene 
expression signature that predicts favorable outcomes in patients. Thus, if gene expression 
within these solid malignancies is owing to TIL gene expression, this would suggest low-
dose stimulation produces a clinically superior ACT product. This observation is supported 
by previous reports [300, 341, 342]. Furthermore, these data demonstrate utility in such an 
analytical approach for ACT drug product evaluation.  
 An interesting observation that could be made from the transcriptional signatures is 
the apparent skew towards type 2 T-cell responses. Both CD4+ and CD8+ T-cells showed 
gene expression patterns akin to Th2 and Tc2 subsets, respectively, following high-dose 
EBV-LCL stimulation. Type 2 T-cells are described as anti-inflammatory and are 
characterized by their expression of IL-13, IL-5, IL-4, and IL-10 [387-389]. Indeed, CD8+ T-
cells cultured using a high-dose EBV-LCL stimulation showed a significant increase in the 
expression of IL13 and IL5 transcripts. Additionally, IL-10 protein expression was found to 
be increased in high-dose EBV-LCL-stimulated cultures. Tc2 cells are described as having 
increased IL-2Rα and decreased cytotoxic molecule production [389, 390]. Consistent with 
this hypothesis, both IL-2Rα protein and gene expression were increased in high-dose 
stimulated T-cells. Cytotoxic molecules were also observed to be down-regulated at both 
protein (Chapter 4) and transcript levels in high-dose-stimulated T-cells. Furthermore, 
GATA3, IRF4, and STAT5 are transcription factors associated with type 2 T-cell responses 
[389, 391-393]. GATA3 and IRF4 transcripts were found to be up-regulated in both T-cell 
subsets following high-dose EBV-LCL stimulation. Additionally, GATA3 protein expression 
was found to be increased in CTV- CD8+ T-cells. The STAT5A gene—a subunit of the larger 
STAT5 protein complex—was also found to be up-regulated following high-dose stimulation 
but only within the CD8+ T-cell population [393]. There were some notable inconsistencies 
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with this hypothesis, specifically transcription factors MAF and BACH2 as well as receptors 
IL-12Rβ2 and PTGDR2, where transcript expression was contrary to their proposed role in 
type 2 T-cell development [389, 394]. In the case of PTGDR2 (encodes CRTH2), expression 
within CD8+ T-cells is consistent with published reports; however, expression within CD4+ 
T-cells is contradictory.  
 Previous experimentation has demonstrated that culture conditions can have a 
significant impact in type 1 vs. type 2 polarization of T-cells [296, 395]. Explicitly, reports 
have implicated TCR signaling and antigen stimulation dose as critical factors in type 1 vs. 
type 2 T-cell polarization [297, 368, 396, 397]. The association reported is that weak TCR 
signaling promotes type 2 T-cell polarization. Moreover, further experimentation has 
demonstrated that co-stimulatory signaling has an integral role in type 1 vs. type 2 
determination [398]. Functionally, a number of experiments have suggested that type 2 T-
cells are sub-optimal in cancer and infectious disease treatment [399-401]. In the context of 
immunotherapy, type 1 CD8+ T-cells (Tc1 cells) have been shown to produce more favorable 
responses owing to their improved cytotoxicity and survival profiles [390, 402]. Taken 
together, these data suggest that high-dose EBV-LCL stimulation propagates T-cells 
towards a type 2 phenotype. In the context of viral or malignant disease treatment however, 
a type 1 response is superior, further indicating that a low-dose stimulation is preferential in 
the expansion of T-cells used for therapy.  
 A few other interesting observations can be made from the transcription data 
presented. Differential gene expression analysis showed the consistent up-regulation of 
ZBTB16, which encodes for the innate cell-associated transcription factor PLZF [403-406]. 
This observation was validated at the protein level, with non-T- or B-cells showing the 
highest expression. This observation suggests that high-dose EBV-LCL stimulation likely 
promotes the expansion of innate cell subsets, which would be consistent with the increased 
expansion of NK cells seen following high-dose stimulation (Chapter 4). Adenosine is known 
to have potent immunosuppressive effects on T-cells [167, 168]. Consistent with an 
immunoinhibitory phenotype, high-dose EBV-LCL stimulation resulted in increased 
expression of members that make up the extracellular adenosine production pathway—
ENTPD1, NT5E, and CD38.  
 In addition to EBV-LCL stimulation, two other methods were employed to expand T-
cells. These methods were also assayed for their transcriptional impact. As previously 
mentioned, both AdE1-LMPpoly infected and EBV-Pepmix-pulsed APC stimulation resulted 
in similar transcriptional signatures. Differential stimulation dose did derive distinct 
transcriptional profiles in CD8+ T-cells after a short-term culture with AdE1-LMPpoly. 
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However, this result did not hold true after a prolonged culture. Furthermore, EBV-Pepmix-
pulsed APC dose did not impart a significant transcriptional difference irrespective of culture 
duration. These results are consistent with previously presented data; which showed that 
these stimulation methods promote only minor phenotypic or functional alterations (Chapter 
4).  
 Results presented within this chapter clearly indicate that EBV-LCL-based stimulation 
has a substantial impact on T-cell transcription. Furthermore, high-dose EBV-LCL 
stimulation promotes an immunoinhibitory phenotype that has indications of T-cell 
exhaustion. Conversely, low-dose EBV-LCL stimulation propagated a transcription profile 
associated with activated effectors cells that predicted favorable patient outcomes across 
numerous oncology settings. Additionally, gene expression data suggests that high-dose 
stimulation polarizes T-cells towards a type 2 phenotype. This observation warrants further 
investigation. Altogether, these results demonstrate that a low-dose EBV-LCL stimulation is 
desirable for the manufacture of an ACT drug product, a result that is contradictory to current 
T-cell expansion protocols [196, 226, 231, 255]. Furthermore, these data highlight the utility 
of comprehensive ACT drug product assessment. Such transcriptional analysis is rarely 
performed on ACT drug products and was able to suggest the outgrowth of type 2 T-cells, 
a phenotype seldom assayed for. Thus, if routinely performed, this analytical approach may 
enable researchers to evaluate their ACT drug product manufacturing approach and 
modulate methodologies to improve therapeutic outcomes.   
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6.0 Assessment of the TCR repertoire expanded by differing 
antigen doses  
6.1 Introduction 
Immunotherapy is revolutionising cancer treatment. The immunotherapy modality ACT is 
particularly promising due to its highly targeted nature. ACT required an in vitro T-cell 
expansion step, to selectively expand efficacious cells with appropriate specificity. 
Numerous methods are currently in use to expand therapeutic T-cells. EBV-LCLs for 
example are a highly used source of both antigen for expansion of EBV-specific T-cells or 
as an APC for the expansion of other T-cell specificities [220, 222-224, 261-264]. Previously 
presented data has demonstrated that the dose of EBV-LCL stimulation can dramatically 
alter the transcriptional, functional, and phenotypic profile of expanded T-cells. Importantly, 
a large number of trials and groups frequently use a high-dose stimulation strategy; which, 
has been shown to produce a sub-optimal T-cell drug product [196, 220, 222, 226, 231, 255, 
266-268]. Given T-cell specificity is critical to immunotherapeutic outcomes it was prudent 
to investigate the impact EBV-LCL stimulation dose has on the resultant TCR repertoire. In 
recent years, sequencing technology has made significant advances allowing the entire 
TCR repertoire to be profiled [407, 408]. TCR sequencing (TCRseq) is herein exploited to 
investigate the impact stimulation dose has on the TCR repertoire of a T-cell drug product. 
 The classical TCR is a product of the unique combination of two chains. Combination 
of the α-chain and β-chain provides antigen specificity to a T-cell. Specifically, the CDR3 
loop—formed via V(D)J junction—confers a large amount of epitope specificity [44, 409]. 
Hence, majority of TCR-based analysis is heavily focused on the CDR3 loop as this 
indicates TCR uniqueness and specificity. Experimentation using TCRseq is beginning to 
elucidate the important role that the TCR repertoire plays in immunotherapy outcomes [28, 
30, 346, 410, 411]. However, TCRseq is rarely used to investigate an ACT drug product 
itself. Therefore, we used this technology to deconstruct the impact manufacturing 
methodology has on the TCR repertoire. Thus, also demonstrating the utility of this analysis 
in evaluating an ACT drug product. Previous research has already demonstrated a link 
between antigen stimulation dose and resultant T-cell avidity [296, 301]. Additionally, 
experimentation has shown the importance T-cell avidity has in anti-viral, anti-tumour, anti-
bacterial, and anti-protozoal immunity [300, 342, 412-416]. Hence, investigation of the TCR 
repertoire impact driven by manufacturing methodology will direct future ACT drug product 
development towards more efficacious and therapeutic outcomes.  
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6.2 Methods 
6.2.1 DNA extraction 
Cells were lysed in buffer RLT then processed using the QIAamp DNA Blood Mini Kit 
(QIAGEN®) as per manufacturer’s instructions. DNA concentration was then estimated 
using a NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific). DNA was stored at 
either -20°C for short-term storage or -80°C for long-term storage. 
 
6.2.2 T-cell receptor sequencing  
Sample Prep: DNA was extracted as previously described from ~0.5–1e6 sorted CD8+ CTV- 
T-cells and subject to ImmunoSEQ immune profiling system (Adaptive Biotechnologies®, 
Seattle, WA, U.S.A). 
 
Library Prep and Sequencing: Sample data was generated using the immunoSEQ assay 
(Adaptive Biotechnologies®). The somatically rearranged Human T-cell receptor beta locus 
(TCRβ) complementarity-determining region 3 (CDR3) was amplified from genomic DNA 
using a two-step, amplification bias-controlled multiplex PCR approach [417, 418]. 
Specifically, the first PCR consists of forward and reverse amplification primers specific for 
every V and J gene segment, and amplifies the hypervariable CDR3 of the immune receptor 
locus. The second PCR adds a proprietary barcode sequence and Illumina adapter 
sequences (4). CDR3 libraries were sequenced on an Illumina Nextseq 500 instrument 
according to the manufacturer’s instructions.  
 
Data Analysis: Raw Illumina sequence reads were demultiplexed according to Adaptive’s 
proprietary barcode sequences. Demultiplexed reads were then further processed to: 
remove adapter and primer sequences; identify and correct for technical errors introduced 
through PCR and sequencing; and remove primer dimer, germline and other contaminant 
sequences. The data is filtered and clustered using both the relative frequency ratio between 
similar clones and a modified nearest-neighbor algorithm, to merge closely related 
sequences. The resulting sequences were sufficient to allow annotation of the V(N)D(N)J 
genes constituting each unique CDR3 and the translation of the encoded CDR3 amino acid 
sequence. V, D and J gene definitions were based on annotation in accordance with the 
IMGT database (www.imgt.org). The set of observed biological TCRβ CDR3 sequences 
were normalized to correct for residual multiplex PCR amplification bias and quantified 
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against a set of synthetic TCRβ CDR3 sequence analogues [418]. Initial alignment and 
bioinformatics was performed using the ImmunoSEQ Analyzer platform.  
 
6.2.3 Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH) 
Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH) analysis was done 
using default settings in version 1.0 [419]. In brief, GLIPH analysis infers epitope specificity 
via grouping of TCRβ CDR3s by paratope motifs. Therefore, GLIPH creates clusters of 
TCRβ CDR3s that share a motif and thus are assumed to share epitope specificity. The core 
of the analysis involves determining paratope motifs significantly enriched within the sample. 
This is done via sequentially listing all possible k-mers (3- or 4-mer) that can be derived from 
a samples TCRβ CDR3 sequences. These k-mers are then compared against a dataset of 
naïve TCRβ CDR3s to test for statistical significance. Clusters are then created by grouping 
clones by statistically enriched motifs in common. Visualisation was achieved using custom 
analysis within the “R” language and Cytoscape version 3.4.0.  
 
6.2.4 Additional T-cell receptor sequencing analysis tools 
T-cell receptor sequencing data was analysed using packages VDJtools (Version 1.1.10) 
[420], VDJmatch (Version 1.2.0) [34] and R package “tcR” (Version 2.2.1.11) [33] 
programmatically using default settings.   
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6.3 Results 
6.3.1  Low-dose EBV-LCL stimulation increases T-cell receptor β-chain 
clonality  
General quality control (QC) analysis for TCRseq at both 10-days and 21-days of culture 
indicated read depth was sufficient (Supplementary figure 9.3.1 & 9.3.2).  
 Investigation of TCRseq data in terms of clonality revealed that 10-day cultures are 
significantly more clonal following a low-dose EBV-LCL stimulation (Figure 6.3.1.1 & 
Supplementary figure 9.3.3). A rarefaction plot clearly demonstrates low-dose EBV-LCL 
stimulated cultures are less diverse (Figure 6.3.1.1A). This clonality difference was primarily 
driven by the top two clones (Figure 6.3.1.1B). However, a difference in cumulative clonality 
extended and increased beyond these top two clones (Figure 6.3.1.1C). In contrast, a 
prolonged culture (21-days with IL-2 supplementation) did not show any clonality differences 
(Figure 6.3.1.2 & Supplementary figure 9.3.4).  
 
 
Figure 6.3.1.1 Low-dose EBV-LCL stimulation produces a more clonal TCR β-chain 
repertoire after short-term culture. TCR β-chain sequencing of CTV- CD8+ T-cells after 
10-days of culture following a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) 
Rarefaction plot of high- and low-dose stimulated samples. (B) Productive frequency of the 
top 10 clones (defined by CDR3 sequence). (C) Cumulative frequency of the top 10 clones 
(defined by CDR3 sequences). n = 6 biological donors per treatment, p values derived from 
two-way repeated measures ANOVA with Sidak’s multiple comparisons test, where α = 0.05. 
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Figure 6.3.1.2 EBV-LCL stimulation dose has no impact on TCR β-chain clonality after 
prolonged culture. TCR β-chain sequencing of CTV- CD8+ T-cells after 21-days of culture 
following a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) Rarefaction plot of 
high- and low-dose stimulated samples. (B) Productive frequency of the top 10 clones 
(defined by CDR3 sequence). (C) Cumulative frequency of the top 10 clones (defined by 
CDR3 sequences). n = 6 biological donors per treatment. 
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6.3.2 TCR β-chain V- and J-gene usage is unchanged by differential EBV-LCL 
stimulation dose 
We evaluated the expansion of specific TCRβ V- and J- genes to investigate the impact that 
differential EBV-LCL stimulation dose has on TCRβ gene usage. Heatmaps of TCRβ V- and 
J-gene usage failed to show any clear clustering by treatment. This was observed for both 
short-term (10-day) and long-term (21-day) cultures (Figure 6.3.2.1 & Supplementary figure 
9.3.5). 
 
 
Figure 6.3.2.1 TCR β-chain V- and J-gene usage is not influenced by EBV-LCL 
stimulation dose. TCR β-chain (TCRβ) V- and J-gene usage in CTV- CD8+ T-cell after 10-
day culture following a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A & B) 
Heatmaps of TCRβ V- and J-gene usage frequency, scaled by column. n = 6 biological 
donors per treatment. 
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6.3.3 TCR β-chain V- and J-gene pairing structure is altered by varying EBV-
LCL stimulation dose 
The frequency of TCRβ V- and J-gene usage fails to consider the complex nature of TCRβ 
gene usage. Thus, the influence of varied EBV-LCL stimulation dose on the resultant gene 
pairing structure of TCRβ V- and J-genes was evaluated. The results were depicted in the 
below circos plots (Figure 6.3.3.1) where the top 5 TCRβ V-genes are shown in the top half 
of each plot, and the top 5 TCRβ J-genes are shown in the bottom half of each plot. Each 
plot shows the results for the 10-day dataset following high (2:1) or low (100:1) dose 
stimulation for each healthy donor tested. Ribbons connecting TCRβ V- and J- genes 
demonstrate the abundance of each gene pairing. Simultaneously, ribbon colouring 
highlights changes in gene usage between treatment conditions for each donor. For 
example, black genes and ribbons indicate a preservation of the gene pairing order between 
treatment conditions for a given donor. Observations are exemplified by the donor ChEng; 
where, the order of the top 5 most abundant TCRβ V-genes are completely altered following 
differential EBV-LCL dose stimulation. Similar observations can be made for TCRβ 
sequencing following a prolonged culture (Supplementary figure 9.3.6). 
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Figure 6.3.3.1 TCR β-chain V- and J-gene pairing structure is altered by varying EBV-
LCL stimulation dose after a 10-day culture. Circos plots showing TCR β-chain (TCRβ) 
V- to J-gene pairing structure in CTV- CD8+ T-cells. Cells were cultured for 10-days following 
a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. Ribbon thickness indicates number 
of pairings. Only the top 5 TCRβ V- and J-genes are shown. Blacked out gene segments 
and ribbons indicate no difference in usage order between treatments. Ribbons are 
preferentially coloured by TCRβ V-gene. n = 6 biological donors per treatment. 
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6.3.4 EBV-LCL stimulation dose does not impact the expansion of public EBV-
specific T-cell clones  
A major challenge of TCRseq is the ability to assign specificity to identified clones. It is 
however, possible to look within TCRseq data for the presence of public clones. Hence, 
analysis was performed to look at the expansion of public EBV-specific T-cell clones from 
cultures stimulated with varied EBV-LCL doses. Despite identification of a number of public 
EBV-specific TCRβ sequences after 10-days of culture, there was no statistically significant 
change between treatments (Figure 6.3.4.1). This was observed both for individual epitopes 
and for clones grouped by antigen (Figure 6.3.4.1A & B, respectively). It is interesting to 
note that identified public TCRβ sequences recognise the lytic antigens BMLF1 and BZLF1 
(Figure 6.3.4.1B). Similarly, varying EBV-LCL stimulation dose had no impact on public 
EBV-specific clones identified after a prolonged culture (Supplementary figure 9.3.7).  
 
 
Figure 6.3.4.1 EBV-LCL stimulation dose has no impact on expansion of public EBV-
specific clones after 10-day culture. Abundance of public EBV-specific T-cell clones 
found within TCR β-chain (TCRβ) sequencing data after a 10-day culture. CTV- CD8+ T-
cells expanded using a high- (2:1) or low- (100:1) EBV-LCL stimulation dose. (A) The top 
three public EBV-specific clones by epitope specificity detected in high- or low-dose 
stimulated samples. (B) Public EBV-specific clones grouped by EBV antigen. Values 
represent the proportion of productive TCRβ sequences that are assigned each specificity, 
where 1 = 100%. Bars represent the mean ± S.E.M. 
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6.3.5 EBV-LCL stimulation dose alters TCR β-chain paratope motif network  
Assigning specificity to TCRβ sequences is a non-trivial task. Previous analysis looked at 
appearance of public TCRβ sequences. However, in a heterogenous HLA-I sample set, 
identification of public TCRβ sequences can under-represent the antigen-specific 
population. Thus, a more comprehensive method was employed. Recently published, the 
Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH) algorithm infers 
specificity via paratope over-representation (Methods 6.2.3) [419]. Using GLIPH, paratope 
networks can be created and thus, the impact of variable EBV-LCL dose stimulation can be 
investigated.  
 Analysis of the TCRβ repertoire after 10-days of culture revealed a number of 
interesting alterations driven by differential EBV-LCL dose. As evident in the representative 
global (hamming distance of 1) similarity network, high-dose EBV-LCL stimulated culture 
results in a more complex and richer network (Figure 6.3.5.1). High-dose EBV-LCL 
stimulation increased both the number of nodes within clusters (largest cluster = 8 vs. 3, in 
high or low dose, respectively) and the overall number of clusters (43 vs. 12, in high or low 
dose, respectively). Similar observations can be made for global similarity networks of all 
remaining donors (Supplementary figures 9.3.8–11).  
 Similarly, clustering by shared paratope motifs provided an interesting visualisation 
of the overall TCRβ repertoire structure. Namely, network complexity (largest cluster = 7 vs. 
5, in high or low dose, respectively) and richness (# of clusters = 5 vs. 2, in high or low dose, 
respectively) are increased following a high-dose EBV-LCL stimulation (Figure 6.3.5.2). This 
observation is dramatically illustrated by paratope motif (S)QVEG(T). Enumeration of the 
productive frequency of the (S)QVEG(T) motif demonstrates an enrichment in the low-dose 
stimulated culture (Figure 6.3.5.2 graph). Similar observations can be made for paratope 
motif networks for the remaining donors (Supplementary figures 9.3.12–16). 
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Figure 6.3.5.1 High-dose EBV-LCL stimulation results in a more complex and richer 
TCR β-chain global similarity network. Representative example showing CD8+ CTV- T-
cells TCR β-chain (TCRβ) global similarity network following a 10-day culture. (Left panel) 
Global network of high (2:1) dose EBV-LCL stimulated culture. (Right panel) Global network 
of low (100:1) dose EBV-LCL stimulated culture. Nodes represent unique TCRβ CDR3 
sequences, size indicates the productive frequency of clone within sample. Edges link 
sequences with a hamming mutation distance of 1 (i.e. TCRβ CDR3 sequences that differ 
by a single amino acid). 
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Figure 6.3.5.2 High-dose EBV-LCL stimulation results in a more complex and richer 
TCR β-chain paratope motif network. Representative example showing CD8+ CTV- T-
cells TCR β-chain (TCRβ) paratope motif network following a 10-day culture. (Left panel) 
Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. (Right panel) 
Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. Nodes represent 
unique TCRβ CDR3 sequences, size indicates the productive frequency of clone within 
sample. Edges link clones that share a paratope motif, edge thickness is proportional to the 
number of motifs shared. (Above clusters) Aggregates of all paratope motifs statistically 
enriched within the sample found within the particular cluster. Paratope motifs name amino 
acids are sized according to their frequency of occurrence within all motifs identified within 
the cluster. Graph represents aggregated motif mean productive frequency and coloured to 
match representative motif name/s.  
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6.3.6 High-dose EBV-LCL stimulation increases low abundance clones 
Previous data has demonstrated that varied EBV-LCL dose stimulation can significantly 
influence TCRβ repertoire clonality and diversity thus, we deconstructed this observation 
further. Within the 10-day dataset, it is evident that the top 5 clones constitute a considerably 
larger proportion of the TCRβ repertoire in low-dose EBV-LCL stimulated cultures (Figure 
6.3.6.1 & Supplementary figure 9.3.17). It is important to note that there is substantial 
overlap in the top clones between treatments for any given donor (Data not shown). 
Furthermore, low-dose EBV-LCL stimulated cultures have a larger fraction of the TCRβ 
repertoire contained within the top 20% quantile. Literature has shown that singleton clones 
correlate appreciably with naïve T-cells [421]. Singleton and doubleton populations do not 
constitute a notable fraction of the TCRβ repertoire. Similar observations were made for the 
21-day dataset; however, differences were notably muted (Data not shown).  
 
Figure 6.3.6.1 EBV-LCL stimulation 
dose impacts distribution of TCR β-
chain top 5 clones and quantiles 
(1/2). Overview of clonotype quantile 
statistics in high- (2:1) or low- (100:1) 
dose EBV-LCL stimulated cultures at 
day 10. Clones are distinguished by 
TCR β-chain CDR3 amino acid 
sequence. Inner most layer represents 
the frequency of singleton (orange), 
doubleton (purple), or high-order (“3+”, 
three or more, blue) clones. The second 
layer sequentially represents the 
abundance of clones within the 3+ 
group, using quantiles of 20% (i.e. top 
20%, next 20%, …). Outermost layer 
represents the frequency of the top 5 
clones. Frequencies derived from 
productive frequency values. 
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To explore these observations further, the 10-day dataset was categorically grouped via 
clonotype frequencies. This analysis reveals a significant increase in smaller frequency 
clones following a high-dose EBV-LCL stimulation (Figure 6.3.6.2). For the majority of 
donors, >50% of the TCRβ repertoire is comprised of hyperexpanded clones (Figure 
6.3.6.2A). However, within the lower frequency clones all groups were found to be 
significantly enriched in high-dose EBV-LCL stimulated cultures (Figure 6.3.6.2B–D). Only 
the hyperexpanded group was found to be significantly enriched following low-dose EBV-
LCL stimulation (Figure 6.3.6.2E). Following a prolonged (21-day) culture similar 
observations can be made. Specifically, small and medium clonotype groups are 
significantly larger in high-dose EBV-LCL stimulated cultures (Supplementary figure 9.3.18).  
 
 
 
 
Figure 6.3.6.2 High-dose EBV-
LCL stimulation promotes 
expansion of low abundance 
TCR β-chain clone groups. TCR 
β-chain (TCRβ) sequencing 
following 10-days culture after a 
high- (2:1) or low- (100:1) dose 
EBV-LCL stimulation. TCRβ 
clones were grouped by clonotype 
abundance. (A) Overall breakdown 
of samples by clonotype groups in 
terms of productive frequency. (B–
E) Frequency of productive 
rearrangements made up by each 
clone size group. n = 6 biological 
donors per treatment, p values 
derived from paired two-tailed 
students T-test where α = 0.05. 
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6.3.7 High-dose EBV-LCL stimulation drives expansion of unique clones 
Previous results demonstrate that varied EBV-LCL stimulation dose can influence the 
expansion of low abundance clones, particularly within a short-term culture. However, it is 
unclear of this result is representative of the emergence of novel clones or a product of 
TCRβ repertoire restructuring. To address this question, analysis was performed to 
determine which clones were statistically enriched across treatment groups (Figure 
6.3.7.1A). In toto, the number of statistically enriched clones is significantly increased 
following a high-dose EBV-LCL stimulation (Figure 6.3.7.1B). Division of enriched clones 
into shared and unique clones provides an interesting insight into clone expansion. Namely, 
shared clones are not significantly altered by differential EBV-LCL dose stimulation (Figure 
6.3.7.1C). Whereas, enriched clones unique to a particular treatment were found to be 
significantly increased in high-dose EBV-LCL stimulated cultures (Figure 6.3.7.1D). A 
prolonged culture (21-days) revealed a significant increase in enriched clones after high-
dose EBV-LCL stimulation (Supplementary figure 9.3.19A & B). No statistically significant 
difference was observed when enriched clones are classified as shared or unique 
(Supplementary figure 9.3.19C & D).  
 
Figure 6.3.7.1 High-dose EBV-LCL stimulation increases the number of unique 
clones. Statistical enrichment of clones in high- (2:1) or low- (100:1) dose EBV-LCL 
stimulated cultures after 10-days. (A) Scatter plot for a representative donor showing how 
statistically significantly enriched clones were determined. Only productive clones with at 
least 10 reads were used. Statistical significance was determined using binomial two-sided 
test with Benjamini-Hochberg multi-testing corrections and an α = 0.01. (B) The total number 
of clones found to be significantly enriched. (C) The number of significantly enriched clones 
that can be found in both (shared) treatments. (D) The number of significantly enriched 
clones unique to only one treatment. n = 6 biological donors per treatment, graph p values 
derived from paired two-tailed students T-test.   
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6.4 Discussion 
Specificity and functionality are critical components of an efficacious therapeutic T-cell drug 
product. These criteria can be modulated by varying factors such as antigen source, duration 
of culture, and the amount of antigen during the in vitro T-cell expansion step involved in the 
manufacture of ACT immunotherapy. Previous results (chapter 4 and 5), revealed that EBV-
LCL-based stimulation had a large impact on numerous T-cell quality metrics including 
functionality, cellular phenotype, and transcriptional profile. Using these metrics we have 
demonstrated that high-dose EBV-LCL stimulation results in a less favourable T-cell drug 
product.  
One aspect that remains to be investigated is the impact of stimulation dose on the 
TCR repertoire. In this regard, previous studies have established a link between antigen 
stimulation dose and T-cell avidity across a number of model systems and disease contexts 
[300, 412, 415, 422, 423]. These reports lead to the hypothesis that high-dose EBV-LCL 
stimulation would produce a sub-optimal TCR repertoire. This hypothesis is concerning 
given EBV-LCLs are frequently used at a high dose to stimulate the expansion of EBV-
specific T-cells and T-cells of other specificities [220, 222-224, 261-264]. Thus, this chapter 
seeks to investigate the impact that stimulation dose, in the context of EBV-LCL stimulation, 
has on the TCR repertoire. Additionally, analysis presented herein serves to demonstrate 
the utility of TCR repertoire assessment of an ACT drug product. 
 TCRβ deep sequencing performed on DNA extracted from CTV- CD8+ T-cells 
following EBV-LCL-based stimulation revealed significant alterations in TCR repertoire 
clonality and diversity. We found that short-term (10-day) culture with a low-dose EBV-LCL 
stimulation produced a significantly more clonal and less diverse T-cell population, whereas 
clonality or diversity alterations were not observed following a prolonged (21-day) culture. 
Given the requirement for IL-2 supplementation within the 21-day culture, this suggests that 
either prolonged culture or IL-2 stimulation can reshape the TCRβ repertoire.  
TCRβ gene usage has been previously shown to be HLA dependent [424]. In 
concordance with this, initial analysis revealed no clustering of stimulation dose based on 
TCRβ V- or J-gene usage. However, it was revealed that TCRβJ2.7 was over-represented 
irrespective of stimulation dose or culture duration. It is probable that this observation is due 
to TCRβ locus structure and inherent rearrangement bias [425, 426]. Given the donor-
dependent nature of TCRβ gene usage analysis in human samples, a more refined 
analytical method was performed whereby TCRβ V- and J-gene usage preference and their 
overall pairing structure was deconstructed. When confined to the top 5 V- or J-genes, it 
was evident that stimulation dose had a substantial impact on TCRβ gene usage. This 
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analysis builds upon clonality observations by demonstrating that the top clones are 
differentially enriched by stimulation dose.  
To evaluate TCRβ specificity, public EBV-specific TCRβ sequences were identified 
within expanded T-cell populations. We found that stimulation dose did not have an effect 
on the expansion of public EBV-specific T-cell clones. These results are in agreement with 
previously presented EBV-specific multimer staining data (Chapter 4). However, it was 
interesting to note that the public EBV-specific clones identified were largely recognising the 
lytic antigens BMLF1 and BZLF1 [427, 428]. In addition to these clones, extending culture 
duration resulted in the emergence of EBNA3A-specific TCRs and an overall decrease in all 
public EBV-specific T-cell clones [429, 430]. These results are important for ACT drug 
product development as EBV-associated diseases display vastly different EBV antigen 
expression profiles [431-435]. For example, EBV latency type I diseases only express the 
EBNA1 protein. Thus, a T-cell drug product used in the therapy of such diseases would 
need to contain TCRs that are specific to this antigen in order to achieve favourable patient 
outcomes. Currently, the majority of EBV-specific ACT drug products are manufactured 
towards EBV latency proteins [196, 220, 226]. However, lytic replication and the expression 
of lytic epitopes has been implicated in the pathogenesis of EBV-associated lymphomas 
[436-441]. Therefore, the expansion of antigen-specific T-cells recognising lytic epitopes 
may provide clinical benefit in a prophylactic ACT immunotherapy setting. Regardless, these 
data reveal the information that can be obtained from TCRseq analysis and its application 
to ACT therapy decisions. A notable limitation of this analysis is the challenge in identifying 
public TCRs. Public TCRs are highly HLA-specific and require previous identification and 
annotation. This is highlighted by the fact that not all HLA-I types present within tested 
donors have public TCRβ sequences published [34]. Therefore, analyses attempting to 
identify and quantify public EBV-specific TCR clones are likely to under-estimate the true 
EBV-specific TCR repertoire present.  
To address the limitations associated with public TCR identification, the novel 
analysis program GLIPH was used [419]. Briefly, GLIPH infers TCR specificity by grouping 
TCR clones according to shared paratope motifs or overall CDR3 sequence similarity. Thus, 
in a case where an epitope is unknown, one can assume that two TCRs sharing a paratope 
motif can recognise the same epitope. This analysis revealed substantial differences driven 
by stimulation dose. Notably, the complexity and richness of both global and paratope motif 
networks are increased following high-dose stimulation. This data extends upon baseline 
clonality and diversity metrics by elucidating how the TCR repertoire is altered by the 
decreased clonality and increased diversity. For example, the increased complexity in 
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shared clusters, demonstrates that an aspect of the increased diversity is directed against 
shared epitopes. Hence, this clonal diversity may not improve epitope coverage and would 
not mitigate against epitope escape. Therefore, it is unlikely that increased diversity in this 
aspect would be therapeutically beneficial [442, 443]. In contrast, high-dose stimulation also 
increased richness of both paratope and global similarity networks. This resulted in an 
increased number of clusters; which, were predominantly made of low frequency clones. 
This increased richness suggests an increase in the number of epitopes covered. 
TCR affinity and overall avidity are important metrics in T-cell responses to disease 
[299, 415, 444, 445]. Additionally, research has demonstrated that antigen load can skew a 
T-cell population away from high avidity TCRs [300, 341, 342]. This is also seen in vivo 
during active disease responses, where T-cell responses evolve towards a high avidity T-
cell population [423, 446]. GLIPH analysis revealed the emergence of novel paratope motif 
clusters in high-dose stimulated T-cells, these clusters were largely composed of low 
abundance clones. Furthermore, cluster networks reveal that there is substantial overlap in 
the high frequency clones between high and low dose treatments. Additionally, analysis 
revealed high-dose stimulated cultures are enriched for both unique clones and lower 
frequency clones. Taken together, these data demonstrate that increased TCR diversity 
within a high-dose culture is driven through the expansion of unique low frequency clones. 
These low frequency clones are assumed to possess low affinity TCRs. In support of this 
notion, previous studies demonstrate that TCR signalling strength regulates T-cell 
proliferation and activation [22, 82, 447-449]. Furthermore, transcriptional analysis in 
chapter 5 revealed an enrichment of gene transcripts associated with T-cell signalling [381, 
382, 450]. High-dose stimulated T-cells also exhibited hallmarks of T-cell exhaustion—
namely, increased co-expression of IRs and decreased polyfunctionality (Chapter 4) [73, 
74, 95]. Altogether, data in previous chapters, in addition to TCR analysis suggests that 
high-dose stimulation has induced substantially higher TCR activation and signalling, which 
has consequently promoted the outgrowth of low affinity TCR clones. In contrast, low-dose 
stimulation promoted a more clonal TCR repertoire by selectively promoting the growth of 
high affinity TCR clones. Further experimentation will aim to directly assess TCR affinity in 
order to validate this hypothesis. Regardless, these data demonstrate the validity of TCR 
repertoire analysis in ACT drug product development. 
 Biologically, high and low affinity clones are described as having similar cytolytic 
activity [22, 451, 452]. Therapeutically however, high affinity clones have been described as 
beneficial for the elimination of disease or infection [412, 445, 453-455], owing to enhanced 
proliferation, survival, and a lower activation threshold [449, 456, 457]. However, some 
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conflicting reports have shown low affinity clones to be functionally superior [458, 459], 
therefore, further experimentation is required. The results presented herein demonstrate 
that low-dose EBV-LCL stimulation generates a T-cell therapy product with increased 
clonality of presumably high affinity TCRs. Thus, it is postulated that the manufacture of ACT 
drug products using a low-dose stimulation method would derive a preferable TCR 
repertoire. This TCR repertoire may subsequently yield improved clinical outcomes.  
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7.0 General discussion and conclusion  
Immunotherapy is a burgeoning field with applications in viral, malignant, and autoimmune 
diseases [250, 460, 461]. Amongst the various forms of immunotherapy, ACT therapy is a 
particularly promising immunotherapeutic modality [196, 197, 226, 227]. This approach to 
disease management involves the in vitro stimulation and expansion of antigen-specific T-
cells. These antigen-specific T-cells are subsequently infused into the patient where they 
seek out target cells and exert cytotoxic functions.  
Previous studies have demonstrated that the number of transferred T-cells correlates 
strongly with therapeutic responses [329-331]. This observation, as well as a progression 
towards third-party cellular immunotherapy, have made the generation of large cell yields a 
primary focus when manufacturing T-cell drug products [199]. As a consequence, 
stimulation regimes have been designed to promote maximal T-cell expansion [462]. These 
regimes often involve high-dose stimulation and frequently include repeated stimulation 
cycles [197, 220, 226, 231], resulting in strong and sustained TCR signalling. Current 
evidence shows that excessive and prolonged stimulation can have an adverse impact on 
T-cell function. For example, chronic stimulation has been shown to promote the 
development of T-cell exhaustion [105, 269]. Furthermore, TCR signalling strength has been 
implicated in the differentiation of type 2 T-cells, the development of T-cell memory, and 
TCR avidity [297, 299, 368, 396, 463]. These metrics have clear consequences in the 
potential therapeutic efficacy of an ACT drug product.  
Interestingly, in addition to using high-dose and repeated-dose stimulations, 
numerous research groups seldom investigate the quality of their ACT drug product aside 
from basic release criteria [198, 334]. Given the current and future potential heralded by 
ACT immunotherapy, we sought to characterise how manufacturing methods influence T-
cell quality. Furthermore, in doing so, we envisioned that the analytical methods and 
approaches employed as part of this study can be validated for use in ACT drug product 
assessment.  
 Overall, our analysis demonstrated that comprehensive ACT drug product 
assessment could delineate clear differences in drug product quality, which is reflected in 
the functional profile of T-cells. This is likely to impact therapeutic potential in vivo. 
Specifically, our investigation of three commonly employed antigen stimulation methods for 
ACT drug product manufacture—EBV-LCLs, adenoviral vector-infected APCs, and peptide-
pulsed APCs [264]—revealed that antigen source and stimulation dose can have a lasting 
impact on the phenotype, function, transcriptional profile, and TCR repertoire of an ACT 
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drug product. Of the tested antigen sources, EBV-LCL stimulation was found to have the 
most substantial influence on T-cell quality and the overall composition of an ACT drug 
product. For example, EBV-LCL-based stimulation resulted in the expansion of non-T-cell 
populations. In contrast, adenoviral vector-infected APC or peptide-pulsed APC stimulation 
resulted in drug products dominated by T-cells. Furthermore, stimulation dose was found to 
have a minimal influence on cells stimulated using these two antigen sources. The dose of 
EBV-LCL stimulation, however, had a significant impact on ACT drug product quality. 
Specifically, a high-dose EBV-LCL stimulation promoted NK cell expansion whilst limiting 
CD4+ T-cell expansion. Although NK cell adoptive transfer is a rapidly growing modality of 
immunotherapy [291, 294, 464], research investigating the therapeutic consequence of T-
cell and NK cell co-transfer is lacking. Additionally, previous studies have demonstrated the 
important role that CD4+ T-cells play in potentiating effective CD8+ T-cell immunotherapy 
[352, 465]. In contrast, low-dose EBV-LCL stimulation promoted an ACT drug product 
significantly enriched for T-cells, with a mix of both CD4+ and CD8+ subsets. These data 
demonstrate that in vitro ACT manufacturing methodology can have a significant impact on 
the resultant drug product generated.  
 Phenotypic and transcriptional profiling further revealed that ACT drug product 
manufacture methodology can have a substantial influence on T-cell quality metrics. We 
observed that T-cell quality, assessed via the expression of cell surface and effector 
molecules, following EBV-LCL-based stimulation was dose-dependent. For example, high-
dose EBV-LCL stimulation promoted a phenotype consistent with T-cell exhaustion. This 
was characterised by an increase in the co-expression of IRs and decreased 
polyfunctionality [73]. Similar observations were made from transcriptional analysis, which 
showed an overall immunoinhibitory phenotype. We hypothesised that this immunoinhibitory 
phenotype is driven by excessive TCR stimulation—a notion supported by previous reports 
and consistent with our transcriptional data [105, 269]. In contrast, adenoviral vector-
infected APC or peptide-pulsed APC stimulation methods showed marginal dose-dependent 
phenotypic or transcriptional alterations. This is in contrast with previous observations of 
dose-dependent functional differences in a peptide-pulsed stimulation setting [299]. 
Regardless, our phenotypic and transcriptional data suggest that the current wide-spread 
use of high-dose and possibly repeated-dose EBV-LCL stimulation is undesirable for the 
manufacture of an efficacious ACT drug product. Thus, a low-dose EBV-LCL stimulation is 
preferable and may enhance therapeutic outcomes. Our transcriptional data also revealed 
that low-dose stimulated CD8+ T-cells were enriched with gene expression signatures that 
are associated with activated and memory subsets. The analysis of the publicly available 
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TCGA database using either a low-dose EBV-LCL CD4+ or CD8+ T-cell gene signature 
demonstrated a clear overall survival benefit for solid tumour patients. These data highlight 
the utility of comprehensive phenotypic and transcriptional assessment of ACT drug 
products [299-301, 342]. Such analysis is seldom performed within the ACT immunotherapy 
field, yet these data reveal the potential to predict therapeutic outcomes. As a consequence, 
the information obtained from these assessment methods could shape manufacturing 
practices towards enhanced efficacy and thus, improve patient prognosis.  
 Unpublished work (manuscript submitted) from our lab, reports the utility of 
comprehensive phenotypic and TCRseq analysis on an ACT drug product, in evaluating 
patient response to ACT immunotherapy. Therefore, we sought to investigate the value 
derived from TCRseq analysis. We also aimed to evaluate the consequence that alternative 
stimulation strategies impart on the TCR repertoire within an ACT product. Broadly, we 
demonstrated that ACT drug product manufacturing methodology can have a substantial 
impact on the resultant TCR repertoire. Notably, high-dose EBV-LCL stimulation promoted 
a significantly more polyclonal population via the expansion of unique, low abundance TCR 
clones. We hypothesised that these low abundance clones are also of low affinity. This 
notion is supported by experimental data on the development and selection of TCR affinity 
both in vitro and in vivo [300, 341, 342, 423, 446]. In contrast, low-dose EBV-LCL stimulation 
derived an ACT drug product with increased clonality and enriched for clones predicted to 
have high-affinity TCRs. Experimentation has demonstrated the therapeutic benefit of high-
affinity TCR clones and thus, suggest that low-dose stimulation promotes a therapeutically 
superior drug product when EBV-LCL stimulation is used [412, 413, 445]. Furthermore, our 
data demonstrates the value of TCRseq analysis in the assessment of potential ACT drug 
products. Additionally, these data explain, at least partially, the phenotypic and functional 
differences observed in cellular analysis by flow cytometry [445, 457]. 
 Results obtained from TCRseq analysis may also explain the type 2 skew observed 
in the transcriptional data for both CD4+ and CD8+ T-cell populations following a high-dose 
EBV-LCL stimulation. Specifically, research has demonstrated that low-affinity TCR 
signalling, coupled with strong co-signalling, can promote type 2 T-cell differentiation [398]. 
Experimentation has shown that type 2 T-cell responses are undesirable for immunotherapy 
[390, 402]. Our data demonstrate that ACT drug product manufacturing methodology has a 
complex, yet intertwined impact on the final drug product. Thus, comprehensive analysis is 
required to deconstruct the potential therapeutic efficacy of a given ACT drug product. 
Additionally, these data reaffirm the notion that current practices of high-dose, and possibly 
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also repeated-dose stimulation with EBV-LCLs is detrimental to the potential efficacy of an 
ACT drug product.  
 Importantly, further experimentation is required to validate the hypotheses derived 
from the data presented herein. These include further validation and characterisation of data 
suggesting a dose-dependent influence on T-cell exhaustion, type 2 polarisation, and TCR 
affinity. The impact of ACT drug product manufacturing methods on T-cell exhaustion must 
be further defined as exhaustion is a complicated multi-faceted cellular state [73]. Whilst 
there are numerous hallmarks of T-cell exhaustion, this project only investigated two of the 
most prominent traits of exhaustion. However, to thoroughly ascertain the extend of 
exhaustion, other facets of T-cell exhaustion including proliferative and apoptotic potential, 
should be tested [74]. The observation that high-dose EBV-LCL stimulation promotes type 
2 polarisation of T-cells at the transcript level should also be further characterised at the 
protein level. To this end, flow cytometry detection of the transcription factor GATA-3, and 
intracellular cytokine staining of type 2 cytokines such as IL-13, should be performed [389, 
392]. The observation of low-affinity TCR clones is an intriguing and significant finding within 
this dataset. Further experimentation should aim to directly measure TCR affinity to validate 
this finding. This validation would further substantiate a precedent for the utility of TCRseq 
analysis of ACT drug products.  
 One additional limitation of this study is the absence of in vivo data demonstrating a 
therapeutic difference following alternative manufacturing methodologies. This limitation can 
be addressed by the use of humanised murine models that seek to recapitulate the human 
immune system in a manipulable murine host [466]. Additionally, in vitro observations and 
findings from this study can be correlated with in vivo consequences in an ACT 
immunotherapy setting. To this end, comprehensive analysis of ACT drug products used 
within early phase human ACT immunotherapy trials can be performed [193, 194, 197, 226]. 
We envision that these data generated will support the utility of such analytics in predicting 
therapeutic outcomes, as well as in validating the hypotheses presented within this project.  
 In summary, this study has demonstrated that the methodology employed to generate 
an ACT drug product can have a significant impact on the composition, phenotype, 
transcriptional profile, functional profile, and TCR repertoire of cells within the ACT product. 
Additionally, low-dose EBV-LCL stimulation results in an ACT drug product that is predicted 
to be therapeutically superior. This is contrary to practices currently used by numerous 
groups and trials for the production of ACT drug products. These data also demonstrate the 
utility of comprehensive ACT drug product analysis, that if adopted by the field may allow 
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researchers to improve current therapeutics on offer and consequently enhance patient 
outcomes.  
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9.0 Supplementary 
9.1 Impact of antigen stimulation dose and source on in vitro expansion 
of CD4+ and CD8+ T-cells for adoptive immunotherapy 
 
Supplementary figure 9.1.1 Cell trace violet proliferation dye marks cells that have 
undergone division during culture period. Representative flow cytometry plots 
demonstrating gating strategy and example staining profiles in CD8+ T-cells after 10-days 
of culture. (A) Cell trace violet (CTV) staining profile, representative tSNE plots with CTV 
populations overlayed. (B) Gating strategy and example plots of functional markers and 
inhibitory receptors.  
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Supplementary figure 9.1.2 High-dose EBV-LCL stimulated EBV-specific CD8+ T-cells 
have increased expression of ICOS, LAG-3, and TIM-3. EBV-LCL stimulation dose 
significantly impacts EBV multimer-specific CD8+ T-cells after 10-days of culture. (A) K-
means clustering of high- (2:1) or low- (100:1) dose stimulated EBV multimer-specific CD8+ 
T-cells using the geometric mean expression values for ICOS, PD-1, LAG-3, TIM-3, CD160, 
CD96, TIGIT, GzmA, GzmB, Prf, CD107a, IFNg, and IL-2. (B) Geometric mean expression 
of ICOS, LAG-3, and TIM-3 in Multimer+ (left panel) or Multimer- (right panel) populations. n 
≥ 6 biological donors from 3 independent experiments. p value derived from two-tailed paired 
students T-test. 
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Supplementary figure 9.1.3 High-dose EBV-LCL stimulated EBV-specific CD8+ T-cells 
have a decreased frequency of GzmA and IL-2. Antigen stimulation dose has a significant 
impact on receptor expression pattern of EBV multimer-specific CD8+ T-cells after 10 days 
of culture. Frequency of EBV-specific (Multimer+, left panel) CD8+ T-cells or the remaining 
population (Multimer-, right panel) after high (2:1) antigen (Ag) or low Ag (100:1) dose 
stimulation. n ≥ 6 biological donors from 3 independent experiments. p value derived from 
two-tailed paired students T-test. 
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Supplementary figure 9.1.4 Human Mitochondrial Energy Metabolism RT2 Profiler 
gene list (1/2). List of genes assayed for in the human mitochondrial energy metabolism 
RT2 profiler kit. 
Array layout (96-well)
For 384-well 4 x 96 PCR arrays, genes are present in a staggered format. Refer to the RT²
Profiler PCR Array Handbook for layout.
 1 2 3 4 5 6 7 8 9 10 11 12
A ATP12A ATP4A ATP4B ATP5A1 ATP5B ATP5C1 ATP5F1 ATP5G1 ATP5G2 ATP5G3 ATP5H ATP5I
B ATP5J ATP5J2 ATP5L ATP5O ATP6V0A2 ATP6V0D2 ATP6V1C2 ATP6V1E2 ATP6V1G3 BCS1L COX4I1 COX4I2
C COX5A COX5B COX6A1 COX6A2 COX6B1 COX6B2 COX6C COX7A2 COX7A2L COX7B COX8A COX8C
D CYC1 LHPP NDUFA1 NDUFA10 NDUFA11 NDUFA2 NDUFA3 NDUFA4 NDUFA5 NDUFA6 NDUFA7 NDUFA8
E NDUFAB1 NDUFB10 NDUFB2 NDUFB3 NDUFB4 NDUFB5 NDUFB6 NDUFB7 NDUFB8 NDUFB9 NDUFC1 NDUFC2
F NDUFS1 NDUFS2 NDUFS3 NDUFS4 NDUFS5 NDUFS6 NDUFS7 NDUFS8 NDUFV1 NDUFV2 NDUFV3 OXA1L
G PPA1 PPA2 SDHA SDHB SDHC SDHD UQCR11 UQCRC1 UQCRC2 UQCRFS1 UQCRH UQCRQ
H ACTB B2M GAPDH HPRT1 RPLP0 HGDC RTC RTC RTC PPC PPC PPC
Gene table: RT² Profiler PCR Array
Position UniGene GenBank Symbol Description
A01 Hs.147111 NM_001676 ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide
A02 Hs.36992 NM_000704 ATP4A ATPase, H+/K+ exchanging, alpha polypeptide
A03 Hs.434202 NM_000705 ATP4B ATPase, H+/K+ exchanging, beta polypeptide
A04 Hs.298280 NM_004046 ATP5A1
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1,
cardiac muscle
A05 Hs.406510 NM_001686 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
A06 Hs.271135 NM_005174 ATP5C1
ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide
1
A07 Hs.514870 NM_001688 ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1
A08 Hs.80986 NM_005175 ATP5G1
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit
9)
A09 Hs.524464 NM_001002031 ATP5G2
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit
9)
A10 Hs.429 NM_001689 ATP5G3
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C3 (subunit
9)
A11 Hs.514465 NM_006356 ATP5H ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d
A12 Hs.85539 NM_007100 ATP5I ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E
B01 Hs.246310 NM_001685 ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6
B02 Hs.521056 NM_004889 ATP5J2 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2
B03 Hs.486360 NM_006476 ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G
B04 Hs.409140 NM_001697 ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit
B05 Hs.201939 NM_012463 ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2
B06 Hs.436360 NM_152565 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2
B07 Hs.580464 NM_144583 ATP6V1C2 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2
B08 Hs.437691 NM_080653 ATP6V1E2 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2
B09 Hs.127743 NM_133262 ATP6V1G3 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3
B10 Hs.471401 NM_004328 BCS1L BCS1-like (S. cerevisiae)
B11 Hs.433419 NM_001861 COX4I1 Cytochrome c oxidase subunit IV isoform 1
B12 Hs.277101 NM_032609 COX4I2 Cytochrome c oxidase subunit IV isoform 2 (lung)
C01 Hs.401903 NM_004255 COX5A Cytochrome c oxidase subunit Va
C02 Hs.1342 NM_001862 COX5B Cytochrome c oxidase subunit Vb
C03 Hs.497118 NM_004373 COX6A1 Cytochrome c oxidase subunit VIa polypeptide 1
C04 Hs.250760 NM_005205 COX6A2 Cytochrome c oxidase subunit VIa polypeptide 2
C05 Hs.431668 NM_001863 COX6B1 Cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous)
C06 Hs.550544 NM_144613 COX6B2 Cytochrome c oxidase subunit VIb polypeptide 2 (testis)
C07 Hs.351875 NM_004374 COX6C Cytochrome c oxidase subunit VIc
C08 Hs.70312 NM_001865 COX7A2 Cytochrome c oxidase subunit VIIa polypeptide 2 (liver)
C09 Hs.339639 NM_004718 COX7A2L Cytochrome c oxidase subunit VIIa polypeptide 2 like
C10 Hs.522699 NM_001866 COX7B Cytochrome c oxidase subunit VIIb
C11 Hs.433901 NM_004074 COX8A Cytochrome c oxidase subunit VIIIA (ubiquitous)
C12 Hs.666459 NM_182971 COX8C Cytochrome c oxidase subunit VIIIC
D01 Hs.289271 NM_001916 CYC1 Cytochrome c-1
D02 Hs.527748 NM_022126 LHPP Phospholysine phosphohistidine inorganic pyrophosphate phosphatase
D03 Hs.534168 NM_004541 NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa
D04 Hs.277677 NM_004544 NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa
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Supplementary figure 9.1.5 Human Mitochondrial Energy Metabolism RT2 Profiler 
gene list (2/2). List of genes assayed for in the human mitochondrial energy metabolism 
RT2 profiler kit. 
Position UniGene GenBank Symbol Description
D05 Hs.406062 NM_175614 NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa
D06 Hs.534333 NM_002488 NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa
D07 Hs.198269 NM_004542 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa
D08 Hs.50098 NM_002489 NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa
D09 Hs.651219 NM_005000 NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa
D10 Hs.274416 NM_002490 NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa
D11 Hs.333427 NM_005001 NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa
D12 Hs.495039 NM_014222 NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa
E01 Hs.189716 NM_005003 NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa
E02 Hs.513266 NM_004548 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa
E03 Hs.655788 NM_004546 NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa
E04 Hs.109760 NM_002491 NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa
E05 Hs.304613 NM_004547 NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa
E06 Hs.718447 NM_002492 NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa
E07 Hs.493668 NM_182739 NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa
E08 Hs.532853 NM_004146 NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa
E09 Hs.523215 NM_005004 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa
E10 Hs.15977 NM_005005 NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa
E11 Hs.84549 NM_002494 NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa
E12 Hs.407860 NM_004549 NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5kDa
F01 Hs.471207 NM_005006 NDUFS1
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q
reductase)
F02 Hs.173611 NM_004550 NDUFS2
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q
reductase)
F03 Hs.502528 NM_004551 NDUFS3
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q
reductase)
F04 Hs.528222 NM_002495 NDUFS4
NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-coenzyme Q
reductase)
F05 Hs.632385 NM_004552 NDUFS5
NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme Q
reductase)
F06 Hs.408257 NM_004553 NDUFS6
NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q
reductase)
F07 Hs.211914 NM_024407 NDUFS7
NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q
reductase)
F08 Hs.90443 NM_002496 NDUFS8
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q
reductase)
F09 Hs.7744 NM_007103 NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa
F10 Hs.464572 NM_021074 NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa
F11 Hs.473937 NM_021075 NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa
F12 Hs.151134 NM_005015 OXA1L Oxidase (cytochrome c) assembly 1-like
G01 Hs.437403 NM_021129 PPA1 Pyrophosphatase (inorganic) 1
G02 Hs.654957 NM_176869 PPA2 Pyrophosphatase (inorganic) 2
G03 Hs.440475 NM_004168 SDHA Succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
G04 Hs.465924 NM_003000 SDHB Succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
G05 Hs.444472 NM_003001 SDHC
Succinate dehydrogenase complex, subunit C, integral membrane protein,
15kDa
G06 Hs.356270 NM_003002 SDHD Succinate dehydrogenase complex, subunit D, integral membrane protein
G07 Hs.8372 NM_006830 UQCR11 Ubiquinol-cytochrome c reductase, complex III subunit XI
G08 Hs.119251 NM_003365 UQCRC1 Ubiquinol-cytochrome c reductase core protein I
G09 Hs.528803 NM_003366 UQCRC2 Ubiquinol-cytochrome c reductase core protein II
G10 Hs.170107 NM_006003 UQCRFS1 Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
G11 Hs.481571 NM_006004 UQCRH Ubiquinol-cytochrome c reductase hinge protein
G12 Hs.146602 NM_014402 UQCRQ Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa
H01 Hs.520640 NM_001101 ACTB Actin, beta
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin
H03 Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
H04 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0
H06 N/A SA_00105 HGDC Human Genomic DNA Contamination
H07 N/A SA_00104 RTC Reverse Transcription Control
H08 N/A SA_00104 RTC Reverse Transcription Control
H09 N/A SA_00104 RTC Reverse Transcription Control
H10 N/A SA_00103 PPC Positive PCR Control
H11 N/A SA_00103 PPC Positive PCR Control
H12 N/A SA_00103 PPC Positive PCR Control
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Supplementary figure 9.1.6 Mitochondrial metabolism is unchanged by EBV-LCL 
stimulation dose following a 21-day culture. The mitochondrial metabolism of CD8+ T-
cells following culture for 21-days after an high- (2:1) or low- (100:1) dose EBV-LCL 
stimulation. (A) Overview of Oxygen Consumption Rate (OCR) before and after stressor 
addition in 21-day CD8+ T-cells. (D) Overview of Extracellular Acidification Rate (ECAR) 
before and after stressor addition in 21-day CD8+ T-cells. n = 4 biological replicates. Error 
bars represent mean ± S.E.M. 
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9.2 Assessment of molecular profile of in vitro expanded T-cells  
 
Supplementary table 9.2.1 nanoString™ custom probe set details 
Customer 
Identifier 
Accession Position 
ACTB1 NM_001101.2 1011-1110 
ADORA2A2 NM_000675.3 1096-1195 
AHR NM_001621.3 1901-2000 
B2M NM_004048.2 26-125 
BACH23 NM_021813.2 3396-3495 
BCL6 NM_138931.1 506-605 
CD272 NM_181780.2 306-405 
CCL44 NM_002984.2 36-135 
CCL5 NM_002985.2 281-380 
CCR4 NM_005508.4 36-135 
CCR5 NM_000579.1 2731-2830 
CCR6 NM_031409.2 936-1035 
CCR75 NM_001838.2 1611-1710 
CCR9 NM_031200.1 1096-1195 
CD160 NM_007053.2 501-600 
CD226 NM_006566.2 164-263 
CD244 NM_016382.2 1151-1250 
CD27 NM_001242.4 331-430 
CD28 NM_001243078.1 2066-2165 
CD300A NM_007261.2 1-100 
CD38 NM_001775.2 1036-1135 
CD3D NM_000732.4 111-210 
CD3G NM_000073.2 516-615 
CD4 NM_001195017.2 504-603 
CD40LG NM_000074.2 1226-1325 
CD69 NM_001781.1 461-560 
CD8A NM_001768.5 1321-1420 
CD8B6 NM_172099.2 440-539 
CD96 NM_005816.4 1356-1455 
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CTLA47 NM_001037631.1 561-660 
CXCL8 NM_000584.2 26-125 
CXCR3 NM_001504.1 81-180 
CXCR5 NM_001716.3 2619-2718 
CXCR6 NM_006564.1 96-195 
EGR2 NM_000399.3 1892-1991 
ENTPD1 NM_001098175.1 8831-8930 
EOMES NM_005442.2 1671-1770 
FAS8 NM_152876.1 1741-1840 
FASLG NM_000639.1 626-725 
FOS NM_005252.2 1476-1575 
FOXP39 NM_001114377.1 350-449 
GAPDH NM_002046.3 105-204 
GATA3 NM_001002295.1 1692-1791 
GFI1 NM_005263.2 2236-2335 
GNLY NM_006433.2 306-405 
GZMA NM_006144.2 156-255 
GZMB NM_004131.3 541-640 
GZMH NM_033423.3 706-805 
GZMK NM_002104.2 701-800 
GZMM NM_005317.2 670-769 
HAVCR2 NM_032782.3 956-1055 
HLA-DRA NM_019111.3 336-435 
HPRT1 NM_000194.1 241-340 
ICOS NM_012092.2 641-740 
IFNAR1 NM_000629.2 3124-3223 
IFNG NM_000619.2 971-1070 
IFNGR1 NM_000416.1 1141-1240 
IL29 NM_172140.1 234-333 
IL10 NM_000572.2 231-330 
IL10RA NM_001558.3 107-206 
IL12RB2 NM_001559.2 1316-1415 
IL13 NM_002188.2 517-616 
IL17A NM_002190.2 241-340 
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IL17F NM_052872.3 211-310 
IL18R1 NM_003855.2 2026-2125 
IL1A NM_000575.3 1086-1185 
IL1RL1 NM_016232.4 701-800 
IL2 NM_000586.2 301-400 
IL2110 NM_021803.2 66-165 
IL21R11 NM_021798.2 2081-2180 
IL22 NM_020525.4 320-419 
IL23A NM_016584.2 412-511 
IL23R NM_144701.2 711-810 
IL27RA NM_004843.2 2966-3065 
IL2RA NM_000417.1 1001-1100 
IL2RB NM_000878.2 1981-2080 
IL32 NM_004221.4 359-458 
IL412 NM_000589.2 626-725 
IL4R NM_000418.2 706-805 
IL5 NM_000879.2 106-205 
IL6 NM_000600.1 221-320 
IL7R NM_002185.2 1611-1710 
IL9 NM_000590.1 301-400 
IRF4 NM_002460.1 326-425 
ITGA4 NM_000885.4 976-1075 
ITGAE NM_002208.4 3406-3505 
CD103 NM_002208.4 904-1003 
ITK NM_005546.3 3431-3530 
JAK1 NM_002227.1 286-385 
JAK2 NM_004972.2 456-555 
JAK3 NM_000215.2 1716-1815 
JUN NM_002228.3 141-240 
JUNB NM_002229.2 1156-1255 
KLF2 NM_016270.2 1016-1115 
KLRB1 NM_002258.2 86-185 
KLRG1 NM_005810.3 46-145 
LAG3 NM_002286.5 1736-1835 
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LCK NM_005356.2 1261-1360 
LGALS1 NM_002305.3 61-160 
MAF NM_001031804.2 6161-6260 
NFATC2 NM_012340.3 1816-1915 
NFKB1 NM_003998.2 1676-1775 
iNOS NM_000625.4 1006-1105 
NT5E NM_002526.2 1215-1314 
PDCD113 NM_005018.1 176-275 
PRDM1 NM_182907.1 311-410 
PRF1 NM_005041.3 2121-2220 
PTGDR2 NM_004778.1 1836-1935 
PTGER2 NM_000956.2 1411-1510 
CD45RA NM_002838.4 259-358 
CD45R0 NM_080921.3 259-358 
PVR NM_006505.3 605-704 
PVRIG NM_024070.3 1391-1490 
RORC NM_001001523.1 1351-1450 
RPLP014 NM_001002.3 251-350 
RUNX1 NM_001754.4 636-735 
RUNX3 NM_004350.1 2086-2185 
S1PR1 NM_001400.3 1066-1165 
SELL NR_029467.1 1586-1685 
SOCS1 NM_003745.1 1026-1125 
SOCS3 NM_003955.3 1871-1970 
SOCS5 NM_014011.4 661-760 
STAT1 NM_007315.2 206-305 
STAT3 NM_139276.2 4536-4635 
STAT4 NM_003151.2 790-889 
STAT5A NM_003152.2 3461-3560 
STAT5B NM_012448.3 201-300 
STAT6 NM_003153.3 2031-2130 
TBX21 NM_013351.1 891-990 
TGFB1 NM_000660.3 1261-1360 
TIGIT NM_173799.2 1969-2068 
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TNF NM_000594.2 1011-1110 
CD134 NM_003327.3 982-1081 
CD137 NM_001561.4 256-355 
ZBTB16 NM_006006.4 1586-1685 
ZNF683 NM_001114759.1 1491-1590 
Full list of genes and target probe locations in nanoString™ custom probe set.  
1Also targets alpha and gamma-actin transcripts and a beta-actin pseudogene @ >91% 
2Also targets SPECC1L-ADORA2A readthrough transcript (NR_103546)@100% 
3Target accesion has been removed from RefSeq but probe hits current RefSeq transcripts 
(4/4) @100% 
4Also targets CCL4L1 and CCL4L2 (NM_001001435 NM_207007)@99% 
5Also targets a couple predicted LOC105371774 transcripts @ 100% 
6Target accession removed from RefSeq - probe targets region common to all current 
variants of gene (6/6) 
7Minor structural allowances;  Spans EXON 2-4 and should not hit NM_005214 
8Target accesion has been removed from RefSeq but probe hits current RefSeq transcripts 
(NM_152872.2;NM_152871.2;NM_000043.4;NR_028034.2;NR_028036.2;NR_028033.2;N
R_028035.2)@100% 
9Inverted repeat tolerance slightly relaxed in order to target deletion junction - increased 
possiblility of secondary structure hampering hybridization efficiency 
10Also targets readthrough transcript NR_104126 (IL21-AS1) @ 100% 
11Also targets readthrough transcript NR_037158 (IL21R-AS1) @ 100% 
12Also targets LOC105379176 (NR_134248) @ 100% 
13Probe has 1 bp mismatch with current RefSeq transcripts 
14Probe will also target pseudogene RPLP0P2 @92% 
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Supplementary figure 9.2.1 Overview of different analysis programs trialled for 
nanoString™ analysis. Three different methods for analysis of nanoString™ were tested 
using the 10-day high (R:S, 2:1) or low (100:1) dose EBV-LCL stimulated dataset. A. Density 
plot of the distribution of false discovery rate (FDR) corrected p values derived from three 
methods trialled. Dashed line indicates the FDR threshold of 0.05. B. Waterfall plot of the 
top 20 up-regulated genes determined by NanoStringDiff [375] which overlap with EdgeR 
analysis. 
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Supplementary figure 9.2.2 Gene sets enriched in low-dose EBV-LCL stimulated T-
cells (1/2). Heatmaps of gene sets statistically (FDR ≤ 0.05) enriched within low (Responder 
to stimulator (R:S) ratio of 2:1) dose EBV-LCL stimulated CD8+ T-cells after a 10-day 
culture. Gene sets were based on human data. n = 6 biological donors per group, red = 
increased expression, blue = decreased expression, DN = down-regulated, UP = up-
regulated. 
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Supplementary figure 9.2.3 Gene sets enriched in low-dose EBV-LCL stimulated T-
cells (2/2). Heatmaps of gene sets statistically (FDR ≤ 0.05) enriched within low (Responder 
to stimulator (R:S) ratio of 2:1) dose EBV-LCL stimulated CD8+ T-cells after a 10-day 
culture. Gene sets were based on mouse data. n = 6 biological donors per group, red = 
increased expression, blue = decreased expression, DN = down-regulated, UP = up-
regulated. 
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Supplementary figure 9.2.5 Pathways and networks down-regulated following high-
dose EBV-LCL stimulation. String database protein interaction map and Gene ontology 
(GO) analysis was performed using significantly down-regulated (FDR < 0.05) genes in high 
(R:S, 2:1) vs. low (100:1) dose EBV-LCL stimulation for 10-days. Analysis shows results for 
CD8+ T-cells. (A) Interaction map showing the protein-protein associations. (B–D) GO 
analysis for the top 10 terms enriched in interaction map for Biological processes, Molecular 
Functions, and KEGG pathways, respectively. Coloured nodes = query genes as proteins, 
white nodes = second shell of immediate interactors. 
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Supplementary figure 9.2.6 Protein expression in NK cells. Protein expression 
differences in 2:1 (red circles) or 100:1 (blue squares) dose EBV-LCL stimulated CD3-CD19- 
cells after 10-days. (A) Protein expression of CD39 was increased in both cell frequency 
(top) and overall expression (bottom) in 2:1. (B) Geometric mean (Geomean) expression of 
GATA3 was increased in 2:1 stimulated cells. (C) Geomean expression of CD38 was 
increased in 2:1 stimulated cells. n = 5 biological replicates from one experiment where p 
values are derived from repeated measures two-way ANOVA with Sidak’s multiple 
comparison testing. 
 
 
Supplementary figure 9.2.7 Protein expression driven by differential EBV-LCL 
stimulation dose. Protein expression differences after 10-days of culture against EBV-LCL 
at either a 2:1 (red circles) or 100:1 (blue squares) stimulation dose. (A) Frequency of 
CD103+ CD8+ T-cells. (B) Frequency of CD39+ CD4+ T-cells. (C) Frequency of FOXP3+ 
CD3-CD19- cells. n = 5 biological replicates from one experiment where p values are derived 
from repeated measures two-way ANOVA with Sidak’s multiple comparison testing. 
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Supplementary figure 9.2.8 CD4+ Treg frequency is unchanged by EBV-LCL 
stimulation dose. Frequency of CD4+ Tregs after 10-days of culture with either a 2:1 or 
100:1 dose EBV-LCL stimulation. (A) Frequency of CD4+ Treg cells is unchanged by LCL 
stimulation dose. (B) Representative sample showing Treg gating in CD4+ CTV- cells. n = 5 
biological replicates from one experiment where p values are derived from repeated 
measures two-way ANOVA with Sidak’s multiple comparison testing. 
 
 
Supplementary figure 9.2.9 Transcriptional signature of EBV-LCL stimulated CD8+ T-
cells after 21 days of culture in comparison to exvivo. Differential gene expression of 
cultured cells in comparison to exvivo CD8+ T-cells. (A) Heatmap of significantly differentially 
expressed genes (DEGs; FDR < 0.05) between 21-day high-dose (2:1) stimulated cells and 
exvivo CD8+ T-cells. (B) Unrooted dendrogram of sample relation. (C) Heatmap of significant 
DEGs (FDR < 0.05) between 21-day low dose (100:1) and exvivo CD8+ T-cells. n = 6 
biological replicates per treatment. Heatmaps and dendrograms generated using Euclidean 
distance and Ward.D2 or Ward.D clustering respectively.  
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Supplementary figure 9.2.10 Transcriptional signature of 10-day AdE1-LMPpoly 
stimulated cells compared to exvivo CD8+ T-cells. Transcriptional signature of AdE1-
LMPpoly stimulated cells after 10 days of culture compared with exvivo CD8+ T-cells. (A & 
C) Heatmaps of all differentially expressed genes (FDR < 0.05) in high-dose (2:1) vs exvivo 
or low-dose (100:1) vs exvivo comparisons, respectively. (B) Unrooted dendrogram showing 
association between samples, clustered using Euclidean distance and Ward.D clustering. n 
= 3 biological replicates for high and low-dose AdE1-LMPpoly stimulated cells and 6 
biological replicates for Exvivo samples. 
−2 0 2
Row Z−Score
Color Key
Exvivo CD8+
2:1
100:1
Exvivo CD8
2:1
100:1
ENTPD1
IL10
FOXP3
CCR9
CD40LG
CD4
IL2RA
CD103
CD137
CTLA4
IL12RB2
CD160
SOCS5
BCL6
ZBTB16
IL23A
CXCL8
CCR6
NT5E
GNLY
GZMB
GZMA
PRF1
CCL5
TGFB1
IL7R
CD3D
SELL
CD8A
LGALS1
HLA−DRA
STAT5B
NFATC2
STAT3
STAT4
RUNX3
CD69
ITK
CD8B
JAK1
CD38
IFNG
HAVCR2
FASLG
CD27
LAG3
TIGIT
CCR5
CXCR6
SOCS3
BACH2
S1PR1
NFKB1
IL21R
KLRG1
ICOS
CD28
GZMM
STAT6
MAF
IL10RA
RUNX1
CD45RA
FOS
CCR7
IL4R
ITGA4
STAT5A
JUN
IFNGR1
SOCS1
JUNB
KLRB1
KLF2
2:1 vs. Exvivo
IFNG
CD38
HAVCR2
EOMES
ITGAE
FASLG
GFI1
CD27
JAK3
LAG3
TIGIT
CCR5
CXCR6
IL10
ENTPD1
IL2RA
CD103
CTLA4
CD137
CD4
ZBTB16
CXCL8
IL23A
NT5E
CCR6
CD226
SOCS5
CD300A
CD160
BACH2
S1PR1
SOCS3
IL10RA
BCL6
MAF
HLA−DRA
CD45R0
GZMK
GZMB
GZMA
CCL5
IL32
CD45RA
FOS
CCR7
GZMM
STAT6
ICOS
IL4R
NFKB1
IL21R
CD28
TBX21
ITGA4
JUN
IFNGR1
STAT5A
STAT5B
TGFB1
IL7R
ITK
SELL
CD8A
JUNB
CD69
KLRB1
SOCS1
KLF2
STAT3
JAK1
STAT4
RUNX3
CD8B
100:1 vs. Exvivo
A C
B
169 
 
 
Supplementary figure 9.2.11 Transcriptional profile of CD8+ T-cells after stimulation 
with AdE1-LMPpoly for 21-days. The transcriptional profile of cells after 21-days of 
stimulation with AdE1-LMPpoly at two different responder to stimulator (R:S) ratios. (A) 
Unrooted dendrogram of samples stimulated with high (R:S ratio, 2:1) or low (100:1) dose 
stimulation, using Euclidean distance and ward.D clustering. (B) Heatmap of significantly 
(FDR < 0.05) differently expressed genes between high- and low-dose stimulated samples. 
n = 3 biological replicates per treatment. 
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Supplementary figure 9.2.12 Transcriptional signature of 21-day AdE1-LMPpoly 
stimulated cells compared to exvivo CD8+ T-cells. Transcriptional signature of AdE1-
LMPpoly stimulated cells after 21 days of culture compared with exvivo CD8+ T-cells. (A & 
C) Heatmaps of all differentially expressed genes (FDR < 0.05) in high-dose (2:1) vs exvivo 
or low-dose (100:1) vs exvivo comparisons, respectively. (B) Unrooted dendrogram showing 
association between samples, clustered using Euclidean distance and Ward.D clustering. n 
= 3 biological replicates for high and low-dose AdE1-LMPpoly stimulated cells and 6 
biological replicates for Exvivo samples. 
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Supplementary figure 9.2.13 Transcriptional signature of AdE1-LMPpoly stimulated 
cells after 10-day or 21-day cultures. Transcriptional signature induced by AdE1-LMPpoly 
stimulation over the duration of a short-term 10-day or long-term 21-day culture. (A & C) 
Heatmaps of significantly (FDR < 0.05) differently expressed genes. (B) Unsupervised K-
means clustering of samples. n = 3 biological replicates per treatment per timepoint.  
 
172 
 
 
Supplementary figure 9.2.14 Transcriptional signature of 10-day EBV-Pepmix 
stimulated cells compared to exvivo CD8+ T-cells. Transcriptional signature of EBV-
Pepmix stimulated cells after 10 days of culture compared with exvivo CD8+ T-cells. (A) 
Heatmap of differentially expressed genes (FDR < 0.05) in high-dose (2:1) vs exvivo 
comparison. (B) Unrooted dendrogram showing the association between samples. (C) 
Heatmap of differentially expressed genes in low-dose (100:1) vs exvivo comparison. n = 3 
biological replicates for high- or low-dose stimulated cells and n = 6 biological replicates for 
exvivo.  
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Supplementary figure 9.2.15 Transcriptional signature of 21-day cultures stimulated 
with EBV-Pepmix. Transcriptional signature of CD8+ T-cells stimulated with EBV-Pepmix 
after 21 days of culture, using two different doses. (A) Waterfall plot of differentially 
expressed genes (FDR < 0.05) derived from high (2:1) vs. low (100:1) dose comparison. (B) 
Paired plot showing the geometric mean normalised counts for each differentially expressed 
gene. (C) Unrooted dendrogram using Euclidean distance and Ward.D clustering. n = 3 
biological replicates.  
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Supplementary figure 9.2.16 Transcriptional signature of 21-day EBV-Pepmix 
stimulated cells compared to exvivo CD8+ T-cells. Transcriptional signature of EBV-
Pepmix stimulated cells after 21 days of culture compared with exvivo CD8+ T-cells. (A) 
Heatmap of differentially expressed genes (FDR < 0.05) in high (2:1) dose vs. exvivo 
comparison. (B) Unrooted dendrogram showing the association between samples. (C) 
Heatmap of differentially expressed genes in low- (100:1) dose vs. exvivo comparison. n = 
3 biological replicates for high- or low-dose stimulated cells and n = 6 biological replicates 
for exvivo. 
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Supplementary figure 9.2.17 Transcriptional signature of EBV-Pepmix stimulated 
CD8+ T-cells during a short (10-day) and long (21-day) culture. Transcriptional signature 
of CD8+ T-cells induced by EBV-Pepmix stimulation for 10 or 21 days of culture. (A & D) 
Heatmaps of differentially expressed genes (FDR < 0.05) in 21-day vs. 10-day comparisons 
for high (2:1) and low (100:1) dose stimulated cells, respectively. (B) Supervised K-means 
clustering plot (K = 2) for all samples. (C) Overlay of the top 20 variables contributing to 
sample separation, orientation matches (B) (10-day samples are on right). n = 3 biological 
replicates per treatment per time point.  
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Supplementary figure 9.2.18 EBV-LCL stimulation results in a distinct transcriptional 
signature in CD8+ T-cells after a 21-day culture. Gene expression of divided (CTV-) CD8+ 
T-cells after a 21-day culture with differing antigenic stimulants. EBV-Pepmix-pulsed cells 
(Peptide), AdE1-LMPpoly infected stimulator cells (Adeno), or autologous EBV-LCLs (LCL) 
were used as antigenic stimulants at either a high (2:1, responder to stimulator ratio) or low 
(100:1) dose. (A) Top graphs demonstrate the results of high-dose stimulated cultures from 
differing antigenic sources. Unrooted dendrogram demonstrates overall sample 
relationships and waterfall plots reveal the differentially expressed genes (FDR < 0.05) from 
all possible comparisons. (B) Same as (A) for low-dose stimulated cultures. Comparisons 
written as sample vs. control. n = 6 LCL, and 3 Adeno/Peptide, biological replicates per 
treatment. 
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Supplementary figure 9.2.19 Gene signatures correlate with immune markers in Head 
and Neck Squamous Cell Carcinoma. RNAseq data from the cancer genome atlas 
(TCGA) was analysed in relation to genes up-regulated or down-regulated in high (2:1) dose 
EBV-LCL stimulated CD8+ T-cells after 10 days of culture. (A) Boxplot showing the log2 sum 
expression of high dose signature (left plot) or low (100:1) dose signature (right plot) in 
patients designated as high or low dose. (B) signature expression correlates with immune 
marker CD8A (top plots) but not epidermal growth factor receptor expression (bottom plots). 
Where levene’s test for homogeneity of variance failed a (p < 0.05) a non-parametric 
students T-test was performed (Welch), otherwise a parametric students T-test was 
performed. Pearson correlation was used. 
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Supplementary figure 9.2.20 Gene signature of 21-day high-dose EBV-LCL stimulated 
CD8+ T-cells predicts poor overall survival in solid tumours. RNAseq data from the 
cancer genome atlas (TCGA) was analysed in relation to genes up-regulated or down-
regulated in high (2:1) dose EBV-LCL stimulated CD8+ T-cells after 21 days of culture. (A–
D) Kaplan-Meier curves of overall survival in patients with Kidney Renal Clear Cell 
Carcinoma, Lower Grade Glioma, Mesothelioma, and Skin Cutaneous Melanoma, where 
patients are split by high-dose up-regulated gene signature (2:1, red) or high-dose down-
regulated gene signature (100:1, blue). p value calculated using log-rank test. 
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9.3 Assessment of the TCR repertoire expanded by differing antigen 
doses  
 
Supplementary figure 9.3.1 TCRβ sequencing quality control overview. Overview of 
TCRβ sequencing from CD8+ CTV- T-cell after 10-day culture with high- (2:1) or low- (100:1) 
dose EBV-LCL stimulation. (A) Total templates sequenced in each sample. (B) Total number 
of unique rearrangements where a rearrangement is defined as a unique sequence 
generated through V(D)J pairing. (C) Number of reads of productive (in-frame and do not 
contain a stop codon) rearrangements. (D) The number of unique productive 
rearrangements. (E) The fraction of productive templates among all templates. n = 6 
biological donors per treatment, p values derived from paired two-tailed students T-test 
where α = 0.05. 
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Supplementary figure 9.3.2 Overview of TCRβ sequencing reads for 21-day culture. 
Overview of TCRβ sequencing from CD8+ CTV- T-cells after 21-day culture with high- (2:1) 
or low- (100:1) dose EBV-LCL stimulation. (A) Total templates sequenced in each sample. 
(B) Total number of unique rearrangements where a rearrangement is defined as a unique 
sequence generated through V(D)J pairing. (C) Number of reads of productive (in-frame and 
do not contain a stop codon) rearrangements. (D) The number of unique productive 
rearrangements. (E) The fraction of productive templates among all templates. n = 6 
biological donors per treatment, p values derived from paired two-tailed students T-test 
where α = 0.05. 
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Supplementary figure 9.3.3 TCR β-chain sequencing diversity metrics after 10-day 
culture. Diversity metrics of TCRβ sequencing from CD8+ CTV- T-cell after 10-days culture 
with high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) Clonality measure for each 
sample calculated over all productive rearrangements where a value of 1 indicates 
monoclonality and a value of 0 indicates polyclonality. (B) Pielou evenness a measure of 
evenness, where a value of 1 represents a sample where clones are evenly represented. 
(C) iChao1 is a measure of lower bound richness of clones, where a larger value indicates 
increased sample richness. Richness represents the number of unique TCR clones. n = 6 
biological donors per treatment, p values derived from paired two-tailed students T-test 
where α = 0.05.  
 
 
Supplementary figure 9.3.4 TCR β-chain sequencing diversity metrics after 21-day 
culture. Diversity metrics of TCRβ sequencing from CD8+ CTV- T-cell after 21-days culture 
with high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) Clonality measure for each 
sample calculated over all productive rearrangements where a value of 1 indicates 
monoclonality and a value of 0 indicates polyclonality. (B) Pielou evenness a measure of 
evenness, where a value of 1 represents a sample where clones are evenly represented. 
(C) iChao1 is a measure of lower bound richness of clones, where a larger value indicates 
increased sample richness. Richness represents the number of unique TCR clones. n = 6 
biological donors per treatment, p values derived from paired two-tailed students T-test 
where α = 0.05.  
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Supplementary figure 9.3.5 TCR β-chain V- and J-gene usage is not influenced by 
EBV-LCL stimulation dose. TCR β-chain (TCRβ) V- and J-gene usage in CTV- CD8+ T-
cell after 21-day culture following high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A 
& B) Heatmaps of TCRβ V- and J-gene usage frequency, scaled by column. n = 6 biological 
donors per treatment. 
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Supplementary figure 9.3.6 TCR β-chain V- and J-gene pairing structure is altered by 
varying EBV-LCL stimulation dose after a 21-day culture. Circos plots showing TCR β-
chain (TCRβ) V- to J-gene pairing structure in CTV- CD8+ T-cells. Cells were cultured for 
10-days following a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. Ribbon thickness 
indicates number of pairings. Only the top 5 TCRβ V- and J-genes are shown. Blacked out 
gene segments and ribbons indicate no difference in usage order between treatments. 
Ribbons are preferentially coloured by TCRβ V-gene. n = 6 biological donors per treatment. 
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Supplementary figure 9.3.7 EBV-LCL stimulation dose has no impact on expansion of 
public EBV-specific clones after 21-day culture. Abundance of public EBV-specific T-cell 
clones found within TCR β-chain (TCRβ) sequencing data after a 21-day culture. CTV- CD8+ 
T-cells expanded using either a high- (2:1) or low- (100:1) dose EBV-LCL stimulation. (A) 
The top three public EBV-specific clones by epitope specificity detected in high- or low-dose 
stimulated samples. (B) Public EBV-specific clones grouped by EBV antigen. Values 
represent the proportion of productive TCRβ sequences that are assigned each specificity, 
where 1 = 100%. Bars represent the mean ± S.E.M. 
 
 
Supplementary figure 9.3.8 High-dose EBV-LCL stimulation results in a more complex 
and richer TCR β-chain global similarity network (BrTh). Sample BrTh showing CD8+ 
CTV- T-cells TCR β-chain (TCRβ) global similarity network following a 10-day culture. (Left 
panel) Global network of high (2:1) dose EBV-LCL stimulated culture. (Right panel) Global 
network of low (100:1) dose EBV-LCL stimulated culture. Nodes represent unique TCRβ 
CDR3 sequences, size indicates the productive frequency of clone within sample. Edges 
link sequences with a hamming mutation distance of 1 (i.e. TCRβ CDR3 sequences that 
differ by a single amino acid). 
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Supplementary figure 9.3.9 High-dose EBV-LCL stimulation results in a more complex 
and richer TCR β-chain global similarity network (ChEng). Sample ChEng showing 
CD8+ CTV- T-cells TCR β-chain (TCRβ) global similarity network following a 10-day culture. 
(Left panel) Global network of high (2:1) dose EBV-LCL stimulated culture. (Right panel) 
Global network of low (100:1) dose EBV-LCL stimulated culture. Nodes represent unique 
TCRβ CDR3 sequences, size indicates the productive frequency of clone within sample. 
Edges link sequences with a hamming mutation distance of 1 (i.e. TCRβ CDR3 sequences 
that differ by a single amino acid). 
CASSQDRITGRPQHF
CASSLTSAAGELFF
CASSLQRVGTEAFF
CASSVLAVNTEAFF
CASSQDRITGRPQHF
CASSVLAVNTEAFF
ChEng
2:1 100:1
186 
 
 
Supplementary figure 9.3.10 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain global similarity network (SaSo). Sample SaSo 
showing CD8+ CTV- T-cells TCR β-chain (TCRβ) global similarity network following a 10-
day culture. (Left panel) Global network of high (2:1) dose EBV-LCL stimulated culture. 
(Right panel) Global network of low (100:1) dose EBV-LCL stimulated culture. Nodes 
represent unique TCRβ CDR3 sequences, size indicates the productive frequency of clone 
within sample. Edges link sequences with a hamming mutation distance of 1 (i.e. TCRβ 
CDR3 sequences that differ by a single amino acid). 
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Supplementary figure 9.3.11 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain global similarity network (SiCr & ThWa). Samples 
SiCr and ThWa showing CD8+ CTV- T-cells TCR β-chain (TCRβ) global similarity network 
following a 10-day culture. (Left panel) Global network of high (2:1) dose EBV-LCL 
stimulated culture. (Right panel) Global network of low (100:1) dose EBV-LCL stimulated 
culture. Nodes represent unique TCRβ CDR3 sequences, size indicates the productive 
frequency of clone within sample. Edges link sequences with a hamming mutation distance 
of 1 (i.e. TCRβ CDR3 sequences that differ by a single amino acid). 
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Supplementary figure 9.3.12 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain paratope motif network (BrTh). Sample BrTh showing 
CD8+ CTV- T-cells TCR β-chain (TCRβ) paratope motif network following a 10-day culture. 
(Left panel) Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. (Right 
panel) Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. Nodes 
represent unique TCRβ CDR3 sequences, size indicates the productive frequency of clone 
within sample. Edges link clones that share a paratope motif, edge thickness is proportional 
to the number of motifs shared. (Above clusters) Aggregates of all paratope motifs 
statistically enriched within the sample found within the particular cluster. Paratope motifs 
name amino acids are sized according to their frequency of occurrence within all motifs 
identified within the cluster. Graph represents aggregated motif mean productive frequency 
and coloured to match representative motif name/s.  
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Supplementary figure 9.3.13 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain paratope motif network (ChEng). Sample ChEng 
showing CD8+ CTV- T-cells TCR β-chain (TCRβ) paratope motif network following a 10-day 
culture. (Left panel) Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. 
(Right panel) Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. 
Nodes represent unique TCRβ CDR3 sequences, size indicates the productive frequency 
of clone within sample. Edges link clones that share a paratope motif, edge thickness is 
proportional to the number of motifs shared. (Above clusters) Aggregates of all paratope 
motifs statistically enriched within the sample found within the particular cluster. Paratope 
motifs name amino acids are sized according to their frequency of occurrence within all 
motifs identified within the cluster. Graph represents aggregated motif mean productive 
frequency and coloured to match representative motif name/s.  
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Supplementary figure 9.3.14 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain paratope motif network (SaSo). Sample SaSo showing 
CD8+ CTV- T-cells TCR β-chain (TCRβ) paratope motif network following a 10-day culture. 
(Left panel) Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. (Right 
panel) Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. Nodes 
represent unique TCRβ CDR3 sequences, size indicates the productive frequency of clone 
within sample. Edges link clones that share a paratope motif, edge thickness is proportional 
to the number of motifs shared. (Above clusters) Aggregates of all paratope motifs 
statistically enriched within the sample found within the particular cluster. Paratope motifs 
name amino acids are sized according to their frequency of occurrence within all motifs 
identified within the cluster. Graph represents aggregated motif mean productive frequency 
and coloured to match representative motif name/s.  
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Supplementary figure 9.3.15 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain paratope motif network (SiCr). Sample SiCr showing 
CD8+ CTV- T-cells TCR β-chain (TCRβ) paratope motif network following a 10-day culture. 
(Left panel) Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. (Right 
panel) Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. Nodes 
represent unique TCRβ CDR3 sequences, size indicates the productive frequency of clone 
within sample. Edges link clones that share a paratope motif, edge thickness is proportional 
to the number of motifs shared. (Above clusters) Aggregates of all paratope motifs 
statistically enriched within the sample found within the particular cluster. Paratope motifs 
name amino acids are sized according to their frequency of occurrence within all motifs 
identified within the cluster. Graph represents aggregated motif mean productive frequency 
and coloured to match representative motif name/s.  
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Supplementary figure 9.3.16 High-dose EBV-LCL stimulation results in a more 
complex and richer TCR β-chain paratope motif network (ThWa). Sample ThWa 
showing CD8+ CTV- T-cells TCR β-chain (TCRβ) paratope motif network following a 10-day 
culture. (Left panel) Paratope motif network of high (2:1) dose EBV-LCL stimulated culture. 
(Right panel) Paratope motif network of low (100:1) dose EBV-LCL stimulated culture. 
Nodes represent unique TCRβ CDR3 sequences, size indicates the productive frequency 
of clone within sample. Edges link clones that share a paratope motif, edge thickness is 
proportional to the number of motifs shared. (Above clusters) Aggregates of all paratope 
motifs statistically enriched within the sample found within the particular cluster. Paratope 
motifs name amino acids are sized according to their frequency of occurrence within all 
motifs identified within the cluster. Graph represents aggregated motif mean productive 
frequency and coloured to match representative motif name/s.  
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Supplementary figure 9.3.17 EBV-LCL stimulation dose impacts distribution of TCR 
β-chain top 5 clones and quantiles (2/2). Overview of clonotype quantile statistics in high- 
(2:1) or low- (100:1) dose EBV-LCL stimulated cultures at day 10. Clones are distinguished 
by TCR β-chain CDR3 amino acid sequence. Inner most layer represents the frequency of 
singleton (orange), doubleton (purple), or high-order (“3+”, three or more, blue) clones. The 
second layer sequentially represents the abundance of clones within the 3+ group, using 
quantiles of 20% (i.e. top 20%, next 20%, …). Outermost layer represents the frequency of 
the top 5 clones. Frequencies derived from productive frequency values. 
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Supplementary figure 9.3.18 High-dose EBV-LCL stimulation promotes expansion of 
small and medium abundance TCR β-chain clonotype groups following 21-day 
culture. TCR β-chain (TCRβ) sequencing following 21-days culture after a high- (2:1) or 
low- (100:1) dose EBV-LCL stimulation. TCRβ clones were grouped by clonotype 
abundance. (A) Overall breakdown of samples by clonotype groups in terms of productive 
frequency. (B & C) Frequency of productive rearrangements made up by small and medium 
clone size groups, respectively. n = 6 biological donors per treatment, p values derived from 
paired two-tailed students T-test where α = 0.05. 
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Supplementary figure 9.3.19 High-dose EBV-LCL stimulation has no impact on the 
enrichment of shared or unique clones following 21-day culture. Statistical enrichment 
of clones in high- (2:1) or low- (100:1) dose EBV-LCL stimulated cultures after 21-days. (A) 
Scatter plot for a representative donor showing how statistically significantly enriched clones 
were determined. Only productive clones with at least 10 reads were used. Statistical 
significance was determined using binomial two-sided test with Benjamini-Hochberg multi-
testing corrections and an α = 0.01. (B) The total number of clones found to be significantly 
enriched. (C) The number of significantly enriched clones that can be found in both (shared) 
treatments. (D) The number of significantly enriched clones unique to only one treatment. n 
= 6 biological donors per treatment, graph p values derived from paired two-tailed students 
T-test. 
